APPLICATIONS AND MECHANISMS OF INTRAVASCULAR DRAG REDUCING POLYMERS by Marascalco, Philip Justin
 APPLICATIONS AND MECHANISMS OF INTRAVASCULAR DRAG REDUCING 
POLYMERS 
 
 
 
 
 
 
 
 
by 
Philip Justin Marascalco 
B.S. in Biomedical Engineering, Wright State University, 2000 
 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
Swanson School of Engineering in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy  
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
 
 
2008 
 ii 
UNIVERSITY OF PITTSBURGH 
SWANSON SCHOOL OF ENGINEERING 
 
 
 
 
 
 
 
 
This dissertation was presented 
 
by 
 
 
Philip Justin Marascalco 
 
 
 
It was defended on 
April 10th, 2008 
and approved by 
James F. Antaki, Ph.D. 
Professor, Departments of Biomedical Engineering & Computer Science, Carnegie Mellon 
University; Professor, Departments of Bioengineering & Surgery, University of Pittsburgh 
 
Harry C. Blair, M.D. 
Professor, Departments of Pathology & Cell Biology and Physiology 
 
Harvey S. Borovetz, Ph.D. 
Professor & Chair, Department of Bioengineering; Robert L. Hardesty Professor, Department 
of Surgery; Professor, Department of Chemical & Petroleum Engineering 
 
Richard R. Koepsel, Ph.D. 
Research Associate Professor, Department of Chemical Engineering 
 
Dissertation Director: Marina V. Kameneva, Ph.D. 
Research Professor, Departments of Bioengineering & Surgery 
 iii 
Copyright © by Philip Justin Marascalco 
2008 
 iv 
 
Blood soluble drag reducing polymers (DRPs) represent a potential novel treatment of 
hypoperfusion and other disorders. Injections of these high molecular weight viscoelastic 
molecules into the blood of experimental animals at sub-nanomolar concentrations were shown 
to increase cardiac output with no changes in blood pressure (a reduction of vascular resistance) 
and enhance tissue perfusion and oxygenation. The DRP intravascular phenomena have been 
successfully utilized in animal models of various pathologies including hemorrhagic shock, 
hypobaric hypoxia, coronary stenosis, and diabetes. Chronic injections of DRPs demonstrated 
the reduction/prevention of atherosclerosis. Two reported potential mechanisms behind the DRP 
intravascular effects were a decrease in flow separations at vascular bifurcations and a 
reduction/elimination of the Fåhraeus effect (cell-free plasma layer existing in the near-vessel-
wall space) in microvessels. The latter effect may enhance blood transport efficiency and 
selectively implement an increased shear stress on the endothelial cells in microvessels. 
This work was aimed to expand the knowledge on the mechanisms behind the 
phenomenological effects of DRPs in the cardiovascular system and to study new biomedical 
applications. 
A rodent model of chemically-induced diabetes illustrated the potential utility of DRPs 
for the improvement of microcirculation impaired by disease development and implicated as an 
etiology of its complications. Additional rodent experiments tested and proved the absence of 
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acute and chronic deleterious effects of hemodynamically effective concentrations of DRPs on 
hematological, serum chemistry, blood gas and blood coagulation parameters. Further 
experiments were performed to determine the DRP concentration thresholds which could be 
safely used intravenously. 
A hypothesis that DRPs affect RBC deformability was tested using bulk blood filtration 
and viscoelastometry techniques. The filterability of RBC suspensions with DRPs was found to 
be slightly increased reflecting a potential increase in RBC deformability. It was also shown that 
DRPs slightly decreased RBC viscoelasticity which was increased due to diabetes in rodents 
which also reflects a potential increase in RBC deformability. 
Finally, DRPs were explored in tissue engineering, demonstrating that this new 
microhemodynamic phenomena could be employed to retard the inflammatory response to 
implanted biodegradable synthetic scaffolds. This resulted in enhanced collagen structure and 
production in tissues that replaced the scaffold material. 
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1.0  INTRODUCTION 
Blood is a living tissue that is transported throughout the circulation to deliver oxygen, nutritive 
metabolites (e.g., glucose), electrolytes (e.g., Na+), vitamins and hormones and heat to all the 
living cells while removing carbon dioxide and other waste products (e.g., urea). Millions of 
patients suffer from conditions and diseases which disrupt the flow of blood causing a state of 
hypoperfusion which results in dysfunction and damage of tissues through tissue ischemia. These 
conditions and diseases include cardiovascular disease (hypertension, arteriosclerosis, 
myocardial infarction, etc.), cerebrovascular disease (thrombosis, embolism, stroke, etc.), 
peripheral vascular disease, diabetes, sickle cell disease, trauma, hypovolemic shock and other 
severe illnesses. Treatment of tissue perfusion includes a wide array of modalities aimed at 
restoring blood flow and oxygenation to the ischemic tissues. Standard therapies available today 
for treatment of tissue hypoperfusion include administration of vasopressive agents to enhance 
pressure and administration of inotropic agents to enhance myocardial contractility and cardiac 
output, hyperbaric oxygenation, clot-dissolving drugs, and surgical intervention. In spite of 
significant progress in the treatment of these diseases and some decline in morbidity and 
mortality due to these diseases, they still represent major killers in the United States and other 
developed countries. Health care costs associated with current treatments continue to increase. 
Tissue engineering and regenerative medicine promise future treatments but are not yet readily 
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available. Therefore, it is imperative that novel methods for the treatment of impaired 
microcirculation continue to be developed. 
A novel bioengineering approach for the treatment of hypoperfusion is being developed 
using special blood-soluble drag reducing polymers (DRPs). These long-chain viscoelastic 
molecules, when injected into blood of experimental animals at nanomolar concentrations, were 
shown to increase cardiac output with no changes in arterial blood pressure and enhance tissue 
perfusion and oxygenation [1-10]. The DRP intravascular phenomena have been successfully 
utilized in animal models of various pathologies including hemorrhagic shock, hypobaric 
hypoxia, coronary stenosis, and diabetes [11-17]. Chronic injections of DRPs were demonstrated 
to reduce/prevent development of atherosclerosis [5, 18-21]. The reported major hemodynamic 
effect produced by the intravenous injection of a small concentration of the DRPs was a 
significant reduction of flow resistance in the vascular system with no effect on vascular tone 
[10]. 
The exact mechanisms behind the beneficial effects of DRPs on blood circulation still 
remain to be identified. However, some hemodynamic and rheological hypotheses regarding the 
DRP intravascular action have been tested. Briefly, it was demonstrated in vitro that under flow 
conditions corresponding to realistic vascular hemodynamics (1≤ Re ≤ 400) DRPs reduced the 
size and delayed the development of flow separations at vessel bifurcations [22]. In vivo, this 
mechanism may reduce pressure loss in arterial vessels and thus increase precapillary pressure 
thereby promoting an increase microcirculatory blood flow. It was also demonstrated that DRPs 
had a significant impact on red blood cell (RBC) flow behavior in microvessels. Experiments on 
the flow of an RBC suspension in 100-micron diameter channels showed a significant decrease 
in the near-wall cell-free layer thickness due to the presence of DRPs (5 – 10 μg/ml (1.25 – 2.5 
 3 
nM)) in suspensions [11]. However, it is plausible that several other mechanisms exist through 
which DRPs enact their beneficial effects. 
The goals of the studies presented in this dissertation were to expand the knowledge on 
the mechanisms behind the phenomenological effects of DRPs in the cardiovascular system and 
to study several potential new biomedical applications of these effects. This was achieved by 
completing the following specific aims: 
(1) Determine whether the DRP additives have a rheological effect on red blood cells 
to establish additional mechanisms behind the DRP microrheological phenomena 
using several techniques to study animal blood hemorheology  
One proposed mechanism behind the intravascular effect of DRPs is a direct 
enhancement of the mechanical properties of the red blood cells, i.e. their deformability. 
This hypothesis was investigated using two techniques: (i) a filtration technique and (ii) 
measurements of viscoelasticity. The filtration of RBC suspensions is an established 
method used to study RBC deformability. The second method was first validated with a 
series of experiments that tested whether measurements of bulk fluid rheological 
properties could indeed discriminate differences in RBC deformability. After this step, 
this method was used to study the effects of DRPs on blood incubated in vitro and in vivo 
with glucose (in diabetic rats). This mechanism would provide insight into the unique 
ability of DRPs to increase the number of functioning capillaries especially in a model of 
diabetes. 
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(2) Demonstrate that the intravenous administration of DRP preparations in rats 
with streptozotocin-induced diabetes enhances impaired microcirculatory perfusion. 
It was hypothesized that the intravascular injection of DRPs, which have the unique 
ability to enhance microcirculatory blood flow, can improve the microcirculation in the 
situation of progressive microangiopathies associated with diabetes. This hypothesis is 
based on the extensive body of work on the hemodynamic and hemorheological effects of 
DRPs in experimental animal models of hypoperfusion caused by severe hemorrhage and 
hypoxia and have defined DRP preparations that may serve as an innovative approach to 
modulate and enhance microcirculatory blood flow and improve oxygen delivery in 
diabetic microangiopathies. The hypothesis was tested through chronic and acute 
hemodynamic studies in which the microcirculatory blood flow in diabetic rats was 
monitored and after diabetes caused impairment of hemodynamics was established, 
minute concentrations of DRPs were infused to examine their efficacy in restoring 
perfusion. Additional rodent experiments tested and proved the absence of acute and 
chronic deleterious effects of hemodynamically effective concentrations of DRP 
preparations on hematological, serum chemistry blood gas and blood coagulation 
parameters. Further experiments were performed to determine the thresholds of DRP 
concentrations which could be safely used for intravenous infusions. 
(3) Demonstrate the potential applications of DRPs in the field of tissue engineering 
by studying the ability of DRPs to improve cell proliferation and tissue in growth 
and facilitate angiogenesis in synthetic scaffolds. 
DRPs were recently shown to regulate the axial distribution of flowing RBCs in in vitro 
models of microvessels with diameters below 300 μm which lead to a significant increase 
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in wall shear stress via an increase in the near-wall viscosity [11]. This effect might 
facilitate gas transport and waste removal through the vessel wall and promote 
angiogenesis via mechanotransduction mechanisms that translate these additional 
mechanical forces into biological responses of endothelial cells. Based on this recently 
discovered microrheological phenomenon, we tested the hypothesis that the chronic 
intravascular injection of DRPs would improve tissue infiltration and structure, facilitate 
blood vessel formation and decrease inflammatory response to a synthetic scaffold 
implanted subcutaneously in rat.  
Experiments were carried out in which porous polymeric scaffolds were 
implanted subcutaneously and the animals were infused twice weekly for 7 weeks post 
scaffold implantation with DRPs (saline as Control). Assessment of tissue infiltration and 
growth and collagen deposition as well as blood vessel growth inside the scaffold matrix 
were made after scaffold explant using histological and digital analysis techniques. 
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2.0  BACKGROUND 
2.1 DRAG REDUCING POLYMERS 
Shortly after the end of World War II, a British scientist named B.A. Toms described the ability 
of soluble high molecular weight (MW > 1000 kiloDaltons (kDa) polymers, so-called drag-
reducing polymers (DRPs), to reduce resistance to turbulent flow in a pipe [23]. It was 
demonstrated that the addition of a minute amount of soluble polymers with long chains, 
relatively linear structure, and unique elastic properties to flowing fluid significantly increased 
the flow rate under a constant driving pressure or decreased the pressure under constant flow 
conditions. The polymers had no effect on flow resistance at laminar flow conditions in a pipe, 
nor did they change the fluid viscosity at the effective concentrations. It was also found that DRP 
additives reduced hydrodynamic resistance in systems with nonturbulent (disturbed laminar) 
flow, such as pulsating flow in straight and spiral pipes or Couette flow with Taylor vortices at 
low Reynolds numbers [24, 25]. The Toms effect has been intensively investigated for decades 
and has been utilized for various industrial applications [26-30]. However, the exact mechanism 
underlying Toms phenomenon is still unknown. 
Based on the extraordinary hemodynamic effects which were shown in various acute and 
chronic animal models, blood-soluble drag-reducing polymers may have potential in multiple 
biomedical applications [1, 3-6, 8-10, 17-19, 21, 31-35]. Kameneva et al. recently reviewed the 
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intravascular effects of DRPs which have been demonstrated in these various animal models 
[11]. Nanomolar concentrations of these polymers injected intravenously caused an increase in 
aortic and arterial blood flow and a decrease in blood pressure and in peripheral vascular 
resistance with no effect on blood viscosity or blood vessel tone [1, 3-6, 8-10, 32]. Briefly, DRPs 
were shown to significantly increase collateral blood flow [31] and the number of functioning 
capillaries in normal and diabetic rats [17]. In canine models, DRPs were shown to reduce 
poststenotic separation flows and flow disturbances in models of a subcritical stenosis in the 
aorta [34, 36] and carotid artery [33], to increase blood flow through stenosis in iliac arteries 
[35], to redistribute wall shear stresses in the area of stenosis in the aorta [21] and most recently, 
in a model of flow-limiting coronary artery stenosis, DRPs reduced microvascular resistance 
increased capillary volume and improved myocardial perfusion [37]. Beneficial effects of DRPs 
on myocardial perfusion were also demonstrated in the rodent model of acute myocardial 
ischemia [38]. Chronic intravenous injections of DRPs were shown to diminish the development 
of atherosclerosis in several atherogenic animal models [18-20]. These experiments, which 
included regular intravenous injections of DRPs into rabbits and pigeons at concentrations 
significantly (50-100 times) exceeding those deemed hemodynamic effectively, demonstrated no 
chronic toxicity. Additionally, Nokes et al. demonstrated the absence of acute toxicity to DRPs 
in studies of DRP-based perfusion of isolated feline hearts [39]. In models of hemorrhagic shock, 
it was demonstrated that the intravenous infusion of DRPs significantly increased tissue 
perfusion and oxygenation and reduced lethality in rats [11, 12]. DRPs were previously applied 
in rats with alloxan-induced diabetes [17] to test the hypothesis that these polymers could 
improve the microcirculation in progressive microangiopathies associated with diabetes. The 
hypothesis that DRPs could improve the microcirculation in progressive microangiopathies 
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associated with diabetes was tested. The study yielded two major results. First, it was shown that 
alloxan diabetes caused a significant reduction in the number of functioning capillaries and the 
capillary blood flow velocity. After a single injection of the DRP (polyethylene glycol with MW 
of ~ 4000 kDa) at the concentration of the polymer in blood as low as 1 μg/ml (0.25 nM), the 
number of functioning capillaries increased by nearly 50%, and the linear velocity of capillary 
flow increased by over 50%. It was hypothesized that the results were attributed to both a 
reduction in vascular resistance and an improvement in deformability of red blood cells. 
Four long chain polymers were applied in previous studies of the DRP effects on blood 
circulation: polyacrylamide, polyethylene oxide (or polyethylene glycol), a polysaccharide 
extracted from okra and characterized as a rhamnogalactogalacturonan (RGGu) [3], and calf 
thymus DNA [32]. Our laboratory added to this list a new natural DRP, which we discovered in 
the inner matter of aloe vera leaves [11]. The polymer was purified, partially characterized in our 
laboratory, and proven to have a very high drag-reducing efficiency in vitro and hemodynamic 
and hemorheological efficiency in vivo in normal rats and in animals subjected to hemorrhage. 
We recently added to this list a synthetic polymer, poly(N-vinylformamide) (PNVF) with a 
molecular weight of 4500 kDa which we found to significantly reduce resistance to turbulent 
flow in a pipe and thus to presents a DRP. PNVF is known to have low toxicity. Our pilot in vivo 
study showed that PNVF had acceptable biocompatibility and hemodynamic effectiveness and 
thus could be considered as a DRP candidate for potential biomedical applications [40]. Of 
significant importance is the fact that although these polymers are chemically dissimilar, they all 
possess the ability to reduce drag in turbulent flow and have a proven efficiency in vivo owing 
this behavior to their high molecular weights and long linear structures. 
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As previously mentioned, the exact mechanisms behind the beneficial effects of DRPs on 
blood circulation remain to be identified. It was demonstrated in vitro that under flow conditions 
corresponding to realistic vascular hemodynamics (1≤ Re ≤ 400), DRPs reduce the size and 
delay the development of flow separations at vessel bifurcations [22]. In vivo, this mechanism 
may reduce pressure loss in arterial vessels and thus increase precapillary pressure thereby 
promoting an increase in the density of functioning capillaries and in tissue perfusion, both of 
which were observed in animal experiments. Figure 2.1 demonstrates a hypothetical distribution 
of mean arterial blood pressure along the vascular system at normal blood pressure levels, and 
after an injection of DRP into the blood. One can see that a decrease in pressure drop in small 
arteries and arterioles caused a significant increase in precapillary pressure. 
 
 
Figure 2.1. Hypothetical distribution of mean arterial blood 
pressure along the vascular system at normal blood pressure levels 
and after a hypothetical injection of DRPs into the blood. 
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2.2 HEMORHEOLOGY 
Blood is a living tissue that is transported throughout the circulation to deliver oxygen, nutritive 
metabolites (e.g., glucose), electrolytes (e.g., Na+), vitamins and hormones and heat to all the 
living cells while removing carbon dioxide and other waste products (e.g., urea). It also serves as 
the organism’s defense against infections and foreign materials and as a clotting mechanism to 
prevent fluid loss when blood vessels are ruptured. Its flow is highly regulated in order to 
maintain the function of the cells it serves, and disturbances in flow can result in serious 
complications. 
Blood is a two-phase fluid consisting of a suspension of solid cellular elements (red and 
white blood cells and platelets) in an aqueous solution known as plasma. Red blood cells 
(RBCs), responsible for delivering oxygen and removing carbon dioxide from cells, constitute 
99% of the cellular elements. The typical hematocrit (volume fraction of red cells in whole 
blood) in humans is between 40-45%. Therefore, these cells strongly influence the flow behavior 
of blood. Red cells are the shape of a biconcave disk (concavity of each face) with a diameter of 
~8 μm and thickness ~2 μm. The red cell is filled with an incompressible, viscous hemoglobin 
solution which is surrounded by a flexible viscoelastic membrane consisting of a lipid bilayer 
and a cytoskeleton [41]. 
The last few decades have had considerable attention placed on the study of the behavior 
of blood flow, hemorheology. However, it was earlier in the 20th century when Fåhraeus began 
to explore the flow properties of blood and modernize the understanding of circulatory 
physiology. In his work, he discovered alterations in the suspension stability and flow of blood in 
disease processes [42]. Further work would uncover the dependence of whole blood viscosity on 
plasma viscosity [43, 44], hematocrit [45-47], temperature [48], and shear rate (making blood a 
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non-Newtonian fluid). The shear rate dependence was found to be a function of red cell 
aggregation at low shear rates [44, 49] and red cell deformation at high shear rates [50-52]. 
Alterations in any of these parameters, which occur in certain disease states, would change the 
flow behavior of blood thus raising clinical interest in blood rheology. A decrease in RBC 
deformability results in an increase in whole blood viscosity at high shear rates. Blood 
viscoelasticity as a function of shear rate was presented by Thurston in 1972 using oscillatory 
flow at a known frequency in a cylindrical tube [53]. This established that blood not only 
behaved as a fluid but also as a solid. Therefore, RBC deformability significantly impacts the 
viscoelasticity of whole blood at high shear rates and a decrease in deformability would result in 
an increase in whole blood viscosity and elasticity. 
Our laboratory research is concerned of the hemorheological effects of blood soluble 
drag-reducing polymer additives in normal and pathological blood. One hypothesis behind the 
intravascular drag reducing phenomena is their effect on RBC deformability. 
The smallest capillaries are ~3-5 μm; therefore the cells must deform a substantial 
amount to be able to pass throughout the microcirculation. Consequently, a small reduction in 
RBC deformability can significantly compromise the number of functioning capillaries and 
hence oxygen delivery, extraction of products of metabolism from the tissue, etc. Diabetes 
Mellitus is associated with hemorheological abnormalities. Rheological studies of blood obtained 
from patients with diabetes have shown increased blood viscosity [54, 55] and reduced RBC 
deformability [56-58]. 
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2.3 DETERMINATION OF BLOOD VISCOSITY AND VISCOELASTICITY AND 
RBC DEFORMABILITY 
Viscosity is typically measured with either a capillary or rotational viscometer. Capillary or tube 
viscometers are the oldest and most popular method of measuring viscosity due to their extreme 
simplicity. This method is based on the Poiseuille flow relationship for steady flow in a long 
circular cylindrical tube and thus with knowledge of flow, applied pressure and tube dimensions, 
viscosity can be determined. These viscometers lend themselves quite useful to measurements of 
Newtonian fluids such as plasma but there are several constraints that limit their use for viscosity 
measurements of the non-Newtonian fluid, whole blood, including measurements at fixed shear 
rates. A summary of these limitations are given in a review on clinical blood rheology [59]. 
Reasonable measurements of the asymptotic viscosity of blood can be obtained using these 
instruments. 
Measurements of the viscosity of non-Newtonian fluids are better accomplished with 
rotational viscometers which consist of radially symmetrical cylindrical/conical elements (one 
fixed and one moving) separated by the test fluid since these devices allow viscosity 
measurements over a wide shear rate range and since blood viscosity is shear dependent. The 
torque resulting from shearing the test sample is recorded and shear stress is calculated based on 
torque measurement and the cylindrical geometry. The three basic types are: (1) cone-plate, (2) 
cone-in-cone, and (3) coaxial cylinder (Couette). The first commercially available rotational 
viscometer to measure blood rheology was Wells-Brookfield cone and plate rheometer. The 
cone-plate and cone-in-cone rheometers are limited due to RBC sedimentation [60]. Couette 
viscometers are made to be extremely sensitive at low shear rates and are reproducible at both 
low and relatively high shears making them an appropriate choice for measurements of blood 
 13 
rheological properties [59, 61]. Conventional rheometers (rotational cone/plate and Couette) 
provided most of the initial data on the effects of temperature, shear rate, hematocrit, and level of 
plasma proteins on human adult blood viscosity. 
Thurston proposed to use oscillatory tube flow measurements to show that viscoelasticity 
was a basic rheological property of blood. With this device, Thurston demonstrated that 
aggregation, deformability, and flow-induced cell organization are the factors that make human 
blood viscoelastic, non-Newtonian, thixotropic, and dilatant [62, 63]. 
A comparison of conventional rheometers (rotational cone/plate and Couette) where 
viscosity is measured under steady flow conditions to a rheometer capable of making oscillatory 
flow measurements shows that in steady flow the strain is increasing continuously whereas in 
oscillatory flow it reverses periodically thus allowing measurements of minimal microstructural 
changes to blood. In steady flow, the relative displacement of neighboring cell groups increases 
without limit and blood structure is modified from its quiescent state. At higher shear rates these 
changes become similar between steady and oscillatory flow [64]. Thurston’s viscoelasticity 
analyzer is capable of making oscillatory measurements with high precision and sensitivity 
where conventional rotational rheometers cannot meet these requirements, operates at 
frequencies near the pulse rate and requires small sample volumes [65].  
Measurements of bulk viscosity and viscoelasticity at high shears (>100 s-1) provide an 
indirect measurement of RBC deformability. A Vilastic Scientific viscoelasticity analyzer and a 
Brookfield cone-plate rheometer were used in the studies performed in this dissertation to study 
the rheological effects of DRPs on blood obtained from normal and diabetic rats to further 
elucidate potential mechanisms behind the beneficial intravascular effects of DRPs. 
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Other techniques have been developed and used to directly measure the deformability of 
RBCs. Bulk filtration has been the most widely used method for clinical studies of RBC 
deformability. This technique, developed in 1976 by Reid and Dormandy [66], involves the 
filtration of RBC suspensions through a 5 micron filter by constant negative pressure of 20 
cmH2O. This method has several technical challenges which affect RBC filtration including 
contaminating particles such as platelet aggregates and white blood cells in the suspension media 
which may clog the filter pores or the effects of storage in suspension media. A complete list of 
in vivo and in vitro factors that influence RBC filtration measurements has been reviewed [59]. 
Commercially available instruments have been designed around this concept. Other techniques 
available for measurement of RBC deformability include micropipette aspiration which directly 
measures the intrinsic deformability of the cell membrane. This method is advantageous in that it 
directly measures the individual RBC deformability independent of other cells. However, only a 
small number of RBCs can be sampled out of an entire population and this method is extremely 
time consuming limiting its use in clinical studies. Another method, ektacytometry, measures 
RBC elongation under a constant shear stress using laser diffractrometry. This instrument is 
particularly versatile even being able to measure the deformability of RBC ghosts [67]. This 
method has the same limitation as ektacytometers characterizing only small population of RBCs 
which may not represent the whole blood rheological behavior. 
The bulk filtration method described above was also used in this dissertation to further 
study and complement the work in which measurements of bulk viscosity and viscoelasticity 
were applied to indirectly measure RBC deformability in the presence of DRPs. 
 15 
2.4 DRP FOR THE TREATMENT OF DIABETES MELLITUS 
Twenty-one million people in the United States have diabetes mellitus. The costs associated with 
their health care and disability are over $132 billion annually [68]. Diabetes is associated with 
high levels of glucose in the blood, hyperglycemia, due to defects in insulin production, insulin 
action, or both. The cumulative effects of hyperglycemia in diabetic patients lead to two types of 
vascular damage: a nonocclusive microcirculatory dysfunction involving the capillaries and 
arterioles of the kidneys, retina, and peripheral nerves, and macroangiopathies characterized by 
atherosclerotic lesions of the coronary and peripheral arterial circulation [69]. The micro- and 
macrovascular damage places diabetic patients at high risk for heart disease and stroke, high 
blood pressure, blindness, dental, kidney and nervous system disease, and delayed wound 
healing and limb amputation. The damage to the microcirculation is a multi-step process 
ultimately ending in microvascular hypoperfusion resulting in cellular damage and eventually 
damage to organs, systems (i.e., nervous), or processes (i.e., wound healing) [70]. 
The treatment of poor tissue and organ circulation is extremely important for millions of 
patients suffering from diabetic complications. Standard therapies available today for the 
treatment of low blood flow, i.e. low oxygen delivery to tissue and organs, include 
administration of vasopressive agents to enhance pressure and the administration of inotropic 
agents to enhance cardiac output (flow) [71]. More advanced treatments include the newly 
developed antihypertensive drugs called ACE (angiotensin-converting enzyme) inhibitors to 
prevent or delay kidney failure; laser treatment for diabetic retinopathies; and the transplantation 
of kidneys and pancreases in patients with kidney failure due to diabetes. Insulin therapy has 
provided significant improvement in capillary perfusion [72]; however, it can cause 
complications such as hypoglycemia, lipoatrophy, allergic reactions, insulin resistance, and 
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insulin edema, especially in children [73, 74]. Although novel drugs possessing radical 
scavenging ability, such as Troglitazone, are expected to improve impaired microcirculation in 
diabetes [75], the maintenance of normoglycemia continues to be the most successful means of 
prevention of diabetes-related complications. This is reflected in the most recent advances in the 
management and treatment of diabetes including the development of a quick-acting insulin 
analog; improved methods to monitor blood glucose; and the development of external insulin 
pumps to replace daily injections. This largely overlooks the hemorheological component and 
the serious damage that altered mechanical properties of RBCs and increased flow resistance 
may cause in microcirculation. This is of particular interest to our laboratory since a potential 
treatment of the diminished blood flow and reduced red blood cell (RBC) deformability [56, 57], 
both of which have been implemented in diabetic complications, may be the intravascular 
injection of DRPs as we described above as having the unique ability to increase 
microcirculatory blood flow and may possess the ability to enhance RBC deformability. Previous 
attempts to address this problem using drugs that improve the deformability of RBCs (Trental®) 
were used in healing of ischemic wounds and showed some improvement [76]. Therefore, the 
need for new therapeutics to treat and prevent these diabetic complications is still crucial for the 
reduction of mortality and morbidity due to diabetes. 
Currently there is no truly effective prevention regimen or treatment for diabetes-related 
microcirculation impairment. In this dissertation, an experimental evaluation of a novel therapy 
for the restoration and maintenance of impaired microcirculation in tissue and organs, which is 
significantly reduced due to diabetes based on the ability DRPs to provide blood with 
exceptionally low resistance to flow in the microcirculatory system which increases functional 
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capillary density and markedly improve blood flow in microcirculatory disorders associated with 
diabetes was performed. 
2.5 DRP IN TISSUE ENGINEERING AND REGENERATIVE MEDICINE 
Angiogenesis plays a very important role in many normal and pathological conditions and it is 
strongly involved in the process of wound healing and tissue regeneration. Angiogenesis is 
required to supply new tissue with oxygen metabolites and to remove waste products of 
metabolism. When angiogenesis is impaired due to a variety of causes (physical, chemical, 
aging, etc.), the gas transport is diminished and the tissue growth is weakened. While inhibition 
of angiogenesis is crucial for suppression of the tumor growth, inducing angiogenesis is a vital 
issue in regenerative therapy, especially in the biointegration and biocompatibility of 
biomaterials and healing of wounds. It was previously shown that a sustained hemodynamic wall 
shear stress stimulates neovascularization and damaged tissue repair in vivo [77]. 
It was long believed that increased blood flow improves wound healing [78], and that 
blood flow acceleration is essential for wound healing angiogenesis [77]. Hemodynamic forces 
produced by flowing blood are strong and important regulators of cell and organ function. Flow 
induced wall shear stresses are known to play an important role in the activation of many signal 
transduction pathways in vascular endothelial cells [79, 80]. Application of a shear stress to the 
surface of blood vessels wall causes deformation of endothelial cells with rearrangement of the 
cytoskeleton which triggers endothelial mechanotransduction. Hemodynamically induced wall 
shear stresses influence vascular function and adaptation affecting vessel tone and the vascular 
remodeling generated during the vasculo- and angiogenesis associated with vascular 
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physiological adaptation or disease [81, 82]. More recently, Van Gieson at al. studied the in vivo 
adaptation of microvessels in the presence of elevated pressure and circumferential wall stress 
and found an enhanced coverage of fully differentiated mature smooth muscle cells in mesenteric 
microvessels related to sustained elevated pressure and wall strain [83]. Therefore, hemodynamic 
stresses are important angiogenic stimuli along with hypoxia, inflammation and other factors, 
and growth of new microvessels is essential for uncompromised wound healing and tissue 
regeneration [82]. Unfortunately, there are very limited possibilities to increase blood flow in 
microvessels to stimulate angiogenesis. In animal models, powerful vasorelaxants are used to 
increase peripheral circulation [77] 
Hemodynamic forces applied to a vessel wall can be estimated by using a force balance 
in the vessel segment schematically shown in Figure 2.2, 
 
 
Figure 2.2: Schematic of forces on blood vessel segment 
 
τw × 2πR × L= ΔP × πR2, (1) 
where τw is the wall shear stress, ΔP is the pressure gradient across the vessel, R is the 
vessel radius and L is the segment length. Therefore,  
τw = ΔP × R/2L. (2) 
Using the Poiseuille equation  
ΔP= Q × 8L × μ/πR4, (3) 
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we obtain τw = 4Q × μ/πR3, (4) 
Substituting Q with the formula Q= v × πR2, where v is velocity of blood flow, we obtain 
a final formula for calculation of the wall shear stress. 
τw = 4 × v × μ/R or τw = f(v, μ, R). (5) 
From this equation one can see that the vessel wall shear stress depends on three 
parameters: velocity of blood flow through the vessel, viscosity of blood and the vessel radius. 
Therefore to increase wall shear stress, one should increase velocity of flow as it was done by 
Ichioka et al. [77] or decrease vessel radius. Blood viscosity is usually considered to be a 
constant. However, in small vessels with a size below 200 μm, the near wall viscosity is much 
lower than the whole blood viscosity, since there is a cell free layer of plasma present there 
which has a lower viscosity. Therefore, to increase wall shear stress via an increase in viscosity, 
one should consider infusion of substances which would increase plasma viscosity such as 
dextran or starch solutions which would significantly increase the whole blood viscosity. 
Another method could be a reduction or elimination of the near wall plasma layer. 
One further hypothesis regarding the mechanisms of the DRP intravascular effects was 
related to the potential impact of the DRPs on RBC flow behavior in microvessels. Experiments 
on the flow of an RBC suspension in 100 μm diameter channels showed a significant decrease in 
the near-wall cell-free layer thickness in the presence of minute concentrations (5 – 10 μg/ml 
(1.25 – 2.5 nM)) of DRPs in suspensions (Figure 2.3). 
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Figure 2.3: Effect of DRPs on the near-wall plasma layer in a 100 μm channel 
 
A decrease in the size of the near-wall plasma layer in a 100 micron channel was demonstrated 
after the addition of DRPs. An increase in the DRP concentration causes a decrease in the near-
wall plasma layer (photo by Dr. ZJ Wu [84]). 
 
The same polymers with lower molecular weight and with no ability to produce the Toms 
effect did not change flow behavior of RBCs in the microchannels. In the vascular system, this 
rheological effect can attenuate the plasma “skimming” and both Fåhraeus and Fåhraeus-
Lindquist effects in small vessels and, thus, increase local hematocrit, apparent viscosity and 
wall shear stress in microvessels and capillaries. In vivo this effect may facilitate gas exchange in 
arterioles and capillaries due to relocation of some RBCs to the near-wall space. In addition, due 
to an increase in the microvessel hematocrit caused by attenuation of the plasma-skimming 
effect, DRPs would produce an increase in local blood viscosity and wall shear stress potentially 
promoting the release of vasodilators in microvessels, and an increase in collateral flow and 
number of functioning capillaries. The decrease in the near wall cell-free layer associated with 
the DRPs is a new phenomenon which has yet to be investigated in detail and explained. We 
speculate that the alignment and stretch of the polymers along the flow paths may diminish RBC 
rotation. RBC rotation is an important contributor to the formation of a near-wall plasma layer in 
microvessels. In addition, an increase in blood viscoelasticity due to the presence of DRPs may 
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strengthen non-Newtonian patterns of the axial velocity profile in vessels (increasing the profile 
bluntness, decreasing the velocity near the central axis and increasing the velocity near 
channel/vessel wall). This would change the RBC distribution in the axial core and shift their 
mean velocity closer to the mean velocity of blood. 
The presence of the DRPs in blood, which selectively increase near wall viscosity and 
thus wall shear stress in microvessels, might promote angiogenesis and change the cellular 
response to biomaterials via the mechanotransduction mechanisms that translate mechanical 
forces into biological responses of endothelial cells (Figure 2.4). 
 22 
 
Figure 2.4: Schematic of DRP action in microvessels 
 
(A) Pre-DRP: RBCs flowing in small vessels (diameter < 0.3 mm) move radially toward the vessel 
center producing a near-wall plasma layer and reducing the apparent viscosity at the vessel wall 
and the shear stress on the endothelium (Fåhraeus-Lindquist effect). (B) Post-DRP: The presence 
of DRPs in blood moves RBCs axially toward the vessel wall, reducing the near-wall plasma layer 
and increasing the local hematocrit. The effective viscosity at the vessel wall and the shear stress 
on the endothelium also rise, possibly stimulating cytokine production or limiting leukocyte 
extravasation. 
 
A study was performed in this dissertation to investigate this innovative hemodynamic 
approach for the enhancement of biointegration of a polymeric scaffold by increasing blood 
circulation in microvessels and stimulating local angiogenesis related to increased shear forces 
applied to endothelial cells. 
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3.0  STUDY OF THE POTENTIAL MECHANISMS BEHIND THE 
MICRORHEOLOGICAL PHENOMENA OF DRPS: A VALIDATION OF 
TECHNIQUES AND THE RHEOLOGICAL EFFECT OF DRP ADDITIVES ON BLOOD 
3.1 INTRODUCTION 
Microcirculatory blood flow is dependent on the ability of red blood cells (RBCs) to deform. A 
reduction in RBC deformability can have significant consequences on the number of functioning 
capillaries, oxygen delivery, extraction of products of metabolism from the tissue, etc. The 
filterability and viscoelasticity of blood significantly depends on RBC deformability and both a 
decrease in filterability and an increase in blood viscosity and elasticity without changes in 
hematocrit and plasma viscosity signify a decrease in RBC deformability. It has been suggested, 
that decreased RBC deformability may be responsible for the pathogenesis of some of the 
complications in diseases such as diabetes. One hypothesis of the mechanism behind the 
intravascular effect of DRPs, in which these blood soluble macromolecules greatly enhance 
blood flow in the microcirculation, is a direct enhancement of the mechanical properties of the 
red blood cells. The exploration of this hypothesis is described in this chapter. 
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3.2 DRP EFFECT ON RED BLOOD CELL (RBC) FILTERABILITY 
3.2.1 Introduction 
The filtration of RBCs through polycarbonate sieves has been extensively investigated and used 
as a method for determining the deformability of RBCs. In this part of the chapter, a study to 
investigate the effect of DRPs on the filterability of RBC suspensions using this technique is 
discussed. 
3.2.2 Methods 
3.2.2.1 Drag-reducing polymer preparation 
Three drag-reducing polymers were used in the in vivo and in vitro experiments outlined in this 
dissertation and include: a synthetic DRP, PEO-4500 (Sentry™ Polyox WSR-301-NF grade, 
MW = 4500 kDa, Dow Chemical, Midland, MI) and two natural DRPs, an aloe vera-based DRP, 
Poly(mannan) (PMNN; MW = ~4000-6000 kDa) which was discovered in our laboratory and a 
hyaluronic acid-based DRP, Hyvisc® (HA; MW = ~2000 kDa, Anika Therapeutic, Bedford, 
MA). An additional polymer, PEO-200 (MW = 200 kDa, Aldrich Chemical, Milwaukee, WI) 
was prepared and used in some experiments as a control. PEO-200 has the same chemical 
structure as PEO-4500 but due to its lower molecular weight, it does not possess drag reducing 
ability (molecular weight must be greater than 1000 kDa to produce drag reduction). The 
preparation of the DRP solutions used in this and all subsequent chapters is provided below to 
forgo repetitiveness in further chapters. 
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PEO-4500 was prepared weekly by dissolving PEO-4500 powder in pyrogen-free sterile 
normal saline (Baxter, Deerfield, IL) at a concentration of 1.5 mg/ml (0.33 μM). The PEO 
solution was slowly mixed by a magnetic stirrer for 2-4 hours until the solution was thoroughly 
homogenized. The solution was then placed in plastic-walled conical centrifuge tube and slowly 
rocked on a laboratory rocker (Type M79700 Platform Vari-Mix Rocker, Barnstead Thermolyne 
Corp., Dubuque, IA) for 16 hours to ensure mixing and homogeneity. Any low molecular weight 
polymer and/or other low molecular weight impurities were removed by subsequent dialysis 
against saline for 48 h using a dialysis membrane with a 50 kDa molecular weight cutoff 
(Spectra/Por membrane; MWCO: 50 kDa, Spectrum Laboratories, Rancho Dominguez, CA). 
The preparation was then centrifuged at 2200 x g for 30 minutes (CR412; Jouan, Winchester, 
VA) to remove the silicate particles, which were added into the PEO powder during 
manufacturing as a desiccant, and stored at 4°C until use. The polymer was dissolved in saline to 
the desired concentration (50 – 100 μg/ml (1.1 – 2.2 nM)) and mixed 4-6 hours prior to use. 
PEO-200 was prepared when needed using the same technique. 
Poly(mannan) (PMNN) was prepared based on the methods previously described by 
Kameneva et al. [85]. PMNN is a naturally occurring DRP that was extracted and purified from 
the viscous mucilage of the aloe vera (Aloe Barbadensis Miller) of the Lily plant family. The 
drag reducing properties of the PMNN polymer were first discovered and reported by Kameneva 
et al. [11, 85]. After the extraction process was completed, PMNN was dissolved in pyrogen-free 
sterile normal saline at a concentration of 2.5 mg/ml (0.42 μM) and stored at -20°C. On the day 
of an experiment, PMNN was thawed at room temperature, centrifuged at 2200 x g for 30 
minutes (CR412; Jouan) to remove any potential precipitates and further dissolved in saline to 
the desired concentration (50 – 1250 μg/ml (8.3 – 208 nM)) and mixed 4-6 hours prior to use. 
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The hyaluronic acid-based DRP, Hyvisc® (HA) was purchased from a veterinary supply 
vendor (NLS Animal Health, Owings Mills, MD). Hyvisc®, a readily available formulation of 
HA, is currently used by veterinarians used to treat joint dysfunction in horses associated with 
equine osteoarthritis. HA was stored as recommended by the manufacturer until use. On the day 
of an experiment, HA was diluted from its supplied concentration of 11 mg/ml (3.7 μM) in saline 
to the desired concentration (50 – 3000 μg/ml (16 – 1000 nM)) and mixed 4-6 hours prior to use. 
All procedures for the preparation and manipulation of the polymer solutions were done 
aseptically to maintain sterility of the solutions. The polymer preparations were tested in an in 
vitro circulating flow loop prior to in vivo experiments to ensure the reproducibility of the 
desired drag reducing ability. 
3.2.2.2 Blood collection and sample preparation 
Since our animal tests with DRPs were performed in rats, we proposed to test the effects of DRP 
of blood in vitro using donor rat blood. Arterial blood was collected from the right carotid artery 
of male Sprague-Dawley rats weighing ~350-500 grams. A surgical plane of anesthesia was 
induced and maintained by an intramuscular (IM) injection of ketamine (90 mg/kg; KetaJect®; 
Phoenix Pharmaceutical; St. Joseph, MO) and xylazine (10 mg/kg; Xyla-Ject®; Phoenix 
Pharmaceutical). A thermistor probe (Yellow Springs Instruments) was inserted into the rectum 
and the animal placed on a heating pad in dorsal recumbency to maintain a body temperature of 
37 °C. The ventral surface of the neck was shaved and a midline incision from the caudal end of 
the larynx to the suprasternal notch was made. To gain access to the right carotid artery, the 
sternothyroideus and omohyoideus muscles were separated from the sternocleidomastoideus 
using blunt dissection and the carotid artery located by direct palpation. The sheath was incised 
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to expose the carotid artery and the vagus nerve. The carotid artery was then carefully dissected 
free from the vagus, ligated distally with 3-0 silk surgical suture (Surgical Specialties, Reading, 
PA), and cannulated with a 22 gauge IV catheter (ProtectIV Plus; Medex, Carlsbad, CA). 
Approximately 50-75% of an animal’s blood volume (3-4% of the lean body weight) was 
obtainable through exsanguination (total blood volume can be approximated as 6% of the lean 
body weight) [86]. The average blood volume collected from the rats ranged from 10-12 ml. 
Blood was allowed to freely flow from the catheter into glass K3EDTA Vacutainer® tubes (BD, 
Franklin Lakes, NJ) for collection. The animals were sacrificed by a bolus of potassium chloride 
(2 mmol/kg). 
Experiments were performed using whole blood dilutions since blood sample volumes 
were small and washing the cells would have diminished the amount of available blood further. 
Suspensions of erythrocytes were prepared by diluting fresh whole blood forty times with 
phosphate buffered saline (PBS; pH 7.4, osmolality 290 mOsm/kg; Sigma-Aldrich, St. Louis, 
MO) containing 1% bovine serum albumin (BSA; Sigma-Aldrich), which served as the 
suspension medium. The erythrocyte suspension was then aliquoted into three equal volumes and 
PEO-4500 (1.5 mg/ml (0.33 μM)) was added to two of the aliquots to yield final DRP 
concentrations of 1 (0.22 nM) and 10 μg/ml (2.2 nM), respectively. The 1.5 mg/ml (0.33 μM) 
PEO-4500 solution was diluted accordingly to allow equivalent volumes of the DRP to be added. 
An equal volume of the original suspension medium was added to the third aliquot to serve as a 
control. In an additional set of experiments, the erythrocyte suspension was aliquoted into two 
equal volumes and PEO-200 (1.5 mg/ml (7.5 μM)) was added to one of the aliquots to yield a 
final polymer concentration of 10 μg/ml (50 nM). The second aliquot received an equal volume 
of the original suspension medium. PEO-200 has an identical chemical structure to PEO-4500 
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but because its molecular weight is below 1000 kDa, it possesses no drag reducing ability and 
therefore serves as another control to exclude chemical effects on the cells. After the 40x 
dilution, the blood suspensions’ hematocrits were in the order of 1%. The micro-
centrifugation/micro-capillary method commonly employed to measure Ht was not used to 
determine the final RBC concentration of the suspensions since it is moderately insensitive at 
such very low Ht values. 
Pathological RBCs or RBCs which exhibit a reduced deformability, as previously 
reported in diabetic patients [56-58], were simulated by incubating the RBCs with 0.015% 
glutaraldehyde for 30 minutes. After the incubation period, the RBC suspension was centrifuged 
and the excess glutaraldehyde was removed. The samples were then washed three times with 
PBS. In between PBS washes, the RBC suspension was centrifuged at 2200 x g for 10 minutes 
(CR412; Jouan) and the PBS was exchanged. A final RBC suspension of glutaraldehyde-
hardened cells was prepared by dilution with PBS + 1% BSA to a final hematocrit of 1%. The 
suspension was then aliquoted into two equal volumes and PEO-4500 (1.5 mg/ml (0.33 μM)) 
was added to one of the aliquots to yield a final polymer concentration of 10 μg/ml (2.2 nM). 
The second aliquot received an equal volume of the original suspension medium. Rigidified 
RBCs are commonly employed in determining the utility of specific techniques to distinguish the 
differences between normal and pathological cells. 
3.2.2.3 Filtration apparatus and experimental procedure 
Filtration experiments were performed using a filtration apparatus, as shown in Figure 3.1, based 
on the system originally described by Reid and Dormandy [66]. The system was comprised of a 
10 ml disposable syringe barrel (BD) attached to the female luer-lock inlet of a 13mm Swinnex® 
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filter holder (Millipore Ireland BV, Tullagreen, Carrigtwohill, County Cork, Ireland) containing 
a straight channel 5-μm pore polycarbonate filter (Isopore; Millipore Ireland BV). According to 
the manufacturer, the filters had a diameter of 13 mm, a maximum thickness of 10 μm and a 
mean pore density of 4x105 pores/cm2. Each filter was used only once, to avoid any potential 
clogging of the filter. The male slip-tip outlet of the Swinnex® filter holder was fit into a 2-way 
stopcock which was subsequently attached to a luer-lock fitting that was tightly secured in one of 
the holes of a two-hole rubber stopper. The two-hole rubber stopper was positioned into the top 
of a 6-liter Pyrex® Erlenmeyer flask (Corning Life Sciences, Acton, MA). The Erlenmeyer flask 
acted as both the filtrate and vacuum reservoir. A piece of ¼” Tygon® tubing (Cole-Palmer 
Instrument Company, Vernon Hills, IL) connected the second hole of the rubber stopper in the 
filtrate/vacuum flask to a water column and to a pipette bulb. The water column’s base was 
submerged in a beaker of water and it served to measure the negative pressure in the system that 
was applied to the bottom of the filter. With the stopcock closed, the pipet filler was used to 
evacuate the air in the system and create a vacuum pressure of -20 cmH2O. This pressure was 
maintained constant after the stopcock was opened by slowly releasing the pipette bulb at a rate 
that corresponded to the flow rate of the filtrate entering the system. 
RBC suspensions, as described above (Control (no polymer), 1 (0.22 nM) and 10 μg/ml 
(2.2 nM) PEO-4500 and 10 μg/ml (50 nM) PEO-200) and the suspension media (Control (no 
polymer), 1 (0.22 nM) and 10 μg/ml (2.2 nM) PEO-4500 and 10 μg/ml (50 nM) PEO-200) were 
loaded into the 10 ml syringe barrel and drawn through the 5 μm filter under the constant -20 cm 
H2O pressure. The efflux time required for 1 ml of the cell suspensions or 4 ml suspension media 
to pass through the filter channels was recorded and the flow rate was calculated by dividing the 
filtrate volume by its efflux time. Two different filtrate volumes were chosen in order to have 
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efflux times that were in the same order between cell suspensions and suspension media. Flow 
rates were standardized to a constant temperature of 24°C by slightly raising or lowering the 
value using linear interpolation. Recorded temperature values were ±1°C. The relative RBC 
filtration index (RFI) was determined to be the ratio of the flow rates of cell suspension (Q) and 
the corresponding suspension medium (Q0): RFI = Q / Q0. An increase in RFI signified an 
increase in RBC filterability. 
In addition, the RBC suspensions were observed using a light microscope (Labophot-2, 
Nikon Instruments, Melville, NY) before and after filtration through the 5 μm filter pores to 
study whether the filtration process had any direct effect on the RBCs shape. 
Results are expressed as the Mean ± SE. Individual data points that were greater than two 
standard deviations from the mean of the remaining data were discarded. Data analysis was 
performed using GraphPad Prism 5 (GraphPad Software, San Diego, CA). A one-way ANOVA 
with Tukey post hoc test was used to compare the means of the experimental groups to that of 
the control group. A p < 0.05 was considered to be statistically significant. 
 31 
 
Figure 3.1: Experimental setup used in filtration experiments 
 
3.2.3 Results and Discussion 
3.2.3.1 Microscopic evaluation of RBC properties 
Visual observation of RBC suspensions revealed cells with a normal biconcave shape and no 
presence of aggregation as shown in Figure 3.2 (A and B). RBC aggregation, although weak, is 
commonly observed in the whole blood of rats due to the presence of the macromolecule 
fibrinogen [87]. However, the suspension media used in these filtration experiments lacked 
fibrinogen and thus RBC aggregation was not expected. Figure 3.2 (C) shows the 5 μm pores of 
the filter membrane. 
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Figure 3.2: Rat red blood cells (before and after filtration) and polycarbonate membrane 
used in filtration experiments 
 
Photomicrographs show rat RBCs before (A) and after (B) passage through the 5 μm pores of the 
filter membrane (C) demonstrating that this process did not alter RBC shape. 
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3.2.3.2 RBC Filtration experiments 
Bulk filtration of red blood cell suspensions was performed to study the effects of DRPs on the 
filterability of RBCs through 5 μm pores. This technique has been previously been employed to 
investigate the effects of disease [88-90] and various pharmaceuticals [91-93] on the filterability 
of RBCs. 
In this study, dilute RBC suspensions were prepared from fresh whole blood and the 
effect of a DRP (PEO-4500 at a final concentration of 1 (0.22 nM) and 10 μg/ml (2.2 nM) on the 
filterability of RBCs was investigated. The RBC suspensions and their corresponding suspension 
media were drawn through a 5 micron filter under 20 cm H2O of negative pressure. A RBC 
Relative Filtration Index (RFI) was determined to be the ratio of the flow rates of a cell 
suspension (Q) to its corresponding suspension medium (Q0). A statistically significant increase 
in RFI was found in normal RBC suspensions containing PEO-4500 (by 13%, p<0.01, 1 μg/ml 
(0.22 nM), n = 24 and 29%, p<0.001, 10 μg/ml (2.2 nM), n = 25) when compared to RBCs 
suspended in the buffer solution (n = 24) (Figure 3.3). No difference in RFI was observed in 
normal blood suspensions containing PEO-200 (10 μg/ml (50 nM), n = 14) compared to RBCs 
suspended in buffer (Figure 3.3). An increase in RFI signifies an increase in RBC filterability. A 
lack of an effect of PEO-200 on RFI suggests that the increase observed in RFI after the addition 
PEO-4500 was unlikely related to a chemical effect on the RBCs since PEO-200 and PEO-4500 
are built from the same monomer and thus chemically similar except in molecular weight. The 
increase in RFI of the RBC suspensions observed after the addition of PEO-4500 is most likely 
related to a change in the extensional flow of the suspensions through the 5 μm pores of filter 
membrane. The flow of both the RBCs and the viscoelastic polymers through these constrictions 
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is highly dependent on both the viscous and elastic forces imparted on the fluid as they pass 
through the constriction. Leyrat-Maurin et al. [94] demonstrated theoretically that as a RBC 
passes through a filter membrane pore, it recoils due to the elastic properties of its membrane and 
effectively aspirates fluid downstream of the pore. As the elastic modulus increases, this 
aspiration becomes more efficient. It may be likely that the same phenomenon occurred through 
the addition of PEO-4500. Although at low concentrations, the addition of these viscoelastic 
macromolecules would bring to a strictly viscous fluid (isotonic saline) some elasticity. As with 
the RBC model, the aspiration of fluid through the constrictions would increase and become 
more efficient. This would effectively help to aspirate the RBCs through the filter pores as well. 
This is confirmed through the increase in RFI by increasing the polymer concentration and thus 
the elasticity of the suspension fluid. Since PEO-200 is not viscoelastic, there was observed 
effect. It may also be possible that this phenomenon lead to better organization or better 
trafficking of RBCs as they passed through the 5 μm pores of the filter membrane. 
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Figure 3.3: DRP effect on red blood cell filterability 
 
Observed increase in the Red Blood Cell RFI of normal RBC suspensions containing PEO-4500 
(by 13%, * - p<0.01, 1 μg/ml (0.22 nM), n = 24 and 29%, ** - p<0.001, 10 μg/ml (2.2 nM), n = 
25) when compared to RBCs suspended in buffer solution alone (PBS + 1% BSA, n = 24). No 
difference in RFI was observed in normal blood suspensions containing PEO-200 (10 μg/ml (50 
nM), n = 14) compared to RBCs suspended in buffer. Results expressed as Mean ± SE. An 
increase in RFI signifies an increase in RBC filterability. 
 
The sensitivity of the filtration technique employed in these experiments was further 
tested by examining the filterability of RBCs rigidified by incubation with glutaraldehyde. These 
experiments also tested the ability of DRPs to enhance the filterability of RBCs whose 
deformability was decreased artificially in order to mimic the RBCs seen in some diseases where 
deformability is impaired. The feasibility of measurement techniques for distinguishing 
differences in RBC deformability is sometimes evaluated using glutaraldehyde fixed cells [95, 
96]. Figure 3.4 shows that the RFI of glutaraldehyde-treated RBC suspensions was 25% lower 
(p < 0.001, n = 14) than the RFI of normal (un-treated, n = 24) RBCs. The addition of PEO-4500 
(10 μg/ml (2.2 nM)) to the hardened RBC suspensions caused a 34% increase (p < 0.001, n = 14) 
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in the RFI of glutaraldehyde-hardened RBCs which brought the RFI of these suspensions to 
within 1% of the RFI of the normal RBC suspensions prior to the addition of PEO-4500 (Figure 
3.4). The 34% increase in RFI that was observed after the addition of PEO-4500 (10 μg/ml (2.2 
nM)) to the hardened RBC suspensions was very similar to the 29% increase in RFI that was 
observed after the addition of the same concentration of PEO-4500 to the normal (un-treated) 
RBC suspensions. 
 
 
Figure 3.4: DRP effect on the filterability of glutaraldehyde-hardened RBCs 
 
Hardening of RBCs with glutaraldehyde (0.015%) resulted in a 25% decrease (* - p < 0.001 vs. 
Control, n = 14) in RFI compared to the RFI of normal (un-treated, n = 24) RBCs. The addition of 
PEO-4500 (10 μg/ml (2.2 nM)) to the hardened RBC suspensions caused a 34% increase (** - p < 
0.001 vs. Hardened RBCs without DRP, n = 14) in the RFI of glutaraldehyde-hardened RBCs. 
Results expressed as Mean ± SE. An increase in RFI signifies an increase in RBC filterability. 
 
 
In these filtration experiments, the rat RBCs with an average diameter of 7.0 μm had to 
deform to be able to pass through the straight channel pores with a diameter of 5.0 μm. This 
process is very similar to a normal RBC passing through the smallest capillaries in the vascular 
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system. Our results signify that the PEO-4500 slightly increased the filterability of RBCs and 
facilitated their flow through the filter channels by some unknown mechanism which may 
include in part the direct DRP effect on the RBC deformability. The filtration technique provides 
insight into the possible mechanisms of DRPs in the circulation system. However, this 
interpretation does not go without its limitations. The results of the filtration technique can be 
significantly affected by the presence of white blood cells and platelet aggregates which can clog 
the filter pores. In this study, this potential artifact was minimized by preparing RBC suspensions 
with a significantly lower hematocrit. To further study the ability of DRPs to enhance RBC 
deformability, a state of the art viscoelastometer to directly measure the elasticity of RBCs along 
with the whole blood viscosity was employed. 
3.3 VALIDATION OF USING A VISCOELASTICITY ANALYZER TO 
DETERMINE DISSIMILARITIES AND ALTERATIONS IN THE RHEOLOGICAL 
PROPERTIES OF ANIMAL BLOOD 
3.3.1 Introduction 
The results of Section 3.2 suggest that DRPs have some effect on enhancing the filterability of 
RBCs where cells with an average diameter of 7.0 μm had to deform to be able to pass through 
the straight channel pores with a diameter of 5.0 μm. The mechanism behind DRPs ability to 
enhance RBC filterability still remains unknown. Further tests were performed to examine the 
effects of DRPs on the viscoelasticity of blood from which we may infer if DRPs have an effect 
of the deformability of RBCs and further explain the results obtained in Section 3.2. In this 
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section, we tested the feasibility of using measurements of viscoelasticity of animal blood as a 
sensitive standard method of evaluation of changes in RBC deformability. This evaluation was 
based on the fact that both viscosity and elasticity of blood significantly depend on RBC 
deformability. Portions of this work have been previously published elsewhere [97]. 
3.3.2 Methods 
3.3.2.1 Study populations 
Bovine: 
Bovine blood was collected at slaughter from healthy cows after transection of the carotid 
and jugular vessels into plastic bottles containing 10 IU sodium heparin/ml blood. Blood 
was also drawn from the jugular vein of donor animals by sterile venipuncture into plastic 
blood collection bags (Baxter, Deerfield, IL) with 10% anticoagulant citrate dextrose 
(ACD; Gambro BCT, Lakewood, CO). All blood was twice filtered through 40 μm pore 
size filters (Pall Biomedical, SQ40S, Fajardo PR) on the day of collection to remove any 
large white blood cell (WBC) and platelet aggregates or other material, and gentamicin 
(0.25 g/L (0.52 mM); American Pharmaceutical Partners, Schaumburg, IL) was added to 
prevent bacterial growth. 
Ovine and Porcine: 
Samples of ovine and porcine blood were obtained via sterile venipuncture and collected 
into plastic K2EDTA tubes (Becton Dickinson, La Jolla, CA). Samples of ovine blood 
anticoagulated with sodium citrate were also obtained from Cleveland Scientific Inc. 
(Bath, OH). 
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RBCs were observed using a light microscope to examine their morphology and confirm 
the absence or presence of RBC aggregation. Due to the multiple origins of these blood samples, 
all samples were stored at 4°C overnight and tests were conducted the day following blood 
collection. 
3.3.2.2 Hematocrit measurement and standardization 
The whole blood hematocrit (Ht) was measured by micro-hematocrit centrifugation (IEC MB 
Centrifuge, International Equipment Company, Needham Heights, MA) at 13,000 x g for 5 
minutes and adjusted by the addition and removal of autologous plasma. Autologous plasma was 
obtained by centrifuging a separate sample tube at 2200 x g for 15 minutes (CR412, Jouan, 
Winchester, VA) and added to blood samples to lower Ht. Ht was increased by centrifuging 
whole blood at 500 x g for 15 minutes, aspirating a calculated volume of plasma and then gently 
mixing the sample to resuspend the RBCs. Ht was adjusted to a standard level of 45-48% except 
in experiments in which the dependence of viscoelasticity on Ht was investigated. In these 
experiments, the Ht in bovine blood was adjusted to 20, 30, 40, 45 and 50%. Ovine and porcine 
blood viscoelasticity was measured at Ht values of 30, 45, 50 and 55% and 30, 40 and 50%, 
respectively. 
3.3.2.3 RBC deformability modification methods 
RBC deformability was altered using methods of fluid shear and heat exposure. The aim of these 
studies was to demonstrate, using common procedures applied for the modification of RBC 
deformability (heat treatment or cell modification by shearing blood), that measurements of 
changes in bovine blood viscoelasticity are detectable and that this method may have 
applicability in assessing changes in RBC deformability.  
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Heat exposure: 
Using a modified method of that previously described by Nash and Meiselman, RBC 
deformability was altered by heat exposure [98]. After adjustment to the standard Ht 
value of 46.2 ± 1.3% , bovine blood was placed in a plastic-walled conical centrifuge 
tube, immersed in a water bath at a temperature of 50°C for 30 minutes, after which the 
tubes were then removed and allowed to cool prior to measurement of viscoelasticity. 
Shear exposure: 
A Wells-Brookfield Cone/Plate viscometer (DVIII+, Middleboro, MA) with CPE-41 
cone (cone radius = 2.4 cm, cone angle = 3°) was used to expose a 2 ml bovine blood 
sample to a uniform mechanical shear stress of 2.3 Pa for 60 minutes at 25°C. Blood Ht 
was adjusted to 46.4±1.9%. Following shear exposure, samples were collected for 
viscoelasticity measurement. 
3.3.2.4 Measurement of viscoelasticity 
Whole blood viscoelasticity was determined using a Vilastic-3 Viscoelasticity Analyzer (Vilastic 
Scientific Inc., Austin, TX) with a stainless steel capillary measurement tube (0.0512 cm inner 
radius, 6.179 cm length) at a constant temperature of 25°C. The blood samples were exposed to 
sinusoidally oscillating flow at a fixed frequency of 2 Hz at logarithmically spaced shear strains 
ranging from 2 to 20. These strains were chosen to reflect the transition from disaggregation to 
deformability effects [62]. Due to the lack of aggregation in bovine and ovine blood [99], the 
viscoelasticity of bovine and ovine blood was not studied at shear strains less than 2. All blood 
samples were gently mixed for 5-10 seconds before being placed in the device’s sample cup (0.5 
ml) to allow for adequate mixing. The sample was then loaded in the capillary measurement tube 
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and the blood was allowed to equilibrate for 30 seconds before testing commenced. 
Measurements of viscoelasticity were also performed at various temperatures of 15, 20, 25, 30, 
35 and 45°C for investigation of the dependence of bovine blood (Ht=45.9±1.5%) viscoelasticity 
on temperature. Since the blood was exposed to a 45°C temperature for at most 2 min, we did 
not anticipate any detrimental effects of this relatively high temperature on RBC deformability. 
As mentioned above, an increase in both blood viscosity and elasticity without changes in Ht and 
plasma viscosity would signify a decrease in RBC deformability and vice versa. 
3.3.2.5 Data Analysis 
Results are expressed as the Mean ± standard error of the mean (SE). Any elasticity value which 
fell below 1/60th of the viscosity value at the same shear rate was disregarded as recommended 
by the device manufacturer as data which was outside the device’s acceptable range of error. 
Viscoelasticity measurements of blood subjected to thermal and shear exposure were normalized 
to the viscoelasticity of blood prior to exposure on the corresponding day the experiment was 
performed. A regression analysis for the data on the viscoelastic dependence on Ht and 
temperature in bovine blood was performed at strains of 2.4, 5.6 and 13.0 using Microsoft Excel 
XP (Microsoft Corp., Seattle, WA). Student’s un-paired t test was used to compare normalized 
blood data before and after heat and shear exposure. A p < 0.05 was considered to be statistically 
significant. 
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3.3.3 Results and Discussion 
3.3.3.1 Findings of microscopic observation 
Visual observation of bovine and ovine RBCs using a light microscope revealed cells with a 
normal biconcave shape and no presence of aggregation while porcine RBCs had a normal 
biconcave shape with the presence of cell aggregation. These are typical findings of blood from 
these species [99, 100]. 
3.3.3.2 Comparison of viscoelasticity of bovine, ovine and porcine blood at 30% hematocrit 
A comparison of the viscosity (Figure 3.5, top) and elasticity (Figure 3.5, bottom) of bovine 
(n=5), ovine (n=7) and porcine (n=5) blood samples at 30.2±0.4%, 29.7±0.5% and 29.6±0.2% Ht 
was performed at shear rates from 40 to 220 s-1. The percent decrease in viscosity between a 
shear rate of 40 and 160 s-1 was 2.9% for bovine blood, 4.5% for ovine blood, and 14.7% for 
porcine blood. The percent decrease in elasticity between these shear rates was 51.1% for bovine 
blood, 69.9% for ovine blood, and 77.9% for porcine blood. 
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Figure 3.5. Dependence of viscosity and elasticity of bovine, 
ovine and porcine on shear rate at 30% hematocrit 
 
Comparison of viscosity (top) and elasticity (bottom) of bovine 
(square, n=5), ovine (circle, n=7) and porcine (triangle, n=5) 
whole blood samples at 30% hematocrit at shear rates ranging 
from 40 to 220 s-1 
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3.3.3.3 Bovine blood viscoelasticity at multiple hematocrit values 
Viscosity and elasticity (Figure 3.6, top and bottom, respectively) measurements were 
performed at shear rates ranging from 30 to 220 s-1 using bovine blood at Ht values of 
20.2±0.3% (n=6), 30.2±0.4% (n=5), 41.2±0.5% (n=6), 46.2±0.4% (n=9) and 49.7±0.3% (n=7). 
The dependence of viscosity and elasticity on shear rate became more evident with increasing 
values of Ht with viscosity and elasticity being almost independent of shear rate at a Ht of 20% 
while at the highest Ht, 50%, bovine blood viscosity decreased 18.5% from 8.1±0.3 mPa⋅s at the 
lowest shear rate of 30 s-1 to 6.6±0.2 mPa⋅s at the highest shear rate of 220 s-1 and bovine blood 
elasticity decreased 80.0% from 0.5±0.02 mPa⋅s at 30 s-1 to 0.1±0.01 mPa⋅s at 220 s-1. 
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Figure 3.6. Effect of bovine blood hematocrit on the dependence 
of viscosity and elasticity on shear rate 
 
Viscosity (top) and elasticity (bottom) of bovine blood as a 
function of shear rate at hematocrit values of 20 (cross, n=6), 30 
(triangle, n=5), 40 (circle, n=6), 45(diamond, n=9), and 50% 
(square, n=7). 
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Equations obtained from a non-linear regression analysis of viscosity and elasticity 
values as functions of Ht at three shear strains (2.4, 5.6, and 13.0) which represent low, middle 
and high shear rate regions are shown in Table 3.1. These equations allow recalculating blood 
viscosity and elasticity of blood samples to a standard Ht and thus determining changes in these 
parameters which are not related the changes in the concentration of RBCs. 
 
Table 3.1: Equations for viscosity (η′) and elasticity (η") of bovine blood as functions of hematocrit at 
Strains of 2.4, 5.6 and 13 
 
Strain Viscosity and Elasticity (mPa•s) Correlation coefficient 
2.4 η′ = 1.67e3.1H R2 = 0.996 
 η" = 4.91 H3 – 0.189 H2 – 9.43E-2 H + 1E-3 R2 = 0.989 
5.6 η′ = 1.72e2.9H R2 = 0.999 
 η" = 1.36 H2 – 0.174 H + 9E-4 R2 = 0.998 
13 η′ = 1.75e2.7H R2 = 0.999 
 η" = 0.572 H2 – 0.067 H + 4E-4 R2 = 0.977 
H is hematocrit as a fraction 
3.3.3.4 Ovine blood viscoelasticity at multiple hematocrit values 
The dependence of viscosity and elasticity (Figure 3.7, top and bottom, respectively) on shear 
rate of ovine blood was compared at Ht values of 29.7±0.5% (n=5), 45.0±0.0% (n=4) and 
55.5±0.5% (n=3) at shear rates of 30 to 220 s-1. Ovine blood also demonstrated an increase in the 
dependency of viscosity and elasticity on shear rate with increasing Ht values.  At a Ht of 30%, 
viscosity and elasticity are almost independent of shear rate while at a Ht of 55%, ovine blood 
viscosity decreased 20.6% from 10.7±1.1 mPa⋅s at the lowest shear rate of 30 s-1 to 8.5±0.8 
mPa⋅s at the highest shear rate of 220 s-1 and ovine blood elasticity decreased 83.6% from 
1.22±0.3 mPa⋅s at 30 s-1 to 0.2±0.03 mPa⋅s at 220 s-1. 
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Figure 3.7: Effect of ovine blood hematocrit on the dependence 
of viscosity and elasticity on shear rate 
 
Viscosity (top) and elasticity (bottom) of ovine blood as a 
function of shear rate at hematocrit values of 30 (square, n=7), 45 
(circle, n=4) and 55% (triangle, n=3). 
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3.3.3.5 Comparison of viscoelasticity of bovine and porcine blood at ~50% hematocrit 
Viscosity (Figure 3.8, top) and elasticity (Figure 3.8, bottom) of bovine (n=7), ovine (n=4) and 
porcine (n=4) blood samples at 49.7±0.3%, 50.0±0.0% and 49.8±0.3% Ht, respectively, were 
compared at shear rates from 20 to 220 s-1. At this Ht, there is a more pronounced non-
Newtonian behavior in all blood samples. Bovine blood demonstrated a 14.0% decrease in 
viscosity between shear rates of 40 and 160 s-1, ovine blood exhibited a 13.6% decline and 
porcine blood exhibited a 34.0% decline. The percent change in elasticity at these shear rates was 
71.4% for bovine blood, 75.9% for ovine blood and 90.3% for porcine blood. 
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Figure 3.8. Dependence of viscosity and elasticity of bovine, 
ovine and porcine on shear rate at 50% hematocrit 
 
Comparison of viscosity (top) and elasticity (bottom) of bovine 
(square, n=7), ovine (circle, n=4) and porcine (triangle, n=4) 
whole blood samples at 50% hematocrit at shear rates ranging 
from 40 to 220 s-1. 
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3.3.3.6 Bovine blood viscoelasticity measured at multiple temperatures 
Viscosity (Figure 3.9, top) and elasticity (Figure 3.9, bottom) of bovine blood at Ht 45.9±0.5% 
were measured at temperatures of 15 (n=2), 20 (n=2), 25 (n=10), 30 (n=2), 35 (n=2), and 45°C 
(n=1) at shear rates ranging from 30 to 220 s-1. Figure 3.9 shows the dependence of viscosity 
(top) and elasticity (bottom) values on both shear rate and the temperature. At low shear rates 
(30 s-1), the viscosity of blood measured at 15°C was over 96% higher than the viscosity of blood 
measured at 45°C while the difference between elasticity values was about 79%. At high shear 
rates (220 s-1), the viscosity of blood measured at 15°C was 144% higher than the viscosity of 
blood measured at 45°C while elasticity was 350% higher which points to a significant increase 
in rigidity of RBCs with a decrease in temperature. 
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Figure 3.9. Effect of temperature on the dependence of 
viscosity and elasticity on shear rate 
 
Viscosity (top) and elasticity (bottom) of bovine blood as a 
function of shear rate at temperatures of 15 (square, n=2), 20 
(triangle, n=2), 25(empty circle, n=10), 30 (diamond, n=2), 35 
(cross, n=2) and 45° C (half-circle, n=1). 
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Equations obtained using a non-linear regression analysis of viscosity and elasticity as 
functions of temperature at three shear strains (2.3, 5.5, and 13.0) are presented in Table 3.2. 
Both blood viscosity and elasticity are dependent on temperature, therefore these equations may 
be used to recalculate these parameters based on a standard temperature and will allow 
determination of differences in these parameters unrelated to temperature. 
 
Table 3.2. Equations for viscosity (η′) and elasticity (η") of bovine blood as functions of temperature at Strains of 
2.3, 5.5 and 13 
 
Strain Viscosity and Elasticity (mPa•s) Correlation coefficient 
2.3 η′ = 53.18 T-0.624 R2 = 0.991 
 η" = 2.38 T-0.538 R2 = 0.851 
5.5 η′ = 56.94 T-0.675 R2 = 0.990 
 η" = 1.03 T-0.530 R2 = 0.753 
13 η′ = 65.23 T-0.752 R2 = 0.976 
 η" = 0.926 T-0.815 R2 = 0.753 
T is blood temperature in Centigrade 
 
3.3.3.7 Bovine blood viscoelastic shear rate dependence following heat and shear-induced 
damage 
The viscoelastic properties of bovine blood with Ht (45.9±0.5%) were evaluated before and after 
exposure to heat and shear stress. The results of the viscosity and elasticity of blood samples 
after exposure to thermal (n=7) and mechanical stress (n=5) were normalized to the viscosity and 
elasticity of blood before exposure (Figure 3.10, top and bottom, respectively). After heat 
exposure, the average increase in blood viscosity was 11.7±0.4% and the average increase in 
blood elasticity was 47.7±10.9% from baseline. The increase in viscosity was statistically 
significant at shear rates of 70 to 220 sec-1 (p<0.05) and the increase in elasticity was statistically 
significant at shear rates of 50 to 160 sec-1 (p<0.05). In blood exposed to mechanical stress, the 
 53 
average increases in the viscosity and elasticity were 4.9±0.4% and 6.6±2.8%, respectively. The 
viscosity increase observed in the sheared blood was statistically significant at shear rates of 50 
to 220 sec-1. The sheared blood elasticity was statistically significantly higher at shear rates of 90 
to 120 sec-1. Figure 3.11 (top) shows an example of the typical dependence of viscosity on shear 
rate of blood with Ht 47.5% before and after exposure to thermal and mechanical stress. In this 
experiment, the viscosity and elasticity of blood after shear exposure increased 4.6±0.3% and 
10.0±2.0% respectively. After heat exposure, the average increase in viscosity and elasticity of 
this blood was 26.6±0.8% and 54.9±8.3%, respectively. Figure 3.11 (bottom) shows the 
changes in blood elasticity at the highest shear rates. 
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Figure 3.10. Viscosity and elasticity of bovine blood after heat 
and shear exposure normalized to control 
 
Viscosity (top) and elasticity (bottom) of bovine blood 
normalized to the viscosity and elasticity of blood prior to 
exposure to heat (circles, n=7) and mechanical stress (squares, 
n=5) on the day the experiment was performed. 
 
 55 
 
Figure 3.11. Effect of heat and shear exposure on the viscosity 
and elasticity of bovine blood 
 
The viscosity (top) and elasticity (bottom) of bovine blood 
before (triangle (top), white bar (bottom)) and after exposure to 
heat at 50°C for 30 minutes (circle (top), gray bar (bottom)) and 
after exposure to a 2.3 Pa shear stress for 60 minutes (square 
(top), black bar (bottom)). Since the difference in the elasticity 
values is an order of 10, this parameter is shown at two the 
highest applied shear rates to clarify the dissimilarity in elasticity 
values before and after exposure. 
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3.3.4 Discussion 
In these studies we tested whether measurements of viscoelasticity of animal blood would 
provide a sensitive standard method of evaluation of changes in RBC deformability. The ultimate 
goal was to use this technique to examine the hypothesis that the intravascular action of DRPs is 
directly related to an effect on RBC deformability. The use of this technique was based on the 
fact that both viscosity and elasticity of blood significantly depend on RBC deformability. The 
deformability of erythrocytes was previously shown to be impaired in many pathological states. 
Therefore, measurements of blood viscoelasticity could provide quantitative and fast assessment 
of RBC deformability status. 
Previous studies have investigated and reviewed the effects of hematocrit, temperature, 
plasma proteins and shear rate on the viscosity [45-48, 51, 59, 61, 100-108] and viscoelasticity 
[53, 62, 98, 104, 109-120] of human adult and pediatric blood as well as that of several other 
mammalian species including some of those studied herein. These studies demonstrated a 
varying degree of non-linear dependence of both blood viscosity and elasticity on hematocrit, 
temperature, plasma protein concentration and shear rate in all species studied. Conventional 
rheometers (rotational cone/plate and Couette) provided most of the initial data on the effects of 
temperature, shear rate, hematocrit and level of plasma proteins on human adult blood viscosity. 
These classical studies are typically assembled in comprehensive reviews such as one on normal 
and pathological human and animal blood viscosity and RBC aggregation and deformability 
[59]. Blood viscoelasticity as a function of shear rate was first presented by Thurston in 1972 
using oscillatory flow at a known frequency in a cylindrical tube [53]. Measurements of flow rate 
and pressure throughout the cycle allowed calculation of shear rate and shear stress. Since shear 
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stress and shear rate are out-of-phase in viscoelastic fluids such as blood, a complex viscosity 
can be written as: η = η′ - iη″ where η′ is viscosity and η″ is elasticity. In a subsequent work, the 
non-linear dependence of viscoelasticity on hematocrit was studied and a set of equations 
allowing for recalculation of measured viscoelasticity values to a standard hematocrit were 
developed for human blood [112]. Long et al. [120] have recently demonstrated the strong 
dependence of pediatric blood viscoelasticity on hematocrit and found that no correlation existed 
between patient age and blood viscoelasticity. Most importantly, no statistically significant 
difference was found between pediatric and adult blood viscosity. A set of viscoelasticity 
equations was also developed to predict the viscosity and elasticity of pediatric blood given a 
known hematocrit. In a study of other mammalian species, differences in the viscoelasticity of 
bovine, ovine and porcine blood have been found but were attributed to a lack of standardization 
of hematocrit between species [118]. However, this study did demonstrate the overall 
dependence of these species blood viscoelasticity on shear rate. This work compared viscoelastic 
properties of bovine, ovine and porcine blood obtained from healthy animals. Blood from these 
species is readily obtainable in large quantities making them useful for investigating the 
hypothesis on the DRP effect on RBC deformability. More importantly, although many studies 
look at the applicability of using DRPs for the treatment of pathologies in rats, pre-clinical 
studies for these uses would most likely be conducted in large animal models such as those 
studied here, i.e. porcine. Therefore, rheological characterization of the blood of these species 
with and without DRPs would play an important role in understanding the mechanisms of the 
intravascular action of DRPs in these species. 
Porcine blood was included in our studies since this blood better simulates human blood 
due to the ability of porcine RBCs to aggregate and their larger size compared to those of bovine 
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and ovine blood. This study tested the effect of hematocrit, temperature and heat and shear stress 
exposure on the viscoelasticity of bovine blood. The latter study demonstrated a statistically 
significant increase in both viscosity and elasticity in blood after exposure to both mechanical 
and thermal stresses. Even after exposure of blood to a very low shear stress (2.3 Pa) over 60 
min, some changes in RBC deformability, which caused a measurable increase in whole blood 
viscosity and elasticity, were observed. Therefore, these results confirm that at relatively high 
levels of hematocrit (~46-47%), bovine blood can provide sensitive measurements of changes in 
deformability.  
The comparative study of blood from three species revealed that at relatively low Ht 
(30%) both bovine and ovine blood demonstrated an almost Newtonian behavior with little 
change in viscosity and elasticity over a wide shear rate range (Figure 3.5 top and bottom). A 
30% Ht was chosen for analysis because it represents the standard physiological hematocrit 
value for these species [100]. As anticipated, due to the lack of RBC aggregation, bovine and 
ovine blood viscoelasticity is almost independent of shear rate. Therefore, it seems that 
measurements of changes in blood viscoelasticity at low Ht values are not practical for 
evaluation of changes in RBC deformability using bovine or ovine blood. However, even a 
moderate increase in Ht makes these measurements meaningful and applicable by demonstrating 
a pronounced dependence of both viscosity and elasticity on shear rate (Figure 3.6 and Figure 
3.7). In general, a very significant transition from almost Newtonian to a pronounced non-
Newtonian rheological behavior due to an increase in blood Ht was shown in bovine and ovine 
blood. Porcine blood, however, exhibited non-Newtonian flow behavior even at low Ht values of 
29-30% making blood from this species more appropriate for the testing of changes in RBC 
deformability. Obviously, this difference in rheological behavior between bovine, ovine and 
 59 
porcine blood is mostly related to the ability of porcine RBCs to aggregate and to the larger 
porcine RBC diameter (~7 μm) compared to bovine (~5.5 μm) or ovine (4.5 μm) RBCs. These 
differences result in porcine blood producing a significant increase in the magnitude of change 
between low and high shear rate viscosity and elasticity compared to that in bovine and ovine 
blood as seen in Figure 3.5. Brookshier and Tarbell previously demonstrated that porcine blood 
viscoelasticity was quite similar to that of human blood at a broad range of shear rates (1-1000 s-
1) and Ht values (20%-80%) [121]. Despite these advantages, bovine blood tended to be more 
readily available and was used more extensively in the rheological studies performed in this 
dissertation. Based on the studies in this section, the samples of bovine blood collected for use in 
viscoelasticity studies were adjusted to a standard Ht of 40% or higher. 
Another benefit of using the Vilastic-3 viscoelastometer used in these studies is the very 
small sample volume required for the measurement of viscoelasticity; an important factor when 
working with blood samples from rats. These tests require at most 0.7 ml of blood (0.05 ml for 
hematocrit, 0.5 ml for the test sample, and about a 0.2 ml loss to the walls of sample tube and 
transfer pipette). 
Therefore, assessment of changes in RBC deformability by measurement of blood 
viscoelasticity would be possible using this technique. 
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3.4 IN VITRO DRP EFFECT ON THE VISCOELASTICITY OF WHOLE BLOOD OF 
NORMAL AND DIABETIC ANIMALS 
3.4.1 Introduction 
In Section 3.3, experiments were performed which confirmed the ability of using measurements 
of viscoelasticity of animal blood as a sensitive standard method of evaluation of changes in 
RBC deformability. This evaluation was based on the fact that both viscosity and elasticity of 
blood significantly depend on RBC deformability. 
Diabetes mellitus has been associated with several hemorheological abnormalities. 
Rheological studies of blood from patients with diabetes have shown increased blood viscosity 
[54, 55] and reduced RBC deformability [56-58]. Since RBCs are roughly 8 μm in diameter and 
the smallest capillaries are ~3-5 μm, the cells must deform a substantial amount to be able to 
pass throughout the microcirculation. Consequently, a small reduction in RBC deformability can 
significantly compromise the number of functioning capillaries and hence oxygen delivery, 
extraction of products of metabolism from the tissue, etc. Diamantopoulos et al reported that the 
deformability of rat RBCs was significantly impaired in a streptozotocin (STZ)-induced 
experimental model of diabetes and preceded the manifestation of diabetic microangiopathy 
[122]. Golub et al. demonstrated that the intravenous injection of DRPs into rats with alloxan-
diabetes increased the number of functioning capillaries to an order close to that of normal 
animals [17]. It is possible that this phenomenon occurred through the enhancement of RBC 
deformability. The results of Section 3.2 suggested that the addition of DRPs to normal and 
glutaraldehyde-treated RBC suspensions enhanced their filterability from which it may be 
inferred that the deformability of RBCs was increased. Using measurements of viscoelasticity, 
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studies were performed to evaluate the hypothesis that the presence of DRPs in diabetic whole 
blood samples would demonstrate enhanced deformability. This work is presented in this section. 
3.4.2 Methods 
These experiments were completed in two stages. The first stage was the development and 
maintenance of a rat model of experimental diabetes. The second stage involved the collection of 
blood samples from the animals with subsequent measurement of their viscoelasticity with and 
without the addition of DRPs. 
3.4.2.1 Animal Care Compliance 
The surgical procedures and animal treatments performed in this study were approved by the 
Institutional Animal Care and Use Committee of the University of Pittsburgh (protocols 
#0408443, #0108461). All animal care and procedures conformed to the National Institutes of 
Health Guidelines for the Care and Use of Laboratory Animals. 
3.4.2.2 Animals 
Male Sprague-Dawley rats (250-300 g, SASCO; Charles River Laboratories, Wilmington, MA) 
were housed in solid bottom micro-isolator containers and fed rat chow and water ad libitum 
except during fasting periods, 2 hours prior to blood glucose measurements. The animals were 
allowed a 6-day acclimatization period after delivery before experimental procedures 
commenced. Animals were housed in plastic animal containers under constant conditions of 
temperature and light cycling (12 h light-12 h darkness). Bedding was changed daily in order to 
keep the animals clean and dry. 
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3.4.2.3 Development and care of a rodent model of diabetes. 
Baseline measurements of blood glucose concentration and weight were attained. Subsequently, 
experimental diabetes mellitus was induced through an intraperitoneal injection of streptozotocin 
(STZ; 65 mg/kg, freshly dissolved in 0.1 M citrate buffer, pH 4.5) after an ~18 hour fasting 
period and confirmed by sustained blood glucose levels of 300 mg/dl (16.7 mM) or greater. The 
age and weight-matched control group received the citrate buffer only. The injectant was 
sterilized via filter sterilization using a 0.22 μm syringe filter (Millipore). 
Blood glucose levels were monitored twice weekly using a OneTouch® FastTake® 
glucometer (LifeScan, Milpitas, CA) from blood (10 μl) obtained by pricking the tip of the tail 
with a fine point lancet. Blood glucose measurements were timed so that they occurred several 
hours after the start of the 12 hour light cycle. Insulin (3-5 IU/day; Humulin® U; Eli Lilly, 
Indianapolis, IN) treatment was initiated ~4 weeks after STZ administration and continued 
throughout the study to reduce mortality and the potential of the animal’s developing 
ketoacidosis. This dose was not enough to normalize blood glucose levels. Body weight was 
measured several times per week to monitor the health of the animals. 
3.4.2.4 Blood collection and sample preparation. 
Approximately 4-8 weeks after STZ administration (buffer in control), blood was collected from 
ten diabetic animals and ten normal animals (non-diabetic) based on the methods described in 
Section 3.2.2.2. The whole blood hematocrit was measured and adjusted to a standard level of 
~40% as previously described in Section 3.3.2.2. The blood samples were then aliquoted into 
three equal volumes and either PEO-4500 (2.5 mg/ml (0.56 μM)), PMNN (2.5 mg/ml (0.42 μM)) 
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or saline (control) was added in equal volumes to an aliquots to yield final concentrations of 10 
μg/ml (1.7 – 2.2 nM) of the DRP. 
3.4.2.5 Measurement of viscoelasticity. 
Viscoelasticity was measured according to the protocol outlined in Section 3.3.2.4 at shear rates 
ranging from 20-180 s-1 at 24°C. 
3.4.2.6 Statistical methods 
Results are expressed as the mean ± SD. A repeated measures two-way ANOVA with 
Bonferroni post hoc test was used to compare the viscosity and elasticity of whole blood of 
diabetic animals to that of normal animals at each shear rate. The same statistical test was also 
used to compare the viscosity and elasticity of whole blood of diabetic and normal animals 
before and after the addition of DRPs. A p < 0.05 was considered to be statistically significant. 
3.4.3 Results and Discussion 
3.4.3.1 Outcomes of development of experimental diabetes in rodents 
The development of experimental diabetes was without adverse events. Two days after animals 
were injected with STZ, blood glucose levels increased to above 300 mg/dl (16.7 mM) and 
remained at this level until blood was taken and the animals were sacrificed. The animals 
exhibited the polyuria, polydipsia and polyphagia commonly associated with diabetes mellitus. 
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3.4.3.2 Results of viscoelasticity measurements 
Whole blood was collected from diabetic (n = 10) and non-diabetic (normal; n = 10) rats after a 
minimum of 4 weeks of diabetes. It has been previously reported that reductions in RBC 
deformability are seen in as little as 5 days after diabetes inception and that this reduction 
reaches its lowest value by 15 days [122]. In this study, the viscoelasticity of diabetic and non-
diabetic rat blood was measured with and without the addition of DRPs. Both the viscosity and 
elasticity of the whole blood of diabetic rats was found to be higher than that of non-diabetic rats 
signifying a decrease in RBC deformability (Figure 3.12). Although no statistical significance 
was found, the viscosity and elasticity of the diabetic rat blood was roughly 20.2 ± 3.0% and 
43.4 ± 9.0%, respectively, higher than that of non-diabetic rat blood over a shear rate range of 20 
to 180 s-1. 
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Figure 3.12: Viscosity and elasticity shear rate dependence of diabetic and non-diabetic rat whole 
blood 
 
The viscosity (open circles) and elasticity (gray circles) of the diabetic rat blood were roughly 
20.2 ± 3.0% and 43.4 ± 9.0%, respectively, higher than viscosity (open squares) and elasticity 
(gray squares) of non-diabetic rat blood over a shear rate range of 20 to 180 s-1 signifying a 
decrease in RBC deformability. 
 
 
The addition of PEO and PMNN to the diabetic whole blood samples, which showed a moderate 
increase in viscosity compared to that of the control, resulted in a slight decrease in viscosity. 
The viscosity of the blood samples at three different shear rates (50, 100 and 150 s-1) is shown 
in Figure 3.13. This suggests that the deformability of the diabetic RBCs was reduced after 
polymer addition. No noticeable difference was observed in the viscosity of the blood of normal 
animals after the addition of the two DRPs or in the elasticity of the blood of both the diabetic 
and normal animals after polymer addition. The absence of measurable DRP effects on the 
viscosity of normal animals and the elasticity of both diabetic and normal animals is most likely 
related to the sensitivity of the measurements of the bulk viscosity and elasticity in the whole 
blood. Additionally, it may also be possible that the effects of DRPs on viscosity and elasticity of 
 66 
blood in normal and diabetic rats were undeterminable due to artifacts of exposure of rat RBCs 
to in vitro conditions. Rat RBCs are extremely sensitive to their environment. It is well known 
that the collection of rat blood into sample vials such as Vacutainer® tubes (BD) can result in 
RBC crenation and undoubtedly introduces error into viscoelasticity measurements. Finally, it is 
possible that DRPs do not directly affect RBC deformability and all the changes which we have 
observed (filtration, etc.), were related to their effect on the RBC flow environment. Studies with 
measurements of single cell deformation using ektacytometry will possibly help to elucidate 
whether DRPs directly affect RBC deformability. 
 
Figure 3.13: Viscosity of whole blood of diabetic 
animals after the in vitro addition of two DRPs 
 
A decrease in blood viscosity is attributed to an increase in the deformability of RBCs after the 
addition of DRPs to blood. Further studies are necessary to completely understand the beneficial 
effects of DRPs on RBC flow through capillaries. These results suggest that DRPs may be 
beneficial in enhancing the deformability of RBCs which has been shown previously to be 
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markedly decreased in diabetes mellitus. The results of these experiments are significant because 
the increased blood viscosity, decreased capillary perfusion, and reduced RBC lifespan due to 
increased splenic sequestration and the pathogenesis of microangiopathy associated with diabetes 
mellitus may be attributed to impaired RBC deformability. Several therapies have been 
investigated for the treatment of decreased RBC deformability such as the use of Pentoxifylline 
(Trental®) [123-125]. However, still no effective standardized treatment exists. Direct 
management of the clinical conditions causing the reduction in RBC deformability remains to be 
the effective treatment/prevention. These results suggest that drag-reducing polymers may 
represent a novel treatment for impaired RBC deformability and the conditions to which it’s 
attributed. 
3.5 IN-VITRO EFFECT OF D- AND L-GLUCOSE ON BLOOD VISCOELASTICITY 
BEFORE AND AFTER THE ADDITION OF DRPS 
3.5.1 Introduction 
In Sections 3.2 and 3.4, we demonstrated that DRPs had the ability to increase RBC filterability 
and decrease whole blood viscosity, respectively. These results support the hypothesis that the 
intravascular DRP phenomena are related to a direct effect of DRPs on RBC deformability. The 
objective of this study was to mimic the reported in-vivo reduction in RBC deformability that has 
been observed in the blood of diabetic patients and which was shown in the studies of 
Section 3.4, in-vitro, by incubating RBC suspensions with varying concentrations of D-glucose 
and examining the effect of DRP additives on the viscoelasticity of these RBC suspensions. D-
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glucose represents a naturally occurring enantiomer of glucose which is used in all cells as 
energy and a metabolic intermediate. However, during hyperglycemia when high levels of D-
glucose are present in the blood, increased non-enzymatic glycosylation of the RBC membranes 
and intracellular hemoglobin can occur affecting the deformability of the cell and 
physicochemical properties of the hemoglobin. In turn, this can lead to reduced RBC 
deformability and increased blood viscosity and elasticity. 
3.5.2 Methods 
3.5.2.1 Blood collection 
Rat (n = 2) and bovine (n = 14) blood samples were collected based on the methods described in 
Sections 3.2.2.2 and 3.3.2.1, respectively. Additionally, human blood samples (n = 2) were 
collected. The first sample was banked blood obtained from a volunteer donor that had been 
collected in ACD (Gambro BCT). IRB approval was not required since informed consent for the 
use of the blood was obtained at the time of collection. The second sample was drawn from a 
healthy adult blood donor into glass K3EDTA Vacutainer® tubes (BD). The rat blood samples 
and the first human sample were only used to test the effect of increasing D-glucose 
concentration on hematocrit. The bovine blood samples and the second human blood sample 
were used to test the effect of increasing D-glucose concentration on hematocrit and on the 
viscoelasticity of the samples. 
3.5.2.2 Blood sample preparation 
Bovine blood was centrifuged at 500 x g for 15 minutes after which the plasma and buffy coat 
were removed. RBCs were then washed two times with PBS with further removal of any residual 
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buffy coat. RBCs were then resuspended in PBS at a hematocrit of 49 ± 3% (n = 14). It was 
found in Section 3.3.3.3 that measurements of viscoelasticity of bovine blood were more 
meaningful at higher hematocrit values due to its small RBC diameter and lack of aggregation. 
The hematocrit of rat and human whole blood samples was not adjusted. A more detailed 
explanation for the adjustment and standardization of blood hematocrit is given in 
Section 3.3.2.2. 
Stock solutions of 16 g/dl (0.8 M) D- and L-glucose (Sigma Aldrich) in PBS were 
prepared and added to the bovine RBC suspensions and to rat and human whole blood to yield 
final D- and L-glucose concentrations of 200 (11 mM), 400 (22 mM), and 800 mg/dl (44 mM) 
(saline in control – 0 mg/dl) and incubated at 25 °C for 1 hour. The effect of incubation time and 
temperature was also investigated with one of the bovine RBC suspension samples. In this 
experiment, the RBC suspension was incubated for 0, 1 and 24 hours and at incubation 
temperatures of 4, 25 and 37°C. After the selected time point, the hematocrit of the samples was 
measured. Osmolality of the suspension media or plasma was obtained by centrifuging the 
samples at 20,000 x g (5417R: Eppendorf, Westbury, NY), removing the supernatant and then 
measuring the osmolality by freezing-point depression (Osmette micro-osmometer, Precision 
Systems, Inc., Natick, Massachusetts, USA). Changes in hematocrit (up – cell swelling, down – 
cell shrinkage) were used to determine if D-glucose was entering the cells since facilitated 
diffusion of D-glucose should give way to an iso-osmotic condition. The RBC deformability in a 
sample of the human whole blood that was used for viscoelasticity measurements was altered by 
heat exposure using the methods described in Section 3.3.2.3. However, in this experiment the 
time of heat exposure was 3 minutes. 
 70 
3.5.2.3 Measurement of viscoelasticity and viscosity. 
After a 1 hour incubation of the bovine RBC suspensions (n = 4) and one of the human whole 
samples with D-glucose at ~25°C, the samples’ viscoelasticity was measured according to the 
protocol outlined in Section 3.3.2.4. An increase in both blood viscosity and elasticity without 
changes in Ht and plasma viscosity would signify a decrease in RBC deformability and vice 
versa. After viscoelasticity measurements were performed, the hematocrit and suspension media 
or plasma osmolality were measured. 
3.5.2.4 Statistical methods 
Results are expressed as the mean ± SD except for the results on the effect of D-glucose 
concentration on bovine blood hematocrit and suspension media osmolality in which case they 
are expressed as mean ± SEM. A repeated measures two-way ANOVA with Bonferroni post hoc 
test was used to compare the viscosity and elasticity of bovine RBC suspensions with D-glucose 
to samples without D-glucose. The same statistical test was also used to compare the change in 
the hematocrit of human, rat, and bovine blood after the addition of D-glucose. A repeated 
measures one-way ANOVA with Tukey post hoc test was used to compare the change in the 
bovine RBC suspensions hematocrit before and after the addition of D-glucose as well as the 
change in the osmolality of the suspension media. A p < 0.05 was considered to be statistically 
significant. 
3.5.3 Results and Discussion 
In Sections 3.2 and 3.4, DRPs were demonstrated to have the ability to increase RBC filterability 
and decrease whole blood viscosity, respectively. It was suggested that the intravascular DRP 
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phenomena was related to a DRP effect on RBC deformability. These experiments were intended 
to emulate, in-vitro, the previously reported alterations in RBC deformability of blood of diabetic 
patients and that which was demonstrated in rat blood in Section 3.4, by incubating RBC 
suspensions with varying concentrations of D-glucose. Secondly, they were intended to study the 
effect of DRP additives on the viscoelasticity of these less deformable RBC preparations. 
The effect of D-glucose concentration on the viscoelasticity and viscosity of bovine RBC 
suspensions (Ht = 51 ± 1%) was measured with a Vilastic-3 viscoelastometer and Wells-
Brookfield Cone/Plate rheometer, respectively. The viscosities of the RBC suspensions (n = 4) 
with (200 (11 mM), 400 (22 mM) and 800 mg/dl (44 mM)) and without (0 mg/dl) D-glucose, 
measured with the viscoelastometer, are shown in Figure 3.14 (A). At shear rates ranging from 
70-285 s-1, the viscosity of the bovine RBC suspensions was statistically significantly higher 
after increasing the D-glucose concentration to 400 mg/dl (22 mM) (p < 0.05 at 70 s-1; p < 0.01 
from 90-285 s-1; vs. 0 mg/dl). Increasing the D-glucose concentration to 800 mg/dl (44 mM) lead 
to a further statistically significant increase in viscosity of the suspensions at shear rates ranging 
from 40-380 s-1 (p < 0.001; vs. 0 mg/dl). A slight increase in the viscosity of the RBC 
suspensions was observed at a D-glucose concentration of 200 mg/dl (11 mM). A comparable 
increase in the viscosity, after the addition of D-glucose at concentrations of 400 (22 mM) and 
800 mg/dl (44 mM) to the RBC suspensions, was obtained from the rotational cone/plate 
viscometer Figure 3.14(C). These results were obtained from a single sample that was used in 
the viscoelasticity measurements. The slightly higher viscosities acquired from the cone/plate 
viscometer are due to the fundamental differences between steady flow and oscillatory flow 
viscosity measurements. In oscillatory flow, minimal microstructural changes occur at the very 
small strains required to invoke a blood response. In steady flow, the blood’s structure is 
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modified from its resting state due to a continuously increasing strain that increases the relative 
displacement of neighboring cell groups [64]. No discernible difference was observed in the 
elasticity of the RBC suspensions after the addition of 200 (22 mM) and 400 mg/dl (44 mM) D-
glucose. However, after the addition of 800 mg/dl (44 mM) D-glucose, a statistically significant 
increase in elasticity was detected at shear rates ranging from 40 to 120 s-1 (p < 0.001 from 40-50 
s-1; p < 0.01 from 70-90 s-1; p < 0.05 at 120 s-1; vs. 0 mg/dl) (Figure 3.14 (B)). The viscosity of 
the 800 mg/dl (44 mM) D-glucose incubated sample was on average, over shear rates from 40-
375 s-1, 12.0 ± 2.3% higher than that of the normal blood sample (0 mg/dl D-glucose). As 
mentioned above, an increase in both blood viscosity and elasticity without changes in Ht and 
plasma viscosity would signify a decrease in RBC deformability and vice versa. Therefore, the 
results on the increase in the viscosity and elasticity presented in this study may be indicative of 
a decrease in deformability of the RBCs. 
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Figure 3.14: Effect of D-glucose concentration on the viscosity and elasticity of bovine RBC 
suspensions 
 
The effect of D-glucose concentration (0-800 mg/dl (0-44 mM)) on the rigidity of bovine RBCs 
suspended in PBS (Ht = 51 ± 1%) was determined by measuring the viscosity (A) and elasticity 
(B) of bovine RBC suspensions containing D-glucose at concentrations of 0 (n = 4), 200 (11 
mM) (n = 4), 400 (22 mM) (n = 4) and 800 mg/dl (44 mM) (n = 4) at shear rates ranging from 
~40 to 375 s-1 with a Vilastic-3 viscoelasticity analyzer. This effect was also examined by 
measuring the viscosity (C) of a bovine blood sample at shear rates ranging ~40 to 400 s-1 with a 
Wells-Brookfield Cone/Plate rheometer. Results in A and B are presented as mean ± SEM. The 
results in C were obtained from a single blood preparation that was used in the experiments 
from A and B. 
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The effect of increasing D-glucose concentration on the viscoelasticity and viscosity of 
human whole blood (Ht = 42%) was also measured. The viscosity and elasticity of the human 
whole blood with (200 (11 mM), 400 (22 mM) and 800 mg/dl (44 mM) and without D-glucose 
(0 mg/dl), measured with a Vilastic-3 viscoelastometer, is shown in Figure 3.15 (A) and (B). 
The addition of D-glucose appeared to have little effect on the deformability of human RBCs as 
evidenced by the lack of an increase in viscosity and elasticity of the sample. The observations 
made with the cone/plate rheometer also demonstrated a lack of increase in viscosity. A sample 
of this blood was heated to 50 °C for several minutes; a process shown to reduce the 
deformability of bovine RBCs in Section 3.3.3.7. The result of the heat hardening process on the 
RBCs deformability is evident in Figure 3.15 (A) and (C) where the viscosity of the heated 
sample is moderately higher than those samples with and without D-glucose. The viscosity of the 
heated blood sample was on average, over shear rates from 10-375 s-1, 6.5 ± 1.2% higher than 
the normal blood sample (0 mg/dl D-glucose) and 5.2 ± 1% higher than the blood sample 
containing 800 mg/dl (44 mM) D-glucose. It is apparent that the deformability of the human 
RBCs was reduced after the heat hardening procedure based on the viscosity measurements. It is 
not completely clear why a change in the elasticity was not observed. However, it may possible 
that the decrease in RBC deformability was small enough that a change was not observable due 
to the accuracy of the measurements. The alteration of bovine RBC deformability by heat 
exposure was shown in Section 3.3.3.7 to increase the viscosity and elasticity of the RBC 
suspensions by approximately 12% and between 20 and 100%, respectively. However, those 
RBC suspensions were heated for 30 minutes instead of the 3 minutes used in the protocol for 
the human whole blood. Therefore, the moderate decrease in human RBC deformability was 
caused by a lesser effect of the heat exposure process on the RBC membrane proteins. 
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Figure 3.15: Effect of D-glucose concentration and heat rigidification on the viscosity and 
elasticity of human whole blood 
 
The effect of D-glucose concentration (0-800 mg/dl (0-44 mM)) and heat on the rigidity of human 
RBCs was determined by measuring the viscosity (A) and elasticity (B) of a human whole blood 
samples (hematocrit = 42%) containing multiple D-glucose concentrations (0, 200 (11 mM), 400 
(22 mM) and 800 mg/dl (44 mM)) at shear rates ranging from ~10 to 375 s-1 with a Vilastic-3 
viscoelasticity analyzer. This effect was also examined by measuring the viscosities (C) of the same 
samples at shear rates ranging ~25 to 450 s-1 with a Wells-Brookfield Cone/Plate rheometer. 
Results obtained from single sample. 
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It was interesting that the addition of D-glucose to bovine blood RBC suspensions 
produced a decrease in RBC deformability but when the same concentrations were added to the 
human RBCs and incubated at the same temperatures and time periods, the deformability did not 
change. Hence, these results agree with previous reports that have shown that the rheological 
properties of human blood were not altered by short-term in vitro hyperglycemia [126]. 
RBCs in hypertonic solutions are known to shrink which causes a decrease in RBC 
deformability [127]. The addition of D-glucose raises solution osmolality leading to RBC 
shrinkage and a reduction in cell volume, i.e. reduction in the centrifuged hematocrit. However, 
D-glucose represents a naturally occurring enantiomer of glucose which can rapidly pass through 
the mammalian RBC membrane via facilitated diffusion by the erythrocytic glucose transporter 
GLUT-1 resulting in an iso-osmotic condition in and outside of the cell [128]. Therefore, 
hematocrit should remain unchanged. 
Studies were performed to investigate whether the addition of D-glucose would result in 
an osmotically active condition in bovine, human and rat blood. The effects of D-glucose 
concentration on bovine blood hematocrit (n = 14) and suspension media osmolality (n = 8) are 
shown as a percent change from the 0 mg/dl condition in Figure 3.16. The addition of 200 (11 
mM), 400 (22 mM) and 800 mg/dl (44 mM) D-glucose to the suspension media resulted in 
statistically significant (p < 0.001 vs. 0 mg/dl) increases in osmolality of 4.5 ± 0.6, 8.7 ± 0.6 and 
16.7 ± 0.6%, respectively. Each consecutive increase in solution osmolality resulted in a 
statistically significant (p < 0.001 vs. 0 mg/dl) decrease in the hematocrit of the RBC 
suspensions. The addition of 200 (11 mM), 400 (22 mM) and 800 mg/dl (44 mM) D-glucose to 
the suspension media resulted in decreases in hematocrit of 2.3 ± 0.2, 4.8 ± 0.4 and 8.4 ± 0.7%, 
respectively indicating a lack of D-glucose transmembrane transport and an osmotically active 
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state. The effect of D-glucose concentration on bovine (n = 14), human (n = 2) and rat (n = 2) 
blood hematocrit was then compared and is shown in Figure 3.17. The rat whole blood 
demonstrated the same tendency as the bovine RBCs in suspension. The addition of 400 (22 
mM) and 800 mg/dl (44 mM) D-glucose to the rat whole blood resulted in statistically significant 
(p < 0.05) decreases in hematocrit of 5.3 ± 1.2 and 8.3 ± 1.2%, respectively. The addition of 200 
mg/dl (11 mM) D-glucose resulted in a moderate 3.0 ± 1.0% decrease in hematocrit. The osmotic 
effects of D-glucose on rat blood compared very closely with those on bovine blood. However, 
when examining the effect of D-glucose on human blood, there was no significant effect present. 
In fact, at a concentration of 200 (11 mM) and 400 mg/dl (22 mM) D-glucose, no change in 
hematocrit was observed. The 0.7 ± 0.9% decrease that occurred at 800 mg/dl (44 mM) was the 
result of a 0.5% decrease in the actual hematocrit value. Bühler et al. previously reported that the 
addition of D-glucose at concentrations upwards of 1440 mg/dl (80 mM) had no effect on the 
hematocrit of human blood and was attributed to the osmotically inactive state that is produced 
by the facilitated diffusion of glucose [126]. Therefore, it is very unlikely that the slight decrease 
observed in the 800 mg/dl (44 mM) sample was due to hyperosmolality of the plasma. The slight 
reduction may be simply attributed to an error in reading of the hematocrit. 
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Figure 3.16: Percent change in the hematocrit bovine RBC suspensions and in 
the osmolality of suspension media 
 
Effect of D-glucose concentration on bovine blood hematocrit (circles; n = 14) 
and plasma osmolality (squares; n = 8). Results are presented as mean ± SEM. 
 
 
 
Figure 3.17: Percent change in hematocrit of bovine, human and rat blood after 
the addition of D-glucose 
 
Effect of D-glucose concentration on the hematocrit of bovine (n = 14), human 
(n = 2) and rat blood (n = 2). Results are presented as mean ± SD. 
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The feeding habits of mammalian species can vary greatly and so can the regulatory 
mechanism of glucose utilization. Herbivorous cattle have lower blood glucose concentrations 
than omnivorous animals such as dogs. The D-glucose transport activities in erythrocytes of 
canines were reported to be similar to the values of those found in humans or rats [129]. This 
same study also demonstrated that the D-glucose transport in bovine blood was approximately 
one-third of that shown in canine blood. Therefore, a study was performed to examine whether 
incubation time (0, 1 and 24 hours) had a role in the osmotically inactive state of bovine blood. A 
study on the effect of incubation temperature (4, 25 (room temp) and 37°C) was conducted at the 
same time. Bovine blood was incubated in 0 and 800 mg/dl (44 mM) D- and L-glucose using 
these conditions. L-glucose represents an optical isomer of D-glucose that lacks stereospecificity 
with the GLUT-1 protein and therefore the ability to enter the cell thus creating an osmotically 
active condition which would result in cell shrinkage. At all three temperatures, immediately 
following and one hour after D- and L-glucose addition the hematocrit decreased roughly 8%, 
from a value of 48% to 44%, compared to baseline. After 24 hours at all three temperatures, the 
hematocrit in control tubes (0 mg/dl) had decreased slightly from a value of 48 to 47%, which is 
expected due to RBC loss of intracellular constituents. The additions of D- and L-glucose again 
reduced the hematocrit 8% compared to control. The results of this study are shown in Figure 
3.18 (A-C). Therefore, it is evident, that the incubation temperature and time were not 
contributing factors to the absence of an iso-osmotic condition in the bovine blood suspensions. 
In general, standard laboratory practice dictates that viscoelasticity measurements be performed 
within a few hours of blood withdrawal since alterations in the its rheological properties occur 
with time [59]. Therefore, had a longer incubation time period proved to be effective in 
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preventing cell shrinkage, it would have been impractical from a rheological standpoint due to 
confounding alterations in cell deformability due to storage. 
 
 
Figure 3.18: Effect of incubation time and temperature on D-glucose transport in 
bovine RBCs 
 
Bovine blood hematocrit is shown after incubation with D- (grey bar) and L-
glucose (black bar) at a concentration of 800 mg/dl (44 mM) for 0, 1 or 24 hours at 
temperatures of (A) 4 °C, (B) 25 °C and (C) 37 °C. A reduction in hematocrit 
indicates RBC shrinkage due to an osmotic activity. 
 81 
It may be that osmotically inert conditions do not present in all species [130]. For 
instance, D-glucose demonstrated a noticeable effect on RBC deformability in the diabetic ob/ob 
mouse due to osmotic stress [131]. Therefore, the changes in the hematocrit of bovine and rat 
blood observed in this study are likely due to the osmotic stress of the D-glucose additive. The 
adaptation of the cells in these two species to uptake glucose based on different feeding habits 
may prohibit high levels of glucose from entering the cells. In this case, the GLUT-1 transporter 
may become overwhelmed by seemingly small concentrations of D-glucose resulting in an 
osmotically active state and cell shrinkage. 
The results of these experiments thus suggest that the increases in viscoelasticity and 
viscosity shown in Figure 3.14 after the addition of D-glucose were due to hyperosmolality of 
the suspension media due to D-glucose addition causing RBC shrinkage and not due to the 
effects of glycosylation of the cell membrane and hemoglobin. This was further confirmed by the 
study on human blood where hematocrit remained unchanged and likewise the viscoelasticity. 
The overall objective of this study was to replicate the decrease in the deformability of RBCs 
which was shown in the blood of diabetic rats in Section 3.4 and to evaluate the DRP effect on 
blood with reduced deformability. Due to the complications of the osmotic conditions that 
existed in the bovine and rat blood, the glycosylation of the RBCs by glucose was not detectable 
because the effect on cell deformability from cell shrinkage dominated. Therefore, experiments 
testing the DRP effect on the deformability of RBCs incubated with glucose should be included 
in future studies. These studies may be performed by equalizing the osmolality of the suspension 
media and re-evaluating the effects of D-glucose on the viscoelasticity of the samples. 
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4.0  ENHANCEMENT OF IMPAIRED MICROCIRCULATION IN RATS WITH 
STREPTOZOTOCIN-INDUCED DIABETES VIA INTRAVENOUS ADMINISTRATION 
OF DRP PREPARATIONS 
4.1 INTRODUCTION 
Previous experimental animal studies have demonstrated the potential clinical applicability of the 
intravenous delivery of DRPs for the treatment of hemorrhagic shock, hypobaric hypoxia, 
coronary stenosis and atherosclerosis. One acute animal study using rats with alloxan-induced 
diabetes mellitus demonstrated a significant increase in the density of functioning capillaries 
after the injection of a DRP solution. These studies are described in more detail in Chapter 2.1 
Currently there is no truly effective prevention regimen or treatment for diabetes-related 
microcirculation impairment. In this chapter, a study designed to experimentally evaluate a novel 
therapy for the restoration and maintenance of impaired microcirculation in tissue and organs, 
which is significantly reduced due to diabetes based on the ability DRPs to provide blood with 
exceptionally low resistance to flow in the microcirculatory system which increases functional 
capillary density and markedly improve blood flow in microcirculatory disorders associated with 
diabetes. 
 83 
4.2 METHODS 
4.2.1 Animal Care Compliance 
The surgical manipulations performed in this section of the study were approved by the 
Institutional Animal Care and Use Committee of the University of Pittsburgh (protocols 
#0408443, #0108461). All animal care and procedures conformed to the National Institutes of 
Health Guidelines for the Care and Use of Laboratory Animals. 
4.2.2 Animals 
Male Sprague-Dawley rats (250-300 g, SASCO; Charles River Laboratories, Wilmington, MA) 
were housed in solid bottom micro-isolator containers and fed rat chow and water ad libitum 
except during fasting periods, 2 hours prior to blood glucose measurements. The animals were 
allowed a 6-day acclimatization period after delivery before experimental procedures 
commenced. Animals were housed in plastic animal containers under constant conditions of 
temperature and light cycling (12 h light-12 h darkness). Bedding was changed daily in order to 
keep the animals clean and dry. The animals were randomly selected to either a diabetic group or 
control group. These two groups were further divided during acute hemodynamic experiments 
based on treatment (DRP or saline). 
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4.2.3 Development and care of a rodent model of diabetes. 
The establishment of microcirculatory impairment caused by streptozotocin-induced diabetes in 
rats was evaluated by monitoring changes in microcirculatory blood flow through measurements 
of tissue perfusion using laser Doppler flowmetry. 
Baseline hemodynamic parameters (systolic blood pressure and tissue perfusion) were 
measured non-invasively prior to diabetes induction and weekly thereafter. Baseline 
measurements of blood glucose concentration and weight were also attained. 
Anesthesia was induced and maintained by inhalation of isoflurane (concentration 1.5-
4%) in O2. A thermistor probe (Yellow Springs Instruments) was inserted into the rectum and the 
animal placed on a heating pad in dorsal recumbency to maintain a body temperature of 37 °C. 
Multiple sites were tested for their applicability in providing reliable and re-producible 
tissue perfusion measurements. The sites examined for the best tissue perfusion probe placement 
were the lip or buccal mucosa, the inner ear, the ear lobe, the ventral surface at the base of the 
tail, the ventral surface of the thigh of the hind-limb and the plantar surface of the front and hind 
paws. Tissue perfusion of the ventral surface of the thigh of the hind-limb and the plantar surface 
of the hind paw was measured with a non-invasive laser Doppler tissue perfusion probe (type DI; 
Transonic Systems, Ithaca, NY) that was affixed to the area with a piece of tape. Using a 
micromanipulator, a second tissue perfusion probe (N18, Transonic Systems) was clamped into 
position over the lip or buccal mucosa, the inner ear, the ear lobe, the ventral surface at the base 
of the tail, or the plantar surface of the front paw. The probes were mounted and positioned so 
that they applied minimal pressure to the surface, as to avoid occlusion of the local vessels and 
reduce perfusion. The probes’ placements were chosen to minimize movement artifact and to 
avoid placement of the probes on a site containing large blood vessels. The perfusion probes 
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were subsequently connected to a BLF 21D tissue perfusion monitor (Transonic Systems). The 
flow monitor’s output is proportional to absolute flow in the tissue being sampled. The tissue 
perfusion monitor’s output was filtered with a 1.0 second time constant. Tissue perfusion 
readings were averaged over a several minute period of stable activity. 
Systolic blood pressure was measured non-invasively by a piezoplethysmography system 
(Kent Scientific, Torrington, CT). Briefly, an inflatable occlusion cuff and a piezoelectric pulse 
sensor (distal placement) were placed on the animal’s tail. The piezoelectric sensor was situated 
directly over the ventral tail artery. The occlusion cuff was inflated until the arterial pulse 
disappeared. The cuff was then slowly deflated until the pulse re-appeared. The systolic pressure 
corresponded to the occlusion cuff pressure at which the first appearance of the pulse was 
observed. The systolic pressure was taken as an average of three measurements. The pressure 
transducer was connected to a pressure channel of the laser Doppler flow meter (BLF 21D; 
Transonic Systems). The piezoelectric pulse sensor was coupled to a pre-amplifier connected to 
an analog input of the laser Doppler flow meter. 
The signals containing the tissue perfusion and piezoplethysmography system data from 
the laser Doppler flow meter were acquired using a notebook PC computer connected via a serial 
connection. The data was continuously recorded (sample rate = 100 Hz) using WinDaq®/Pro 
software (DATAQ Instruments, Akron, OH) throughout the entire experiment. Average systolic 
blood pressure and the average tissue perfusion (minimum of 1 minute) were determined post 
hoc. 
Diabetes was induced through an intraperitoneal injection of streptozotocin (STZ; 65 
mg/kg, freshly dissolved in 0.1 M citrate buffer, pH 4.5) after a ~18 hour fasting period and 
confirmed by sustained blood glucose levels of 300 mg/dl (16.7 mM) or greater. The age and 
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weight-matched control group received the citrate buffer only. The injectant was sterilized via 
filter sterilization using a 0.22 μm syringe filter (Millipore). 
Blood glucose levels were monitored twice weekly using a OneTouch® FastTake® 
glucometer (LifeScan, Milpitas, CA) from blood (10 μl) obtained by pricking the tip of the tail 
with a fine point lancet. Blood glucose measurements were timed so that they occurred several 
hours after the start of the 12 hour light cycle. Insulin (3-5 IU/day; Humulin® U; Eli Lilly, 
Indianapolis, IN) treatment was initiated ~4 weeks after STZ administration and continued 
throughout the study to reduce mortality and the potential of the animal’s developing 
ketoacidosis. 
Body weight was measured several times per week to ensure the health of the animal. 
Hemodynamic parameters (systolic blood pressure and tissue perfusion) were measured once 
weekly throughout the study period until the animals were taken into acute experiments. 
4.2.4 Animal preparation and instrumentation for hemodynamic parameter measurement 
Fifteen weeks after STZ administration, rats of both experimental and control groups were 
brought into acute experiments for testing the DRP effect on their hemodynamics (tissue 
perfusion and blood pressure). 
Rats were catheterized in the right carotid artery for collection of arterial blood samples 
and for instantaneous measurement of arterial blood pressure and in the right jugular vein for 
intravenous infusion of the test solution (DRP or saline). Hemodynamic parameters including 
systolic, diastolic and mean arterial blood pressure, heart rate, spO2 and skin tissue perfusion 
(plantar surface of hind paws) were monitored. Arterial blood samples were collected for the 
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measurements of PO2, PCO2, pH, HCO3-, aBE, hematocrit, total hemoglobin concentration, 
lactate, Ca++, Na+, and K+. 
Anesthesia was induced and maintained by inhalation of isoflurane (concentration 1.5-
4%) in O2. A thermistor probe (Yellow Springs Instruments) was inserted into the rectum and the 
animal placed on a heating pad in dorsal recumbency to maintain a body temperature of 37 °C 
and the ventral surface of the neck shaved. The carotid artery was cannulated with a 22 gauge IV 
catheter (Medex) as described in section 3.2.2.2. This catheter was used for arterial blood 
sampling and blood pressure measurement. A T-connector (Medex) filled with heparin lock 
(3.33 IU/ml of heparin in saline) was connected to the carotid artery catheter. A 3-way stopcock 
(Medex) also filled with heparin lock was then connected to the T-connector. One port of the 
stopcock was connected to a pressure transducer (Transpac, Abbott Laboratories, Abbott Park, 
IL) for arterial pressure measurement. The pressure transducer was connected to the pressure 
channel of the laser Doppler flow meter (BLF 21D; Transonic Systems). The other port of the T-
connector was used for arterial blood sampling. Next, an incision approximately 1.5 cm long was 
made in the skin on the right ventrolateral aspect of the neck above the clavicle. The right 
external jugular vein was dissected free of surrounding fascia (caudal most landmark being 
where the vein courses underneath the pectoral muscle), ligated distally and cannulated with a 24 
gauge IV catheter (Medex) for intravenous infusion of the test solutions. A 3-way stopcock 
(Medex) filled with heparin lock solution was connected to the IV catheter and then one port of 
the stopcock was connected through microbore extension tubing (Arrow International, Reading, 
PA) to a syringe filled with the test solutions on a syringe pump (Kent Scientific). 
A pulse oximeter sensor (8600V, Nonin Medical, Plymouth, MN) was clipped onto a 
front paw and used to measure arterial blood oxygen saturation (SpO2) and heart rate.  
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Non-invasive Laser Doppler tissue perfusion probes (type DI; Transonic Systems) were 
taped to the plantar surface of the hind paws to measure tissue perfusion. The perfusion probes 
were connected to the BLF 21D tissue perfusion monitor (Transonic Systems). The tissue 
perfusion monitor’s analog output was filtered with a 1.0 second time constant. 
The signals containing the tissue perfusion and blood pressure data from the laser 
Doppler flow meter and the pulse oximetry data were acquired using a DI-720 series acquisition 
system (DATAQ Instruments) connected to a notebook PC computer connected via a universal 
serial bus. The data was continuously recorded (sample rate = 80 Hz) using WinDaq®/Pro 
software (DATAQ Instruments) throughout the entire experiment. The systolic, diastolic, and 
mean arterial pressures and the average tissue perfusions (all based on a 500 sample average) 
were continuously monitored via the WinDaq Meter Add-on (DATAQ Instruments). 
Arterial blood samples were collected after recording base hemodynamics (base sample) 
and the end of each acute experiment, 60 minutes post-infusion. DRPs were injected via the 
jugular vein at a final concentration of 1 μg/ml (0.22 nM). 
Vascular resistance was calculated by dividing mean arterial pressure by mean tissue 
perfusion over the time period of interest. An increase in tissue perfusion and decrease in blood 
pressure indicate a reduction in vascular resistance and, thus, the ability of DRPs to improve 
microcirculatory flow. 
4.2.5 Drag-reducing polymers 
The synthetic drag-reducing polymer polyethylene oxide (MW – 4500 kD; PEO-4500; 
Dow Chemical) was employed in these studies at a final blood concentration of 1 μg/ml (0.22 
nM). A description of the DRP preparation procedure was outlined in Chapter 3.2.2.1. A control 
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solution consisted of sterile nonpyrogenic isotonic saline (0.9%, Baxter). The diabetic and 
control (non-diabetic) animal groups were each further subdivided based on treatment: PEO-
4500 or Control (saline) resulting in four total groups. 
4.2.6 Statistical methods 
A paired t-test was applied to determine the statistical significance of the difference between 
base and post injection parameters within each group. A student’s un-paired t-test was applied to 
determine the statistical significance of the difference between diabetic and control groups. A p < 
0.05 was considered to be statistically significant. 
4.3 RESULTS AND DISCUSSION 
The specific aim of this study was to demonstrate that the intravenous administration of DRP 
preparations in rats with streptozotocin-induced diabetes enhances impaired microcirculatory 
perfusion. This was accomplished through two phases; the first phase was to induce diabetes to 
begin the development of microcirculatory flow insufficiencies and other diabetic complications 
during which hemodynamic parameters (systolic blood pressure and tissue perfusion) were 
monitored non-invasively and the second phase was to evaluate in acute experiments the ability 
of DRP preparations to treat the microcirculatory hypoperfusion which developed due to diabetes 
in the first phase. 
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4.3.1 Streptozotocin-induced diabetic rat model 
During the chronic development of diabetic complications, measurements of weight, blood 
glucose (BG), tissue perfusion (TP) and systolic blood pressure (SBP) were obtained before the 
initiation of diabetes and weekly thereafter. Animals were considered hyperglycemic if their 
blood glucose was above 300 mg/dl (16.7 mM). Diabetic animals exhibited a significant increase 
in blood glucose levels after diabetes induction as well as classic clinical symptoms associated 
with diabetes (i.e., polyuria, polydipsia and polyphagia). Diabetic animals also exhibited a 
decrease in weight during the study, another classic symptom of diabetes, while animals in the 
control group gained weight according to normal age-growth charts [132]. One of the biggest 
challenges in using diabetic animals in a chronic study is maintaining their health for the survival 
period needed to develop the complications. Some of the initial diabetic animals showed up to a 
25-30% loss of weight from baseline and had to be sacrificed prematurely in order to minimize 
pain and distress. Therefore, daily administration of long acting insulin (3-5 IU/day, a dose to 
reduce ketone bodies but not normalize blood glucose) was started ~4 weeks after diabetes 
induction. Tissue blood perfusion was measured with a non-invasive laser-Doppler method 
which provided information on microcirculation near the surface (skin, mucosa). Initially we 
were planning to measure TP on the lip mucosa and a shaved area of the hind leg. However, the 
mask required to deliver the isoflurane anesthesia during the chronic studies obstructed access of 
the TP probe to the lip mucosa. Additionally, we stopped using the thigh of the hind leg as to 
avoid the transient hyperemia associated with shaving the area prior to performing 
measurements. Most importantly, due to a loss of subcutaneous adipose tissue in diabetic rats, 
we believed that the flow probe was affected by muscle perfusion which is much higher than the 
skin perfusion. Therefore, we examined several other sites for tissue perfusion measurements 
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including the inner ear, the ear lobe, the base of the tail, and surface of the front and hind paws. 
We found that measurements of perfusion on the plantar surface of hind paws seemed more 
informative since this area provides an easily accessible, hairless, flat surface which allowed us 
to take several measurements in different locations to obtain an average perfusion of the entire 
surface. 
The STZ model of diabetes is a current and well-established animal model of diabetes. 
Alternatives for diabetes mellitus models are alloxan-induced diabetes, genetically-induced 
diabetes and pancreatectomy. Alloxan has been associated with a significantly higher mortality 
than STZ. It is also pointed out that STZ may induce a diabetic state that more closely resembles 
that observed in many humans in that human patients with diabetes exhibit hyperglycemia 
usually in the absence of ketone body formation. Alloxan-induced diabetes in rats is associated 
with an increase in free fatty acid levels and ketone bodies not seen in STZ diabetic animals. 
Chemical induction of diabetes mellitus with agents such as STZ and alloxan is advantageous 
over pancreatectomy because of the maintenance of pancreatic function in cells other than the β-
cell. The surgical removal of the pancreas results in the removal of not only the β-cell and loss of 
insulin secretory function but also removal of both the α- and δ-cells and the loss of the 
counterregulatory hormones glucagons and somatostatin. In addition, there is a loss of the 
pancreatic enzymes necessary for proper digestion; therefore, the diet for pancreatectomized 
animals must be supplemented with these pancreatic enzymes [133]. 
The genetically diabetic BB/Worcester rat has been considered as an alternative but the 
expense and unpredictability with regard to diabetes onset made this model undesirable. For 
accuracy, it is not particularly feasible to acquire animals which may or may not become diabetic 
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during a large window of time. The literature demonstrates that the streptozotocin model is the 
most widely used, accepted, and characterized for this type of research. 
4.3.2 Chronic hemodynamics in a streptozotocin-induced diabetic rat model 
Based on the published information, we hypothesized that the development of diabetic 
microangiopathies would result in a significant decrease in tissue perfusion in the diabetic 
animals. Table 4.1 shows the hemodynamic parameters of a subset of animals that were 
measured chronically under very light anesthesia prior and after diabetes induction. 
Measurements of SBP and TP did not show statistically significant changes from baseline in 
either group. However, mean values of tissue perfusion decreased by 19% in the diabetic group 
and by 9% in controls. In addition, Table 4.1 shows the relative changes in SBP which increased 
in the control group by 6% and in the diabetic group by 20% (p>0.05 in both groups). Based on 
the blood pressure and TP data, microvascular resistance in these groups calculated as a ratio of 
blood pressure and TP, decreased in the Control group by 15% and in the diabetic group by 50% 
(p < 0.05). Causes for a decrease in TP and an increase in microvascular resistance might be 
different in the studied groups. The control animals gain weight and adipose tissue, which is 
much less vascularized. The diabetic rats do not gain and can even lose adipose tissue and thus a 
decrease in TP can be explained only by rarefaction of the perfused arterioles and capillaries. 
Blood glucose levels shown in Table 4.1 significantly increased in diabetic rats and did not 
change in controls over an 8 week time period. Finally, Table 4.1 shows that control rats gained 
about 17% body weight while diabetic rats have lost about 10% of their base weight in spite of 
insulin injections. Thus, these results suggest that we were able to develop severe diabetic 
conditions in rats with deterioration of microcirculation. 
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Table 4.1: Measurements of hemodynamic and physiological 
parameters in diabetic and normal (control) animals 
 
 Diabetic Control 
Parameter Base Final Base Final 
TP (TPU) 35.8±3.0 29.1±3.3 40.7±3.3 36.9±6.4 
SBP (mmHg) 101±4 121±5 108±4 115±3 
BG (mg/dl) 114±4 533±33 100±14 97±4 
Weight (grams) 359±32 326±29 355±46 417±17 
Measurements of hemodynamic and physiological parameters in diabetic 
(n = 7) and normal (control; n= 4) animals. Base parameters were 
measured prior to induction of diabetes. Mean ± SEM 
 
4.3.3 Effect of DRPs on vascular hemodynamics in streptozotocin-induced experimental 
diabetes 
After at least 15 weeks post diabetes induction, animals were taken in acute experiments 
and, after collection of base hemodynamic data (blood pressure and tissue perfusion), injected 
with PEO-4500 (final blood concentration 1 μg/ml (0.22 nM), saline in control). 
Table 4.2 shows the base hemodynamic data of control and diabetic rats collected in 
acute experiments. Note that the base TP is significantly lower in these animals than it was 
shown in Table 4.1. This may be potentially due to the depressive effects of long term, surgical 
plane anesthesia and invasive procedure on cardiovascular hemodynamics and respiratory 
parameters. 
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Table 4.2: Base hemodynamic data of control and diabetic rats collected in acute experiments.  
 
Group Tissue Perfusion 
(TPU) 
Mean Arterial Pressure
(mmHg) 
Vascular Resistance 
(mmHg/TPU) 
Heart rate 
(beats/min)
Control 14.2±6.0 90.2±6.8 7.7±3.9 322±28 
Diabetic 9.4±4.6 92.0±8.6 11.9±6.2 287±29 
p-value* 0.014 0.567 0.011 0.010 
Mean ± SEM, p < 0.05 was considered to be statistically significant 
 
Microvascular resistance and heart rate are statistically significantly lower in diabetic 
animals. Changes in microvascular resistance are consistent with the results of our chronic 
measurements of hemodynamics in normal and diabetic animals given in Table 4.1. Changes in 
heart rate are consistent with those reported in the literature [134]. 
Figure 4.1 (A) shows the results of tissue perfusion measurements made in Control rats 
before and after the injection of 1 μg/ml (0.22 nM) PEO-4500 solutions (saline in Control-
Controls). The injection of saline in normal (non-diabetic) animals did not change tissue 
perfusion (p>0.05). However, the injection of PEO-4500 caused a statistically significant 
increase in TP by 40% (p=0.014). Figure 4.1 (B) shows the changes in TP after the injection of 1 
μg/ml (0.22 nM) PEO-4500 in diabetic animals (saline in Diabetic-Controls). Again, the 
injection of saline in diabetic animals did not change tissue perfusion (p>0.05). However, the 
injection of PEO-4500 caused a statistically significant increase in TP by 20% (p=0.027). 
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Figure 4.1: Effect of DRPs on the tissue perfusion in diabetic and non-diabetic (normal) rats 
 
(A) Tissue perfusion in the hind-limb plantar surfaces of normal rats before (white bars) and after (black bars) the 
infusion of a DRP (PEO-4500) or saline. (B) Tissue perfusion in the hind-limb plantar surfaces of normal rats 
before (white bars) and after (black bars) the infusion of a DRP (PEO-4500) or saline. 
 
Other hemodynamic parameters (MAP and heart rate) did not change statistically 
significantly after the injection of the DRPs (or saline in Control subgroups) in both Control 
(non-diabetic) and Diabetic groups. 
 
Table 4.3 shows data obtained from blood samples collected in both Control (non-
diabetic) and Diabetic groups. A statistically significant difference was found between base 
hematocrit values in Control and Diabetic groups. The higher hematocrit in diabetic animals 
could be related to a certain level of tissue hypoxia which can stimulate hematopoiesis. Other 
blood gas parameters were not statistically significantly different between Control and Diabetic 
groups in both the base and post-injection blood samples. A small but statistically significant 
difference between base and end blood gas parameters observed in both groups was related to the 
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acute experiment conditions (depressive effects of long term, surgical plane anesthesia and 
surgery on cardiovascular hemodynamics and respiratory parameters). 
 
Table 4.3: Blood gases parameters of Control and Diabetic rats before and after 
PEO-4500 injection in acute experiments 
 
 Pre-injection Post-injection  
Parameter Control Diabetic p-value Control Diabetic p-value p-value 
Hematocrit (%) 46.4±2.2 48.8±2.5 0.020a 44.8±1.3 45.8±3.9 p > 0.05a 0.005b, 0.000c 
pH 7.41±0.06 7.37±0.06 p > 0.05a 7.38±0.05 7.33±0.09 p > 0.05a 0.004b, 0.000c 
pCO2 (mmHg) 44.1±8.7 49.6±8.1 p > 0.05a 46.6±7.2 48.1±11.3 p > 0.05a p > 0.05b, p > 0.05c 
ABE (mmol/L) 2.51±1.25 2.7±2.9 p > 0.05a 1.9±1.4 1.0±3.8 p > 0.05a p > 0.05b, 0.005c 
K+ (mmol/L) 4.7±0.5 4.8±0.7 p > 0.05a 4.8±0.4 5.2±0.6 p > 0.05a p > 0.05b, 0.013c 
Na+ (mmol/L) 136.9±2.1 137.1±4.1 p > 0.05a 137.6±2.2 138.0±4.5 p > 0.05a p > 0.05b, p > 0.05c 
Ca++ (mmol/L) 1.35±0.07 1.33±0.14 p > 0.05a 1.33±0.09 1.33±0.14 p > 0.05a p > 0.05b, p > 0.05c 
a Control vs. Diabetic, b Control pre vs. post and c Diabetic pre vs. post 
 
This study demonstrates that a reproducible model of experimental diabetes in small 
animals (rats) with the ability to measure hemodynamic parameters using non-invasive methods 
was developed. Diabetic rats were found to have statistically significantly lower tissue perfusion 
than their non-diabetic matched control. We tested our polymers in both diabetic and control 
animals and have found that nanomolar concentrations of DRPs statistically significantly 
increased tissue perfusion in diabetic rats (as well as in normal animals) without affecting other 
hemodynamic parameters (blood pressure and heart rate). The stronger increase in tissue 
perfusion after the injection of DRPs in normal animals was probably related to the fact that 
diabetes mellitus causes significant changes in the vessel wall which reduces its response to 
shear stress. 
The importance of this study is that we demonstrated the beneficial effects of our drag-
reducing polymers on the microcirculation of diabetic animals which most likely was related to 
the ability of the DRPs to enhance blood flow structure and mechanical properties of red blood 
cells in microvessels. Therefore, DRPs may have a significant impact in the treatment of patients 
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suffering from microcirculatory related complications of diabetes. The future direction of this 
research should be focused on the treatment/prevention of those complications by chronically 
injecting DRPs over the course of diabetes development. This may includes studies on wound 
healing or diabetic neuropathy; conditions whose etiologies have been linked to poor 
microvascular perfusion. 
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5.0  STUDY OF POTENTIAL SIDE EFFECTS OF THE DRPS VIA ACUTE AND 
CHRONIC ANIMAL TESTS 
5.1 INTRODUCTION 
Previous in-vivo studies with DRPs have demonstrated that they represent great utility in many 
potential acute and chronic clinical applications. These were described in-depth in Chapter 2.1. 
However, before DRPs can be used clinically, any potential side effects and toxicity must be 
evaluated including deleterious effects on clotting and hemostasis. Therefore, in this chapter, 
experiments which were performed to evaluate the effects of acute and chronic DRP injections 
on several hematological, blood gas and blood coagulation parameters are described. This 
chapter also describes several studies which were designed and performed to determine the 
thresholds of DRP concentrations which could be safely used for intravenous infusions. In acute 
experiments, the hemodynamic response of normal animals to an intravenous infusion of high 
concentrations of several DRPs (PMNN, PEO and hyaluronic acid) was assessed. Tests also 
included bolus injections of several different concentrations of DRPs to determine if/which 
preparations of DRPs could be injected in relatively high concentrations in short time periods 
without an undesirable hemodynamic reaction. 
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5.2 METHODS 
5.2.1 Animal Care Compliance 
The surgical manipulations performed in this section of the study were approved by the 
Institutional Animal Care and Use Committee of the University of Pittsburgh (protocol 
#0408097 and #0510080). All animal care and procedures conformed to the National Institutes 
of Health Guidelines for the Care and Use of Laboratory Animals. 
5.2.2 Animals 
Male Sprague-Dawley rats (300-350 g, SASCO; Charles River Laboratories, Wilmington, MA) 
were housed in solid bottom micro-isolator containers and fed rat chow and water ad libitum. 
The animals were allowed a 6-day acclimatization period after delivery before experimental 
procedures commenced. 
5.2.3 Acute DRP effect on hematological parameters 
Any new blood additive must be evaluated for its potential effects on the blood coagulation 
system to exclude any deleterious effects on clotting and hemostasis. Accordingly, the potential 
acute effects of DRPs on several hematological parameters after IV administration to rats were 
evaluated in blood of these animals. These parameters included the measured parameters of a 
complete blood count with differential (CBC differential; hematocrit (Ht), hemoglobin (Hgb), 
mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH), 
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mean corpuscular volume (MCV), red blood cell count (RBC), white blood cell count (WBC), 
platelet count and differential white blood cell count (“differential”)), prothrombin time (PT), 
activated partial thromboplastin time (aPTT), and fibrinogen and D-Dimer concentration. The 
effect of DRPs on clot formation time was also evaluated with blood collected from donor rats in 
vitro. 
A surgical plane of anesthesia was induced and maintained with an IM injection of 
ketamine/xylazine (90/10 mg/kg; Phoenix Pharmaceutical) and heparin (60 IU heparin/kg body 
weight; Abbott Laboratories) was administered subcutaneously in eleven rats. IV catheters were 
placed in the right carotid artery for collection of arterial blood samples and for instantaneous 
measurement of arterial blood pressure and right jugular vein for IV infusion of the test solution 
(DRP or saline (control)) as described in Sections 3.2.2.2 and 4.2.4, respectively. 
After the animal preparation was complete and after a stabilization period of 15 minutes, 
blood was drawn from the arterial catheter via a plastic syringe (Becton Dickinson (BD), 
Franklin Lakes, NJ) and transferred into glass blood collection tubes containing 3.2% sodium 
citrate (2.7 ml; BD) and 7.5% EDTA (2.7 ml; BD) to measure the CBC differential, PT, aPTT, 
and fibrinogen and D-Dimer concentration. Fifteen minutes post blood sampling, a 
predetermined volume (≤1.5 ml) of saline (Control; n = 5) or Poly(mannan) (PMNN; at the 
concentration of 100 μg/ml (16.7 nM); n = 6), as described in Section 3.2.2.1, was injected in the 
jugular vein over a 20 minute period through a microbore catheter (Arrow International) 
connected to a syringe on a syringe pump (PhD 2000; Harvard Apparatus, Holliston, MA). The 
infused volume (1-1.5 ml) was calculated based on animal weight, original DRP concentration 
(100 μg/ml (16.7 nM)) and the desired DRP dosage to be given to the animal (300 μg/kg or 5 μg 
DRP/ml blood (0.83 nM); a concentration that is known to be hemodynamically effective). 
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Blood volume was estimated as 6% of lean body weight. The animals of the Control group 
received the same weight-based volume of the control solution (NS). Thirty minutes following 
the end of the IV injection, post-injection blood samples were collected as described above. The 
animal was then sacrificed with an intracardiac (IC) bolus of supersaturated (2 mmol/kg) 
potassium chloride while under general surgical plane anesthesia. The blood collection tubes 
were sent to a veterinary diagnostic laboratory (Antech Diagnostics, Lake Success, NY) for 
hematological parameter measurement. Results are expressed as the mean ± standard deviation 
(SD). Hematological parameters in the DRP and Control groups were compared. Statistical 
significance of the difference in hematological parameters between groups and statistical 
significance of the difference in hematological parameters within each group before and after 
treatment was computed using a Student’s un-paired t-test and a paired t-test, respectively. A p < 
0.05 was considered to be statistically significant. 
Additionally, the time for clot formation with and without DRPs was tested in vitro. 
Briefly, blood (un-heparinized) was collected via an IV catheter (Chapter 3.2.2.2) from three 
anesthetized rats and was transferred into glass tubes, with no anticoagulant, containing equal 
volumes of one of two DRPs (PMNN (10 μg/ml (1.7 nM) and PEO-4500 (10 μg/ml (1.7 nM))) 
solutions or saline (Control). Tubes were rocked on a laboratory rocker (Speci-Mix tube rocker, 
Barnstead Thermolyne, Dubuque, IA) until clot formation (a change in the consistency of the 
blood in the tube to a thick and fibrinous state). Results are expressed as the mean ± standard 
deviation. Clotting times between the DRP and Control tubes were compared. A one-way 
ANOVA with Tukey post hoc test was used to compute the statistical significance between the 
clotting times of DRP and Control tubes. A p < 0.05 was considered to be statistically 
significant. 
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5.2.4 Chronic DRP effect on arterial blood gas, blood serum chemistry and hematological 
parameters. 
Blood additives must also be evaluated for their potential chronic effects on basic physiological 
function. Therefore, the potential chronic effects of DRPs on several physiological parameters, 
including arterial blood gas, blood serum chemistry and hematological parameters, after chronic 
IV administration (7 weeks) to rats were evaluated. 
Healthy male SASCO Sprague-Dawley rats with pre-implanted jugular vein catheters 
were used in these studies (as approved by the Institutional Animal Care and Use Committee). 
The catheters (polyurethane tubing, 0.025” x 0.040”) were placed by experienced technicians at 
Charles Rivers Laboratories several days prior to delivery. The catheter was routed under the 
skin and exited centrally between the scapulae and was tucked into a subcutaneous pocket when 
not in use. The catheter was filled with a lumen lock solution consisting of a 1:1 solution of 50% 
dextrose (Hospira, Lake Forest, IL) and heparin (1000 U/ml; Baxter) and was flushed twice 
weekly to maintain patency. The exterior end of the catheter was plugged when not in use. 
After a 6 day acclimatization period, the animals (n=17) began to receive twice weekly 
injections of DRP solutions (PEO-4500, n=6; PMNN, n=6; and saline (Control), n=5) for a 
period of 7 weeks. The DRP solutions were prepared as described in Chapter 3.2.2.1. These 
animals were in a study that was being performed co-currently with this project so the end point 
chosen to evaluate chronic toxicity was based on the end point of the other project. This was 
done in order to minimize animal numbers. The animals were anesthetized for each injection 
procedure due to the time required for administration of the DRPs. Anesthesia was induced and 
maintained by inhalation of isoflurane (1.5-4%) in O2. Animals were placed on a warming pad in 
ventral recumbency and the IV catheter was prepared for infusion. The catheter plug was 
 103 
removed and the lumen lock solution was cleared from the catheter by connecting a 1 ml syringe 
with 23 gauge needle to the catheter and drawing back slowly until blood entered the syringe. A 
23 gauge needle attached to a microbore catheter (Arrow International) and a syringe on a 
syringe pump (Kent Scientific) was then connected to the catheter and the DRP solutions (saline 
in control) were infused at a controlled rate over 3-5 minutes. The infused volume (1-2 ml) was 
calculated based on animal weight, original DRP concentration (PEO-4500 – 20 μg/ml (4.4 nM); 
PMNN – 40 μg/ml (6.7 nM)) and the desired DRP dosage to be given to the animal (PEO-4500 – 
60 μg/kg or 1 μg DRP/ml blood (0.22 nM)); PMNN – 120 μg/kg or 2 μg DRP/ml blood (0.33 
nM)). Blood volume was estimated as 6% of lean body weight. These concentrations were 
chosen because they are the typical doses applied to yield an effective hemodynamic response to 
DRPs. Control animals (n=5) were injected with an equal volume of the vehicle (saline). Upon 
completion of the infusion, the lumen lock solution was replaced. The catheter was plugged, 
disinfected with 70% ethanol alcohol and 5% povidone-iodine solution and tucked back into its 
subcutaneous pocket. 
At the end of 7 weeks, the animals were anesthetized with isoflurane (1.5-4.0%) and 
blood samples were collected through an arterial catheter (Chapter 3.2.2.2) to measure blood gas 
parameters (pH, pCO2, pO2, cHCO3, ABE, tHb, K+, Na+, Ca2+ and Lactate) using an ABL725 
blood gas analyzer (Radiometer America, Westlake, OH), hematological parameters (CBC 
differential as previously described in Chapter 5.2.3) using a HESKA® CBC-Diff™ System 
(Heska, Loveland, CO) and several serum chemistries including blood urea nitrogen (BUN), 
glucose, alkaline phosphatase (ALP), total protein (T-Pro), alanine aminotransferase (ALT) and 
creatinine using a HESKA® Spotchem™ EZ System. These parameters were chosen as a measure 
of cardiovascular, respiratory, liver and renal function. The data was averaged amongst each 
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group, standard deviations calculated, and one-way ANOVA with Tukey post hoc test was used 
to compare each experimental group (animals injected with either PEO or PMNN) to the control 
group (animals injected with saline). A p < 0.05 was considered to be statistically significant. 
5.2.5 In-vivo efficacy of hyaluronic acid and the hemodynamic effects of bolus infusions and 
infusions of extremely high concentrations of DRPs. 
In this section of the chapter, some additional experiments which were performed to study the in-
vivo efficacy of high molecular weight hyaluronic acid (Hyvisc®, Anika Therapeutics) on 
enhancing cardiovascular hemodynamics is discussed. Hyvisc® is a commercially available 
pharmaceutical grade hyaluronic acid preparation (MW=~2000 kD) that is currently used by 
veterinarians used to treat joint dysfunction in horses associated with equine osteoarthritis, In-
vitro experiments revealed that Hyvisc® had good drag reducing properties and due to its 
commercial availability, it is a promising candidate for larger animal trials and future clinical 
use. Several other experiments were performed to investigate the hemodynamic effects of bolus 
injections of DRP solutions with relatively high concentrations (up to 100 μg/ml (50 nM)) and 
slow infusions of DRP solutions with extremely high concentrations (up to 3 mg/ml (1.5 μM) in 
the syringe). These injections resulted in blood concentrations up to 150 times the 
hemodynamically effective concentration. 
5.2.5.1 Animal preparation for hemodynamic parameter measurement 
Seven rats were prepared as described in Chapter 4.2.4 for the measurement of 
hemodynamic parameters (instantaneous arterial pressure (carotid artery) and tissue perfusion 
(left and right hind limb plantar surface)). In addition, the left carotid artery was exposed as 
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described in Chapter 3.2.2.2 and an ultrasonic perivascular flow probe (0.7VB; Transonic 
Systems) was placed around the vessel to monitor carotid artery blood flow. The probe was 
stabilized in position on the artery with a micromanipulator to minimize movement and ensure 
that the artery was centered within the probe window. The ultrasonic flow probe was connected 
to a T206 flow meter (Transonic Systems) whose signal was acquired and continuously recorded 
as described in Chapter 4.2.4. The maximum, minimum and mean flow rates were also 
monitored as described in that chapter. Data acquisition was performed at a minimum sample 
rate of 167 Hz. 
5.2.5.2 Experiments to examine the hemodynamic efficiency of intravenous hyaluronic acid 
Two experiments were performed to examine the effectiveness of a commercially 
available hyaluronic acid pharmaceutical on enhancing hemodynamics in a rat. In the first 
experiment, baseline hemodynamics were monitored and recorded for 20-30 minutes. Then, 
predetermined volumes of a hyaluronic acid solution (Hyvisc®; Anika Therapeutics) were 
intravenously infused via the jugular vein at concentrations of 50 (25 nM), 125 (62.5 nM), 250 
(125 nM) and 250 μg/ml (125 nM) to yield final blood concentrations of 1 (0.5 nM), 6 (3 nM), 
16 (8 nM) and 33 μg/ml (16.5 nM) of the DRP, respectively. Hemodynamic parameters were 
monitored and recorded for 30 minutes in between each increasing dose. After recording the 
final set of hemodynamic parameters, the animal was euthanized by an intracardiac bolus of 
supersaturated (2 mmol/kg) potassium chloride (Hospira). 
In the second experiment, baseline hemodynamics were monitored and recorded for ~15 
minutes and then, predetermined volumes of a hyaluronic acid solution were intravenously 
infused via the jugular vein at concentrations of 1.0 (0.5 μΜ) and 1.5 mg/ml (0.75 μM)to yield 
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final blood concentrations of 50 (25 nM) and 150 μg/ml (75 nM) of the DRP, respectively. 
Hemodynamic parameters were monitored and recorded for 30 minutes in between doses. After 
recording the final set of hemodynamic parameters, the animal was euthanized by an intracardiac 
bolus of supersaturated (2 mmol/kg) potassium chloride (Hospira). 
5.2.5.3 Experiments to investigate the hemodynamic response to bolus infusions of PMNN 
and PEO-4500 
As a measure of acute toxicity and in order to test the applicability of giving higher doses (PEO-
4500 at ~100 μg/ml (22 nM) and PMNN at ~50 μg/ml (8.3 nM)) of DRPs in a short bolus 
infusion as it may be employed in the resuscitation during hemorrhagic shock, several 
experiments were performed in which DRPs were infused at concentrations ranging from 2 
μg/ml (0.3 – 0.4 nM) to 100 μg/ml (22 nM) in a fixed volume (1 ml) over 10 seconds. In the case 
of a human patient with a normal blood volume of 5 liters, this would represent a bolus infusion 
of ~150 ml given in 10 seconds. Therefore, this procedure represents a radical simulation of a 
bolus infusion. 
Two experiments were performed. In both experiments, baseline hemodynamic 
parameters were first monitored and recorded for ~10 minutes. In the first experiment, saline was 
injected as a control and then PEO-4500 was injected as a 1 ml bolus (rate of 6 ml/min) at 
concentrations of 2 (0.44 nM), 10 (2.2 nM), 50 (11.1 nM) and 100 μg/ml (22.2 nM) via the 
jugular vein which yielded final blood concentrations of ~0.06 (0.013 nM), 0.36 (0.08 nM), 1.90 
(0.42 nM), and 4.90 μg/ml (1.09 nM) of the DRP, respectively. Hemodynamic parameters were 
monitored and recorded for 15 minutes in between each dose. The second experiment was 
carried out identically to the first except PMNN was injected at concentrations of 2 (0.33 nM), 
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10 (1.67 nM) and 50 μg/ml (8.33 nM) via the jugular vein which yielded final blood 
concentrations of ~0.06 (0.01 nM), 0.36 (0.06 nM) and 1.90 μg/ml (0.32 nM) of the DRP, 
respectively. After recording the final set of hemodynamic parameters, the animals were 
euthanized by an intracardiac bolus of supersaturated (2 mmol/kg) potassium chloride (Hospira). 
5.2.5.4 Experiments to investigate an animal’s response to infusions of hyaluronic acid and 
PMNN at extremely high concentrations. 
An additional two experiments were performed to study the effects of a slow infusion of 
extremely high concentrations of PMNN and hyaluronic acid (Hyvisc®, Anika Therapeutics) on 
hemodynamic parameters and cardiovascular function. 
In both experiments, baseline hemodynamic parameters were first monitored and 
recorded for ~30 minutes. In the first experiment, one ml of PMNN was infused via the jugular 
vein at a concentration of 1250 μg/ml (0.21 μM) at 0.05 ml/min resulting in a total blood 
concentration of ~60 μg/ml (1.0 nM) of the DRP. At the end of the infusion, an arterial blood 
sample was collected and then hemodynamic parameters were monitored and recorded for ~60 
minutes. A final arterial blood sample was collected and the animal euthanized as previously 
described. The experimental conditions and procedures in the second experiment were identical 
to those of the first experiment except that one ml of hyaluronic acid was infused via the jugular 
vein at a concentration of 3000 μg/ml (1.0 μM) at 0.05 ml/min resulting in a total blood 
concentration of ~143 μg/ml (47.7 nM) of the DRP. 
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5.3 RESULTS AND DISCUSSION 
DRPs may be utilized in many clinical applications for the treatment of various pathologies and 
conditions. These pathologies and conditions may be associated with coagulopathic conditions 
and increased risk of bleeding. Therefore, an investigation on the effects of DRPs on a variety of 
coagulation and hematological parameters was performed in vitro and in vivo after acute and 
chronic DRP administration to rats to exclude any deleterious effects of these long-chain 
molecules on clotting and hemostasis. Studies were also performed to investigate the effects of 
the intravenous infusion of high concentrations of DRP solutions. In acute experiments, the 
hemodynamic response of normal animals to an intravenous infusion of high concentrations of 
several DRPs (PMNN, PEO and hyaluronic acid) was assessed. Tests also included bolus 
injections of several different concentrations of DRPs to determine if preparations of DRPs could 
be injected in relatively high concentrations in short time periods without an undesirable 
hemodynamic reaction. 
5.3.1 Effect of the acute injection of PEO-4500 solutions on hematological and blood 
coagulation parameters. 
Experiments were performed in which arterial blood samples were collected before and 30 min 
after the intravenous injection of PEO-4500 (5 μg/ml (1.11 nM), saline in control) into 
anesthetized rats. Complete blood count (CBC) plus differential, prothrombin time (PT), partial 
thromboplastin time (PTT), fibrinogen and the fibrin degradation product D-Dimer were 
measured in these blood samples. Additionally, the time for clot formation with and without 
DRPs was tested in vitro. 
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Results of acute PEO injections in rats on hematological and blood coagulation 
parameters are given in Table 5.1. No change in PT (sec) was observed when comparing Control 
pre vs. post. However, a slight but statistically significant increase (3.8%, p<0.05) was observed 
in PT (sec) when comparing DRP pre vs. post. No statistically significant change was observed 
in PTT, D-Dimer MCV, MCH, MCHC, and platelet count when comparing pre vs. post samples 
of both PEO-4500 and Control animals suggesting that the drag-reducing polymer PEO-4500 did 
not alter these measured hematological and hemostatic parameters. Slight but statistical changes 
were observed in fibrinogen concentration, Ht, Hb, and WBC count. Since a similar difference 
was observed in Control Post and PEO-4500 Post samples, these changes did not signify any 
effect by the DRP but can be attributed to blood sampling (~25% of blood volume) during these 
in-vivo experiments. 
The clotting times were 295 ± 66, 321 ± 85 and 279 ± 48 for the Control, PMNN and 
PEO samples, respectively. No statistical significance was found in these tests. 
In general, no significant alteration was found in the major measured hematological and 
hemostatic parameters after PEO-4500 infusion demonstrating that PEO-4500 does not have any 
deleterious effects on clotting and hemostasis. It might be suggested that similar experiments be 
repeated in which smaller blood samples are drawn to reduce the effects of sampling. 
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Table 5.1: Results of acute PEO injections in rats on hematological and blood coagulation 
parameters 
 
 Control PEO  
Parameters Pre Post Pre Post p-value 
Coagulation 
PT (sec) 15.5±0.5 15.7±0.4 15.6±0.8 16.2±1.0 > 0.05a,< 0.05b 
PTT (sec) 19.4±3.2 19.4±2.0 18.5±2.1 18.2±2.1 > 0.05a,b 
Fibrinogen (mg/dl) 257±22 234±27 265±29 226±12 < 0.05a,b 
D-Dimer (ng/ml) < 250 < 250 < 250 < 250 N/A 
Complete Blood Count 
Hb (g/dl) 14.4±0.6 13.3±0.5 14.8±0.7 13.8±1.4 < 0.01a,< 0.05b 
Ht (%) 44±2 40±2 45±3 41±4 < 0.001a,b 
WBC (103/µl) 4.1 ±1.1 2.8 ±1.2 5.5±1.7 2.8±1.2 > 0.05a,< 0.05b 
RBC (106/µl) 7.8±0.3 7.0±0.4 8.0±0.5 7.4±0.6 < 0.01a,< 0.001b 
MCV (fl) 60.0±1.9 59.4±2.6 58.3±3.4 58.0±3.5 > 0.05a,b 
MCH (pg) 18.5±0.6 19.0±0.6 18.5±0.6 18.5±1.1 > 0.05a,b 
MCHC (%) 30.9±1.2 32.0±2.0 31.7±1.2 31.9±0.5 > 0.05a,b 
Platelet Count (103/µl) 855±149 774±158 836±257 722±289 > 0.05a,b 
Differential 
Neutrophils (%) 18±7 28±8 23±7 40±15 < 0.001a,< 0.01b 
Bands (%) 0 0 0 0 N/A 
Lymphocytes (%) 79±7 69±8 75±7 57±15 < 0.001a,< 0.005b 
Monocytes (%) 1±0 1±1 1±0 2±1 > 0.05a,b 
Eosinophils (%) 1±1 1±1 2±1 2±2 > 0.05a,b 
Basophils (%) 0 0 0 0 N/A 
aControl pre vs. post bDRP pre vs. post 
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5.3.2 Effects of chronic infusions of DRPs on parameters of cardiovascular, respiratory, 
liver and renal function. 
Experiments were performed in which blood gas, CBC differential, and blood serum chemistry 
parameters were measured in order to investigate the effects of chronic infusions of DRPs 
(2x/week over 7 weeks) on cardiovascular, respiratory, liver and renal function. Measurements 
of blood gas parameters (Table 5.2) showed relatively little difference between experimental and 
control animals. In these particular groups isoflurane anesthesia was administered via 100% O2. 
The results of the measurement of CBC differential parameters showed no difference between 
control and experimental groups (Table 5.3). Blood serum chemistry measurements also 
demonstrated that no difference exists between control and experimental groups (Table 5.4). The 
abnormally high blood glucose levels seen in these results are likely due to the animal’s response 
to the stress of being handled, anesthesia and blood collection. 
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Table 5.2: Blood gas parameters measured in rats injected twice weekly with DRPs 
(PEO and PMNN, saline in control) for 7 weeks 
 
Parameter Control PEO PMNN p-value 
pH 7.403±0.036 7.389±0.044 7.422±0.042 >0.05a,b 
pCO2 (mmHg) 46.8±5.5 45.7±7.1 44.4±6.4 >0.05a,b 
pO2 (mmHg) 105.3±24.3 94.2±6.6 80.9±16.0 >0.05a,b 
cHCO3 (mmol/L) 28.4±1.1 26.8±1.8 28.2±1.2 >0.05a,b 
ABE (mmol/L) 3.4±0.6 1.8±1.1 3.7±0.2 >0.05a,b 
tHb (%) 14.7±0.4 14.6±0.7 14.9±0.3 >0.05a,b 
K+ (mmol/L) 4.5±0.5 4.8±0.5 4.6±0.4 >0.05a,b 
Na+ (mmol/L) 136±2 136±1 136±1 >0.05a,b 
Ca2+ (mmol/L) 1.39±0.02 1.40±0.04 1.38±0.02 >0.05a,b 
Lactate (mmol/L) 0.9±0.2 0.7±0.2 1.4±0.3 >0.05a,b 
aControl vs. PEO, bControl  vs. PMNN 
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Table 5.3: CBC differential results measured in rats injected twice weekly with DRPs (PEO and 
PMNN, saline in control) for 7 weeks 
 
Parameters Control PEO PMNN p-value 
Complete Blood Count     
Hemoglobin (g/dl) 14.0±0.4 14.1±0.7 14.2±0.5 >0.05a,b 
Hematocrit (%) 41.3±1.4 41.0±2.0 42.3±1.1 >0.05a,b 
WBC (103/ul) 8.1±2.6 6.9±1.7 8.6±5.0 >0.05a,b 
RBC (106/ul) 8.1±0.3 8.1±0.4 8.4±0.2 >0.05a,b 
MCV (fl) 50.8±1.9 50.7±2.1 50.6±0.5 >0.05a,b 
MCH (pg) 17.2±0.7 17.4±0.8 17.0±0.2 >0.05a,b 
MCHC (g/dl) 34.0±0.7 34.4±0.4 33.6±0.6 >0.05a,b 
MPV (fl) 6.4±0.4 6.2±0.1 6.1±0.2 >0.05a,b 
Platelet Count (103/ul) 731±96 678±114 741±103 >0.05a,b 
RDW (%) 14.1±0.3 14.4±1.6 15.2±1.2 >0.05a,b 
Differential     
Lymphocytes (103/ul) 6.0±2.1 5.3±1.4 5.2±1.8 >0.05a,b 
(%) 74.1±10.5 77.0±6.4 66.0±16.0 >0.05a,b 
Monocytes (103/ul) 0.5±0.1 0.3±0.2 1.0±0.6 >0.05a,b 
(%) 7.1±1.1 4.1±2.7 7.8±2.0 >0.05a,b 
Granulocytes (103/ul) 1.9±1.1 1.5±0.7 3.0±3.0 >0.05a,b 
(%) 23.1±7.8 20.7±5.1 30.1±13.0 >0.05a,b 
aControl vs. PEO, bControl  vs. PMNN 
 
 
Table 5.4: Blood serum chemistry results measured in rats injected twice weekly with DRPs (PEO 
and PMNN, saline in control) for 7 weeks 
 
Parameters Control PEO PMNN p-value 
BUN (mg/dl) 19±5 18±3 20±3 >0.05a,b 
Glucose (mg/dl) 300±52 306±32 270±35 >0.05a,b 
ALP (IU/l) 240±42 284±46 263±72 >0.05a,b 
T-Pro (g/dl) 4.9±0.3 5.3±0.5 5.1±0.3 >0.05a,b 
ALT (IU/l) 16±3 16±5 15±3 >0.05a,b 
Creatinine (mg/dl) 0.5±0.1 0.5±0.1 0.6±0.1 >0.05a,b 
aControl vs. PEO, bControl  vs. PMNN 
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These experiments demonstrated that long-term (7 week) intravenous injections of DRPs 
(PEO and PMNN) at concentrations found to be hemodynamically effective (1-2 μg/ml (0.17 – 
0.44 nM)) for the reduction of vascular resistance have no effect on the blood gas, CBC 
differential, and blood serum chemistry parameters measured in this study and suggests no effect 
on the cardiovascular, respiratory, liver and renal function. 
5.3.3 Hemodynamic efficiency of the intravenous infusion of the pharmaceutical grade 
hyaluronic acid solution 
Two experiments were performed to evaluate the in vivo hemodynamic efficiency of a 
pharmaceutical grade hyaluronic acid preparation (Hyvisc®, Anika Therapeutics). In these 
experiments, healthy male Sprague-Dawley rats were anesthetized and instrumented in order to 
monitor arterial blood pressure (right carotid artery), heart rate, carotid flow rate (left carotid 
artery), and skin tissue perfusion (plantar surface of both hind paws – relative changes compared 
to baseline). 
In the first experiment, the hyaluronic acid solution was intravenously infused via the 
jugular vein at concentrations of 50 (16.7 nM), 125 (41.7 nM), 250 (83.3 nM) and 250 μg/ml 
(83.3 nM) to yield final blood concentrations of 1 (0.33 nM), 6 (2.0 nM), 16 (5.33 nM) and 33 
μg/ml (11.0 nM) of the DRP, respectively. Figure 5.1 shows a portion of the record of the 
measured hemodynamic parameters (tissue perfusion (left and right plantar surface of hind paw), 
average arterial blood pressure and average carotid flow rate) taken before infusion and 20 
minutes after infusion of the hyaluronic acid DRP. In this particular case, at the highest polymer 
dose (33 μg/ml (11.0 nM)), there was an increase in tissue perfusion in the left and right plantar 
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hind paw, of up to 37 and 51% respectively and an increase in carotid flow rate by 33%. The 
percent change in each hemodynamic parameter at each polymer dose is shown in Table 5.5. No 
change was observed in blood pressure and heart rate. The calculated vascular resistance for 
tissue perfusion measurements (MAP/tissue perfusion) of the left and right plantar surface of the 
hind paw and for carotid flow measurements (MAP/average carotid flow rate) before the 
infusion and 20 minutes after each polymer dose is shown in Figure 5.2. 
 
 
Figure 5.1: Portion of a hemodynamic recording of the infusion of a hyaluronic acid DRP at 
concentrations up to 33 μg/ml (11 nM). 
 
A portion of a record of the hemodynamic parameters (tissue perfusion (left and right plantar surface of hind 
paw), average arterial blood pressure and average carotid flow rate) shown before infusion and 20 minutes after 
infusion of the hyaluronic acid DRP Hyvisc® at a final blood concentration of 1 (0.33 nM), 6 (2.0 nM), 16 (5.33 
nM) and 33 μg/ml (11.0 nM). 
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Table 5.5: Percent change in hemodynamic parameters from baseline measurements 20 minutes after 
infusion of the hyaluronic acid DRP, Hyvisc® 
 
 Blood Concentration of Hyaluronic Acid (μg/ml)
Parameters 1 6 16 33 
Tissue Perfusion (LP, TPU) no effect 24 % 43 % 37 % 
Tissue Perfusion (RP, TPU) 4 % 35 % 44 % 51 % 
Average Carotid Flow Rate (ml min-1) 6 % 24 % 32 % 33 % 
The percent change in hemodynamic parameters (tissue perfusion (left and right plantar (LP and RP, 
respectively) surface of hind paw) and average carotid flow rate) from baseline measurements 20 minutes after 
infusion of the hyaluronic acid DRP, Hyvisc®, at final blood concentrations of 1 (0.33 nM), 6 (2.0 nM), 16 (5.3 
nM) and 33 μg/ml (11.0 nM). No change was observed in average carotid blood pressure. 
 
 
 
 
Figure 5.2: Calculated vascular resistance for hemodynamic measurements 
during baseline and 20 minutes after the infusion of the hyaluronic acid 
DRP, Hyvisc® at 4 final concentrations 
 
Vascular resistance was calculated for tissue perfusion measurements 
(MAP/tissue perfusion) of the left and right plantar surface of the hind paw 
and for carotid flow measurements (MAP/average carotid flow rate) during 
baseline and 20 minutes after each polymer dose. 
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In another study, hyaluronic acid was injected at concentrations up to 1500 μg/ml (0.5 
μM) to yield a final blood concentration of 150 μg/ml (50 nM). Figure 5.3 shows a portion of a 
record of hemodynamic parameters (tissue perfusion (left and right hind paw), mean arterial 
blood pressure, and average carotid flow rate) taken before the infusion and 15 and 10 minutes 
after the infusion of the hyaluronic acid DRP at a final blood concentration of 50 (16.7 nM) and 
150 μg/ml (50 nM), respectively. An increase in tissue perfusion in the left and right plantar hind 
paw, an increase in carotid flow rate and a slight increase in mean arterial pressure were 
observed. However, after increasing the DRP concentration in blood to 150 μg/ml (50 nM), the 
tissue perfusion and carotid flow rate slightly decreased but were still significantly higher than 
before DRP infusion. The percent change in each hemodynamic parameter at each the polymer 
dose is shown in Table 5.6. A potential reason for this decrease might be an increase in blood 
viscosity due to this high polymer concentration (relative to the usual concentration given to 
observe beneficial hemodynamic effect of DRPs, ~1 μg/ml (0.17 – 0.33 nM)). The animal 
tolerated the higher concentration infusion very well, and no adverse effects (i.e., hematuria) 
were found from infusing the hyaluronic acid DRP at these higher concentrations. 
In these experiments, Hyvisc® (Anika Therapeutics), a commercially available 
pharmaceutical grade hyaluronic acid preparation, demonstrated a hemodynamic effect (decrease 
in vascular resistance) similar to other commonly used DRPs (PEO and PMNN). 
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Figure 5.3: Portions of a record of the hemodynamic parameters taken before infusion and 30 minutes after 
infusion of the hyaluronic acid DRP Hyvisc® 
 
Shown above is a portion of a record of the hemodynamic parameters (tissue perfusion (left and right plantar surface 
of hind paw), average arterial blood pressure and average carotid flow rate) taken before infusion and 30 minutes 
after infusion of the hyaluronic acid DRP Hyvisc® at a final blood concentration of 50 (16.7 nM) and 150 μg/ml (50 
nM). 
 
 
 
 
Table 5.6: Percent change in hemodynamic parameters from baseline measurements 30 minutes after 
infusion of the hyaluronic acid DRP, Hyvisc® 
 
 Blood Concentration of Hyaluronic Acid (μg/ml)
Parameters 50 150 
Tissue Perfusion (L; TPU) 43 % 29 % 
Tissue Perfusion (R; TPU) 10 % 18 % 
Average Carotid Flow Rate (ml/min) 10 % 8 % 
Average Carotid Pressure (mmHg) 7 % 9 % 
The percent change in hemodynamic parameters (tissue perfusion (left and right plantar surface of hind paw) 
and average carotid flow rate) from baseline measurements 30 minutes after infusion of the hyaluronic acid 
DRP, Hyvisc®, at final blood concentrations of 50 (16.7 nM) and 150 μg/ml (50 nM). 
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5.3.4 Outcomes of bolus infusions of PMNN and PEO-4500 
As a measure of acute toxicity and in order to test the applicability of giving higher doses (~100 
μg/ml (up to ~22 nM)) of DRPs in a short bolus infusion as one might see in the resuscitation 
during hemorrhagic shock, two experiments were performed in which PEO-4500 and PMNN 
were infused at concentrations ranging from 2 (0.44 nM) to 100 μg/ml (22.2 nM) and 2 (0.33 
nM) to 50 μg/ml (8.33 nM), respectively, in a fixed volume (1 ml) over 10 seconds. In the case 
of a human patient with a normal blood volume of 5 liters, this would represent a bolus infusion 
of ~150 ml given in 10 seconds. Therefore, this procedure represents a radical simulation of a 
bolus infusion. 
In general, the animals tolerated the bolus infusions at tested DRP concentrations well 
and no adverse reactions were observed. A slight increase in mean arterial pressure was observed 
after the DRP injection but quickly returned to pre-injection values. 
The results of these experiments suggest that PMNN and PEO-4500 can be delivered in 
small volumes at relatively higher concentrations without adverse effects. This may prove to be 
relevant in the treatment of hemorrhagic shock where small volume resuscitation is important. 
A limitation in the significance of this test is the gradual increase in the blood DRP 
concentration versus a primary bolus of 50 (1.1 – 8.3 nM) or 100 μg/ml (22.2 nM). By gradually 
increasing the DRP concentration, the vascular system may adapt to the DRP intravascular effect 
therefore masking any potential side effects that would occur by a single bolus infusion of 100 
μg/ml (22.2 nM). Future studies may focus on investigating the side effects of giving a series of 
short bolus infusion of gradually increasing concentration versus a single short bolus infusions of 
 120 
higher DRP concentration. This would provide insight into dosing protocols for conditions where 
DRPs need to be infused via a bolus injection. 
5.3.5 Outcomes of the infusions of extremely high concentrations of PMNN and a 
pharmaceutical grade hyaluronic acid solution. 
Two experiments were performed to investigate the hemodynamic effect of a slow infusion of 
extremely high concentrations, up to 150 times the hemodynamically effective concentration, of 
PMNN and hyaluronic acid (Hyvisc®; Anika Therapeutics). PMNN was infused at a 
concentration of 1250 μg/ml (0.42 μM) over 20 min resulting in a total blood concentration of 
~60 μg/ml (20 nM) of the DRP. A slight deterioration of the measured hemodynamic parameters 
(a slight increase in arterial blood pressure, and decrease in tissue perfusion and carotid artery 
flow rate) was observed during the infusion and might be explained by a local increase in blood 
viscosity due to poorer mixing of the DRP solution in the venous system. Blood samples 
obtained immediately following the infusion of PMNN and immediately prior to the end of the 
experiment showed little to no difference in blood gas values and blood hematocrit. However, a 
high plasma free hemoglobin concentration (hemolysis), ~300 mg/dl, was detected in the final 
blood sample (60 minutes post infusion). This may have lead to vasoconstriction related to a free 
hemoglobin effect on endothelial nitric oxide (reduction of the NO concentration) which may 
further explain the slight decrease in tissue perfusion and carotid artery flow rate that were 
observed. This phenomenon was previously discussed in the literature where in earlier animal 
studies using much higher doses of DRPs (both synthetic and natural) than those which are 
needed to produce beneficial hemodynamic effects, hematuria and hemolysis occurred through 
unknown mechanisms [6, 32]. Interestingly enough, the infusion of the hyaluronic acid DRP 
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solution at the same flow rate and at a much higher concentration in the syringe (3000 μg/ml (1 
μΜ), asymptotic viscosity ~40 cP at 22°C) did not cause any hemolysis, although the final DRP 
concentration in the animal’s blood was ~150 μg/ml (50 nM). The test results with Hyvisc® 
show that this DRP may be a strong candidate for larger animal trials and future clinical use. 
5.4 SUMMARY 
In this chapter, an investigation on the effects of DRPs on a variety of coagulation, hematologic, 
blood gas and serum chemistry parameters was performed in vitro and in vivo after acute and 
chronic DRP administration, at hemodynamically effective concentrations, to rats to exclude any 
deleterious effects of these long-chain molecules on hemostasis, hematology and organ function. 
Acute injections of DRPs (PEO-4500) showed no significant effects on clotting and hemostasis. 
Likewise, long-term (7 week) intravenous injections of DRPs (PEO-4500 and PMNN) produced 
no noticeable effect on the studied hematologic, blood gas and serum chemistry parameters 
suggesting that chronic injections of DRPs do not alter cardiovascular, respiratory, liver and 
renal function. 
In another set of experiments, a new DRP Hyvisc® (Anika Therapeutics), a commercially 
available pharmaceutical grade hyaluronic acid preparation, demonstrated a hemodynamic effect 
(decrease in vascular resistance) similar to other previously used DRPs (PEO and PMNN). These 
results are significant for the future clinical translation of DRPs. Potential “off-label” use of 
pharmaceutical grade hyaluronic acid preparations could dramatically lessen the time required to 
move these studies from the laboratory bench to use in patients. 
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Pilot studies were also performed to investigate the potential problems related to the 
intravenous infusion of high concentrations of DRP solutions. In acute experiments, the 
hemodynamic response of normal animals to an intravenous infusion of high concentrations of 
several DRPs (PMNN, PEO-4500 and hyaluronic acid) was assessed. Tests also included bolus 
injections of several different concentrations of DRPs (PMMN and PEO-4500) to determine if 
these preparations could be injected in relatively high concentrations in short time periods 
without an undesirable hemodynamic reaction. Tests with bolus injections of solutions with 
relatively high concentrations of DRPs and slow infusions of solutions with extremely high DRP 
concentrations, up to 150 times the hemodynamically effective concentration, showed that the 
hyaluronic acid can be safely delivered into the vascular system in small volumes and at high 
infusion rate. However, PMNN, which was shown to be safe and effective when injected at 
relatively low concentrations, was found to produce hemolysis in blood after a slow injection at 
extremely high concentration which can be related to the fact that there are still some impurities 
in this homemade preparation.  Delivery of small volumes at relatively high concentrations is 
relevant in the treatment of hemorrhagic shock in situations where small volume resuscitation is 
important. 
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6.0  EFFECTS OF DRPS ON BIODEGRADATION AND TISSUE DEVELOPMENT 
IN SYNTHETIC SCAFFOLDS 
6.1 INTRODUCTION 
Over the last decade tissue engineering has intensively explored the development of biological, 
synthetic or biosynthetic hybrid substitutes of almost every mammalian tissue. One of the 
challenges of these new regenerative therapies is the restoration and maintenance of blood flow 
to provide nutrients to and remove waste products from these engineered tissues and 
biomaterials. Angiogenesis, the growth of blood vessels from those pre-existing, is a critical 
component of this process, especially in the biointegration and biocompatibility of biomaterials 
and healing of wounds. It was previously shown that a sustained hemodynamic wall shear stress 
stimulates neovascularization and repair of damaged tissue in vivo [77]. Blood-soluble drag 
reducing polymers (DRPs) were recently shown to restructure the distribution of red blood cells 
(RBCs) in in vitro models of microvessels with diameters below 300 μm and significantly 
increase wall shear stress [11]. Previously demonstrated beneficial hemodynamic effects of 
DRPs are related in part to this ability to decrease the cell-free plasma layer in microvessels 
leading to facilitation of gas transport and, at the same time, to an increase in the near-wall blood 
viscosity which would load vessel walls with higher shear stresses. This latter effect might 
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promote angiogenesis and vasculogenesis via mechanotransduction mechanisms that translate 
these mechanical forces into biological responses of endothelial cells. 
The original focus of the study presented in this chapter was to investigate the hypothesis 
that the chronic intravascular injection of DRPs, which are able to increase microcirculatory 
blood flow and wall shear stresses in microvessels, would facilitate increased blood vessel 
formation and thus improved tissue infiltration in a biodegradable synthetic scaffold implanted 
subcutaneously in rat. Later we reconsider the aim of this study mostly concentrating on the 
collagen tissue formation and structure and amount of foreign bogy giant cells (FBGC) presented 
in biodegraded scaffolds. Experiments were carried out with porous polymeric scaffolds which 
were implanted subcutaneously in rats. The animals were injected prior to and twice weekly for 7 
weeks post scaffold implantation with DRP solutions (saline as Control). Histological and digital 
analysis techniques were used for assessment of tissue infiltration and growth and collagen 
deposition as well as blood vessel growth inside the scaffold matrix following scaffold explant. 
6.2 METHODS 
6.2.1 Fabrication of PLLA scaffolds 
Porous poly(L-lactide) (PLLA) scaffold implants were prepared by the combination of solvent 
casting and thermally induced phase separation (TIPS) by Dr. Ravikumar Thangappan in the 
laboratory of Professor Alan J. Russell (McGowan Institute of Regenerative Medicine, 
University of Pittsburgh, Pittsburgh, PA). Medical grade PLLA (RESOMER® L 210; 
Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany) was used in the 
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fabrication of the scaffolds. The PLLA used had an inherent viscosity of 3.3-4.3 dl/g (0.1% in 
chloroform, 25 °C) and a residual monomer of less than 0.1%. To obtain ~100 cm2 of the 
scaffold sheet, 1.0 g of amorphous PLLA was dissolved in 10 ml of anhydrous 1,4-Dioxane 
(99.8%, Sigma Aldrich, St. Louis, MO) and mixed by a magnetic stirrer for 2 hours. After the 
polymer was thoroughly mixed and homogenized, it was poured into a pre-cooled (-20º C) 
aluminum pan (10 cm x 10 cm) to form a 1-mm thick PLLA sheet. The aluminum pan with 
PLLA sheet was immediately placed into a freezer (–20° C). After 24 hours, the PLLA sheet was 
lyophilized for three days to completely remove the solvent. The polymer sheet was sliced into 
~1 cm2 size pieces using a surgical blade to make the scaffold implants and subsequently cold 
gas sterilized (38 °C) by exposure to ethylene oxide (EtO). The EtO sterilization process 
included a 4.5-hour cycle with exposure to EtO gas and a subsequent 36-hour aeration cycle for 
the complete removal of the EtO gas. The scaffolds were stored in their sterilization pouch until 
implantation.  
6.2.2 Examination of PLLA scaffolds by SEM 
PLLA scaffold pieces (n = 4) were examined before and after EtO sterilization using a scanning 
electron microscope (SEM) (JEOL JSM6330F, Tokyo, Japan) at 2.5 kV at 25x, 50x, 150x, 
1000x, and 2500x magnification to examine gross morphology, to ensure uniformity and to 
measure scaffold porosity. For SEM examination, scaffolds, randomly chosen before and after 
sterilization, were cut into smaller sections by a surgical blade, mounted on an aluminum stub 
covered with a carbon adhesive, critical point dried and then sputter-coated with gold particles. 
The images were collected at 1000x and 2500x from various regions of the scaffold. 
Using the public domain NIH Image program (Version 1.38x; developed at the U.S. National 
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Institutes of Health and available on the Internet at http://rsb.info.nih.gov/nih-image/) on a 
personal computer, pores were differentiated from the PLLA scaffold structure using image 
thresholding. The thresholded image was subsequently used to calculate porosity (%). An 
average porosity was calculated for the scaffolds before and after sterilization and statistical 
analysis was executed using a pair wise comparison (paired t-test). A p < 0.05 was considered to 
be statistically significant. 
6.2.3 Animal Care Compliance 
The surgical procedures and animal treatments performed in this study were approved by the 
Institutional Animal Care and Use Committee of the University of Pittsburgh (protocol 
#0511167). All animal care and procedures conformed to the National Institutes of Health 
Guidelines for the Care and Use of Laboratory Animals. 
6.2.4 Animals 
Male Sprague-Dawley rats (350-400 g, SASCO; Charles River Laboratories, Wilmington, MA) 
were housed in solid bottom micro-isolator containers and fed rat chow and water ad libitum. 
The animals were allowed a 6-day acclimatization period after delivery before experimental 
procedures commenced. 
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6.2.5 Drag-reducing polymers 
Two drag-reducing polymers were employed in these studies: a synthetic DRP (polyethylene 
oxide with MW of 4500 kD, PEO-4500; Dow Chemical) and a natural aloe-based DRP obtained 
in our laboratory (Poly(mannan), PMNN; MW=~4000-6000 kD). Descriptions of these DRP 
preparation were outlined in Chapter 3.2.2.1. A control solution consisted of sterile nonpyrogenic 
isotonic saline (0.9%, Baxter). Three groups (5 animals/group) were included in this study: PEO, 
PMNN and Control. 
6.2.6 Chronic intravenous infusion of DRP solutions in animals  
The animals received intravenous (IV) injections of DRPs two times per week, on Monday and 
Thursday, via the dorsal penile vein beginning on the day prior to scaffold implantation. The 
animals were anesthetized for the injection procedure due to the time required for administration 
of the DRPs and to minimize pain and distress on the animals. Anesthesia was induced and 
maintained by inhalation of isoflurane (1.5-4%) in O2 to sustain a surgical plane of anesthesia 
evidenced by the absence of pedal reflex. Animals were placed on a warming pad in dorsal 
recumbency and the penis was extruded from its sheath to visualize the dorsal penile vein. The 
injection site was disinfected with 70% ethanol alcohol and then a 5% povidone-iodine solution. 
The DRP solutions were infused using a 27 gauge needle, attached to a microbore catheter 
(Arrow International, Reading, PA) and a syringe on a syringe pump (PhD 2000; Harvard 
Apparatus, Holliston, MA), that was inserted into the penile vein at a controlled rate of infusion 
over 3-5 minutes. The infused volume (~1 ml) was calculated based on animal weight, original 
DRP concentration (50 μg/ml (1.1 – 8.3 nM)) and the desired DRP dosage to be given to the 
 128 
animal (120 μg/kg or 2 μg DRP/ml blood (0.33 – 0.44 nM)). Blood volume was estimated as 6% 
of lean body weight. The animals of the Control group received the same number of intravenous 
injections and the same weight-based volume of the control solution. Sterile gauze was held over 
the injection site until bleeding ceased. 
Due to their very high MW and long-chain structure of molecules, the DRPs can be only 
delivered into blood through IV administration. Although the DRP solutions were injected at 
concentrations as low as 50 μg/ml (1.1 – 8.3 nM), the ~ 1 ml solution was injected slowly (over 
3-5 min) to provide better mixing of the DRP molecules with the blood, to eliminate the risk of 
potential hemolysis due to rapid injecting the polymers as a bolus infusion as previously reported 
[6], and to reduce the risk of overwhelming the capacity of the small veins during the injection. 
6.2.7 Surgical procedures and animal care during 7-week scaffold implantation study 
6.2.7.1 Scaffold implant procedure. 
The scaffolds were implanted on the day following the first DRP infusion. Anesthesia was 
induced and maintained by inhalation of isoflurane in O2. The isoflurane concentration (1.5-4%) 
was adjusted to maintain a surgical plane of anesthesia evidenced by the absence of pedal reflex. 
Animals were placed on a warming pad in ventral recumbency and the surgical site prepared. A 
portion of the dorsal surface, from the base of the skull to the midline of the dorsum, was shaved 
and disinfected with 70% ethanol alcohol and then a 5% povidone-iodine solution. Aseptic 
technique was followed by using sterile instruments, drapes and techniques. A 1.5-cm incision 
was made at the dorsum midline, orthogonal to the sagittal plane, down to the level of the 
panniculus carnosus, 1 cm caudal to the scapulae. A subcutaneous pocket was created caudal to 
the incision with blunt scissors, and a saline-moistened and sterile 1 cm2 PLLA scaffold was 
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positioned in the pocket ~2-cm from the incision in order to avoid possible effects from healing. 
The incision was closed using several sterile 9-mm stainless-steel wound clips (MikRon 
Precision, Gardena, CA) which were removed by post-operative day (POD) 7.  
6.2.7.2 Post-operative care. 
All animals received a single subcutaneous (SQ) post-surgical prophylactic dose of gentamicin 
(5 mg/kg, APP Pharmaceuticals, Schaumburg, IL). The dorsal surface was cleansed with sterile 
saline and the animal was then removed from anesthesia and allowed to recover fully before 
returning to normal housing with free access to food and water for the remainder of the study 
duration. 
Post surgical analgesia was provided by acetaminophen (PCCA, Houston, TX) 
administered via the animals’ drinking water at a dose of 3.7 mg acetaminophen/ml drinking 
water during the 7 days prior to surgery and 5.4 mg acetaminophen/ml drinking water post-
operatively up to POD 3. This dosage calculation is based on the normal water consumption of a 
rat which is 8-11 ml/100 gm body weight/day and that a daily oral dose of acetaminophen 
adequate to provide post surgical analgesia is 300 mg/kg [135]. The addition of the 
acetaminophen to the drinking water during 7 pre-operative days was necessary to allow 
adaptation of the animals to the altered taste of the water and avoid “neophobia”. The 
concentration of acetaminophen was increased after surgery based on the assumption of reduced 
water consumption during the post surgical period. 
6.2.7.3 Scaffold explant procedure. 
At 7-weeks post-operative, the animals were anesthetized using isoflurane to obtain a surgical 
plane of anesthesia. The animal was placed in dorsal recumbency and was euthanized by an 
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intracardiac bolus of supersaturated (2 mmol/kg) potassium chloride (Hospira). Following 
euthanasia, the implant site of the PLLA scaffold was identified. The implant, along with 
adjacent native tissue, was surgically excised, photographed, and fixed in 10% neutral buffered 
formalin (Surgipath Medical Industries, Richmond, IL) for 24 hours at 25°C. 
6.2.8 Histological Analysis 
After fixation of the samples, the implants were prepared for histological analysis using routine 
processes. Briefly, the implants were dehydrated using a graded ethanol-xylene series, bisected 
in cross-section through the center and embedded in paraffin with the cut side down to provide 
cross section of the scaffold center. Two 5-μm thick sections, 100 μm apart, were prepared with 
a microtome and mounted on a microscope slide. By bisecting the scaffold, two samples per 
scaffold center were created. The sections were then deparaffinized and hydrated by a xylene-
ethanol series and subsequently stained with Masson’s trichrome which labeled collagen tissue 
blue and inflammatory cells of the granulomatous tissue a red to purple hue. The percentage of 
the area of the scaffold consisting of collagen and foreign body giant cells, collagen fiber 
orientation, and remaining scaffold material were quantified in the Masson’s trichrome-stained 
cross-sections. Physical parameters (height, width, perimeter and area) of the implants were also 
evaluated. 
Brightfield microscopy was performed on a Leica DM IRB inverted phase-
contrast/fluorescence microscope (Leica Microsystems, Bannockburn, IL) equipped with a 4x 
objective (HI PLAN 4x/NA 0.10; Leica Microsystems). The cross section was panned in both the 
x- and y-axis and six to eight overlapping images (2560 x 1920 pixels; 8.90 mm2) were obtained 
with a 12 bit 2588 x 1960 pixel CCD camera (DFC 480; Leica Microsystems) and PC-based 
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imaging management software (IM50; Leica Microsystems). The captured images were 
subsequently joined together (Canon Utilities PhotoStich; Canon USA, Lake Success, NY) to 
produce a composite image that consisted of the entire scaffold cross section. Digital analysis to 
quantify collagen and granulomatous tissue content, collagen alignment and the remaining PLLA 
implant area and measurements of the scaffold cross section physical parameters was performed 
on personal and Macintosh computers using the public domain NIH Image program and Adobe 
Photoshop 7.0 (Adobe Systems, San Jose, CA). A total of 30 images (2 images/scaffold) were 
analyzed. 
6.2.8.1 Quantification of the number of blood vessels 
Brightfield images of the tissue cross sections were captured with a 10x objective (N PLAN 
10x/NA 0.25; Leica Microsystems) on the same inverted phase-contrast/fluorescence microscope 
system used to create composite images of the scaffold sections. The images were analyzed post 
hoc using NIH Image. Blood vessels were identified and counted in each field in a single-blinded 
manner. Blood vessels were identified by a luminal structure bordered with endothelial cell 
pattern containing RBCs within the intra luminal space. A total of 13 non-overlapping fields 
(1.43 mm2) were examined in one of the two cross sections prepared from each scaffold. The 
cross section was chosen randomly. The number of vessels was counted and the tissue area of 
each image was quantified. Vessels were categorized in three sizes: 0-25 μm, 25-50 μm and 
greater than 50 μm. A blood vessel density was then calculated for each scaffold. Results are 
expressed as the mean ± standard deviation. 
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6.2.8.2 Quantification of granulomatous and collagen tissue 
The quantification of the granulomatous and collagen tissue content of the scaffold cross sections 
was performed using a threshold HSI filter (Hue-Saturation-Intensity; Fovea Pro 1.0; Reindeer 
Graphics, Ashville, NC) in Adobe Photoshop 7.0. The Threshold HSI plug-in allowed for easy 
discrimination of the different tissue types by converting the color space to a graphical 
representation of the Hue-Saturation-Intensity space. Hue and Saturation were presented on a 
circle where the angle corresponded to the hue and the radius to the saturation while the darkness 
of the point (gray level) represented the number of pixels with that particular value. The user 
then highlighted the area on the circle corresponding to particular region of interest. To begin the 
analysis, the pixel dimensions of the 32-bit true color composite images produced from the 
Masson’s trichrome-stained cross sections were decreased to reduce the image size from ~ 8 
million to ~2 million pixels to make image analysis more manageable. The area in the image 
representing the scaffold was then selected in order to exclude the tissue area outside (i.e., the 
fibrous collagen capsule) from the analysis. The total number of pixels of the implant area was 
then computed from this selection and recorded. The Threshold HSI plug-in was then used to 
highlight the regions in the implant area corresponding to granulomatous and collagen tissue, 
respectively. The filter output was 2-bit images in which either the granulomatous or collagen 
tissue appeared black and all other tissues white. The total number of thresholded (black) pixels 
in the implant area was then computed and recorded. For each cross section, the area 
corresponding to granulomatous and collagen tissue was added to yield the total stained tissue 
area. The area in the scaffold cross sections consisting of granulomatous or collagen tissue as a 
percentage of the total stained tissue area was then calculated. Individual data points that were 
greater than two standard deviations from the mean value of the remaining data were discarded. 
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6.2.8.3 Collagen alignment analysis 
The quantification of the alignment of the collagen tissue in the scaffold cross sections was 
performed using NIH Image using modifications to the methods previously described by 
Noorlander et al. [136]. The 32-bit true color composite images produced from the Masson’s 
trichrome-stained cross sections were first converted into three separate 8-bit grayscale images 
containing the Red (R), Blue (B) and Green (G) color components of the original image using 
RGB Split. The red color component image was digitally subtracted from the blue color 
component image resulting in an 8-bit grayscale image which highlighted the collagen, 
represented by gray levels, against a black background. By subtracting color components, the 
probability of error in the analysis associated with potential variability in the levels of staining 
between tissue specimens is reduced. The grayscale image was then thresholded using the 
automatic threshold function in NIH Image to produce a 2-bit image in which pixels that met the 
threshold criteria (i.e., collagen fibers) were set to 0 (black) and all other pixels (i.e., 
background) were set to 255 (white). A flowchart illustrating the steps in the process to isolate 
collagen tissue in a scaffold cross section is shown in Figure 6.1. Automatic thresholding in NIH 
Image is based on the iterative technique developed by Ridler and Calvard [137]. Briefly, the 
image histogram was first divided into two parts based on an initial threshold which was chosen 
as half the maximum dynamic range. Then, the sample means of the gray values associated with 
the foreground pixels and those associated with the background pixels were computed and a new 
threshold was chosen as the average of these two sample means. This step was repeated until the 
new threshold value was the same as the threshold value in the previous iteration. The use of the 
automatic threshold function eliminates the potential bias introduced by a human observer. The 
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area in the image pertaining to the implant area (i.e., scaffold) was then selected to exclude area 
outside (i.e., the fibrous capsule) from further analysis. 
An analysis was then performed on the thresholded (black) pixels with an area greater 
than 50 pixels2 in which best fitting ovals were calculated for each black object. The area 
(pixels2), length (number of pixels) of the major and minor axis, angle and circularity of each 
best-fit oval were then determined. Angle was defined as the angle (0-180°) between the major 
axis and a line parallel to the x-axis of the image. Circularity was defined as 
4*π*(area/perimeter2). A value of 1.0 indicated a perfect circle. As the value approached 0.0, it 
indicated an increasingly elongated polygon. Ovals with a circularity above 0.75 were eliminated 
from the analysis to reduce the probability of introducing error in the analysis. The results of the 
NIH Image calculations were copied into a spreadsheet (Excel XP; Microsoft Corp) and sorted 
based on major axis length. The coincidence of the angles of the 50 longest major axes was 
determined using the frequency function in Excel. This function produced an angle histogram 
with bins 10° wide starting from 0°. A collagen orientation index was then calculated by dividing 
the max value of the angle histogram (the angle that occurred most often) by the arithmetic mean 
of the angle frequency (the average of all angles). This produced a collagen orientation index 
ranging from a value of 1 (least organized) where the maximum value of the angle histogram 
was equal to the mean angle frequency to a value of 19 (most organized; equal to the total 
number of 10° angle bins) where all angles were in the same angle bin. Since the desired range 
was 0 to 1 for the collagen orientation index, the result above was divided by the total number of 
bins, 19, to product an index with a range of 1/19 to 1, which was considered close enough to a 
range of 0 to 1 to be easily interpreted. Individual data points that were greater than two standard 
deviations from the mean of the remaining data were discarded. 
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Figure 6.1: Flowchart illustrating the digital image analysis used to isolate collagen tissue in a scaffold cross section 
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Figure 6.2: Demonstration of the techniques performed to quantify the 
orientation of collage fibers in the scaffold cross sections 
 
(A,B) Brightfield images of PLLA scaffolds stained with Masson’s 
trichrome from the Control group (A) which demonstrates disorganized 
collagen and the PEO group (B) which demonstrates organized 
collagen. (C) 8-bit grayscale image showing isolated collagen 
structures of the image B. (D) 2-bit image obtained after thresholding 
on the collagen fibers (black). (E, F) Best fit ovals were placed around 
collagen structures. A major axis length and its angle from a line 
parallel to the x-axis were calculated which were used to determine an 
orientation index. 
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6.2.8.4 Quantification of the remaining scaffold material 
The birefringence of the PLLA polymer was used to quantify the amount of remaining PLLA 
material in the Masson’s trichrome-stained scaffold cross sections via polarized light 
microscopy. 
Scaffold cross sections were placed between two crossed polarization filters and images 
were captured on a Nikon TE2000 inverted phase-fluorescence microscope (Nikon Instruments, 
Melville, NY) equipped with a 10x plan fluorite objective (Plan Fluor DL 10x/NA 0.30 w/phase 
ring PhL; Nikon Instruments) and a 12 bit 1600 x 1200 pixel CCD camera (Spot; Diagnostic 
Instruments, Sterling Heights, MI) coupled to a Macintosh computer (Power PC; Apple 
Computer, Cupertino, CA). Two 10x images (0.95 mm2) were captured from each scaffold cross 
section. A corresponding brightfield image was also captured of the same area to allow for 
comparison. 
The polarized light images were then analyzed with NIH Image on a personal computer. 
The 32-bit true color composite images were first converted into 8-bit grayscale images. The 
grayscale image was then manually thresholded to produce a 2-bit image in which pixels that 
met the threshold criteria (i.e., remaining PLLA particles) were set to 0 (black) and all other 
pixels (i.e., background and tissues) were set to 255 (white). The total area of each 10x image 
(0.95 mm2) that was comprised of black pixels was then computed. The results obtained from the 
two images captured from each scaffold cross section were averaged. Individual data points that 
were greater than two standard deviations from the mean value of the remaining data were 
discarded. 
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6.2.8.5 Statistical analysis 
Results are expressed as the mean ± standard error for each group unless previously noted. Each 
cross sectional image was considered to be an independent sample from the group. In each 
group, a total of five animals were each implanted with a single scaffold. During histological 
processing, two cross-sections were cut from a single scaffold. Therefore, the mean and standard 
error calculations of the measured parameters were based on 10 samples/group unless otherwise 
noted. Since there were three treatment groups in this study, a one-way ANOVA with Tukey 
post-hoc test was used to compare the mean value of the parameter of interest in the 
experimental groups (i.e., PEO-4500 and PMNN injected animals) to that of the Control group. 
A p < 0.05 was considered to be statistically significant. 
6.3 RESULTS AND DISCUSSION 
6.3.1 SEM analysis of PLLA scaffolds before implantation 
Scanning electron micrographs were collected at 25x, 50x, 150x, 1000x and 2500x to assess the 
general morphology of PLLA scaffold samples (Figure 6.3). Examination of four samples, each 
from different preparations, demonstrated consistency in the fabrication technique. The scaffold 
morphology closely resembled that previously described in the literature [138]. Using these 
images, we also confirmed that the EtO sterilization process did not affect the scaffold 
morphology. 
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Figure 6.3: SEM micrographs of a PLLA scaffold 
 
SEM images show a piece of a PLLA scaffold taken at (A) 25x, (B) 
50x, (C) 150x and (D) 2500x 
 
Micrographs taken at 1000x and 2500x magnification underwent further examination to 
estimate the porosity of the PLLA scaffolds for comparison before and after EtO sterilization. 
NIH Image was able to distinguish the pores from the scaffold structure and porosity was 
estimated from these images. The scaffold porosity, as calculated in 1000x magnification 
images, was 49 ± 7% before sterilization (n = 4) and 52 ± 2% after sterilization (n = 4) (Figure 
6.4). No statistical difference was observed. The porosities were 47 ± 15 vs. 57 ± 2 when 
estimated in the 2500x images taken before (n = 3) and after (n = 4) sterilization, respectively (p 
> 0.05). The slight differences can be attributed to the region chosen for the SEM analysis. Since 
the scaffold structure thickness is not completely uniform, there may be regions where more 
scaffold structure is present and the image analysis technique resulted in a lower porosity. 
However, comparison by gross examination revealed that the porosities tend to be fairly uniform 
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over the entire scaffold structure and also pre- and post-sterilization. It is also noteworthy to 
mention that the pore size ranged from ~10-50 μm. 
 
 
Figure 6.4: Scaffold porosity calculated before and after cold-gas 
EtO sterilization 
 
Scaffold porosity was calculated from SEM images (1000x 
magnification) taken before and after cold-gas EtO sterilization of 
the PLLA scaffolds. Porosity did not change (49±7% vs. 52±2%, 
Pre vs. Post, respectively, p > 0.05, n = 4) demonstrating that the 
implants retained their porous structure after the EtO cold-gas 
sterilization procedure; Mean ± SEM. 
 
6.3.2 Outcomes of Scaffold Implantation and Bi-weekly DRP injections 
The subcutaneous implantation of the PLLA scaffolds into the animals was without adverse 
events. No complications were seen from the twice-weekly intravenous infusions of PEO-4500 
and PMNN (saline in control animals). All animals (n=5 for each group – Control, PEO-4500 
and PMNN) survived to the study endpoint (7 weeks) at which time the animals were 
anesthetized, euthanized and the scaffolds explanted for histological examination. The scaffolds 
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were dissected free from the subcutaneous tissue without any issues. The constructs were 
encapsulated by thin, vascularized tissue. 
6.3.3 Histologic Findings for the Subcutaneously Implanted PLLA scaffolds 
Histologic examination was first performed by a blinded expert (Professor Harry C. Blair, MD, 
Departments of Pathology and Cell Biology and Physiology, University of Pittsburgh). At 7 
weeks post implant, chronic inflammation or a typical foreign body reaction to the PLLA 
implant characterized by the presence of foreign body giant cells (FBGCs) and the components 
of granulation tissue: macrophages, fibroblasts and capillaries [139, 140], to the PLLA implant 
was observed. In addition, macrophages and FBGCs were present at the tissue-PLLA interface. 
A similar fibrous capsule that ranged in thickness from 50 to 400 μm surrounded scaffolds of all 
groups. 
Upon further examination, a major difference was apparent between the PLLA scaffolds 
of DRP-treated and saline-treated groups. In all but one (both cross-sections) of the scaffolds of 
the Control group (saline-treated), the PLLA implant was comprised of mainly randomly 
oriented collagenous tissue and granulomatous inflammation with a large number of apparent 
macrophages and FBGCs. Scaffolds explanted from both PEO and PMNN-treated animals 
showed significantly less granulomatous inflammation. The collagenous tissue in the scaffolds of 
the DRP-treated animals also appeared to be greater in concentration and significantly more 
organized. The collagen tissue fiber bundles were not only similarly oriented to each other but 
were preferentially aligned parallel to the transverse plane or the short axis of the scaffold. In 
other words, the collagen fiber bundles ran perpendicular to the muscle and skin layers between 
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which the scaffold was implanted. No apparent difference in vascularization was noticeable 
during the initial histological assessment and further microscopic analysis had to be performed. 
Figure 6.5 shows the histologic appearance of the PLLA implants of each treatment 
group (Control (saline), PEO-4500 and PMNN) 7 weeks after surgery. 
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Figure 6.5: Sample cross sections of PLLA scaffolds explanted from animals infused with DRPs 
(saline in control) 
 
Photomicrographs show composite images Samples of Masson’s trichrome-stained PLLA scaffold cross 
sections explanted from animals infused with either saline (Control; top), poly(ethylene oxide) (MW = 4500 
kDa; middle) or poly(mannan) (bottom). 
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6.3.4 Results of the quantification of inflammatory and collagenous tissue content and 
analysis of collagen organization 
The initial histological examination of the Masson’s trichrome-stained scaffold sections revealed 
a clearly discernable difference between scaffolds of Control and DRP groups. This prompted a 
histomorphometric analysis to quantify the area in the scaffolds that was comprised of 
inflammatory cells and collagen tissue. Each tissue element was easily discriminated using the 
Threshold HSI filter (Fovea Pro 1.0; Reindeer Graphics), which operated as a subroutine in 
Photoshop 7.0 (Adobe Systems). Figure 6.7 (A) shows photomicrographs of sample fields (0.77 
mm2) of Masson’s trichrome-stained scaffold cross-sections before (left panels) and after the 
separation of collagen (middle panels) and FBGCs (right panels) by digital subtraction of 
Threshold HSI selected groups. This demonstrates the effectiveness of the selection algorithm in 
discriminating tissue elements. Additionally, a meaningful quantitative interpretation of the 
tissue was achieved with scaffold sections prepared with a simple, inexpensive and routine 
histology stain. In each row, the same field is represented as either a 24-bit RGB image or a 
digitally separated element. 
The quantitative digital analysis showed that the IV administration of PEO-4500 and 
PMNN had a profound effect on the percentage of the total stained tissue area of the explanted 
scaffolds that was inflammatory cells (FBGCs) or collagenous tissue (Figure 6.7 (B)). The 
quantitative analysis confirmed the findings of the initial histologic examination in which 
scaffolds explanted from both PEO and PMNN-treated animals showed significantly less 
granulomatous inflammation and increased amounts of collagenous tissue. The reduction in the 
percentage of FBGCs per stained tissue area was the greatest and statistically significant (p = 
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0.0012 vs. Control) in scaffolds explanted from animals treated with PEO-4500 (by 30%) and 
slightly less so in scaffolds explanted from animals treated with PMNN (by 11%). The observed 
reduction in FBGC content in the scaffolds of the DRP-treated animals was balanced with 
increased amounts of collagenous tissue. Therefore, since the scaffolds of the animals treated 
with PEO-4500 showed the largest reduction in inflammatory tissue, they also demonstrated the 
biggest increase in the percentage of collagen per stained tissue area (by 30%, p = 0.0012 vs. 
Control). A modest increase (10%) in collagen tissue occurred in scaffolds explanted from 
animals treated with PMNN. 
The FBGC area to collagen area was inversely proportional suggesting that the areas not 
filled with FBGCs contained active fibroblasts that secreted collagen. This implies that the 
reduction in the inflammatory response is extremely significant for the integration of other cell 
types in the scaffolds. The percentage of the two tissue types were nearly equal (~50%) in the 
scaffolds of the Control group whereas the scaffolds of the PEO-4500 group contained roughly 
65% collagen and only 35% FBGCs. The secreted substances of activated macrophages, such as 
reactive oxygen and nitrogen intermediates, acidic hydrolases and cytokines are capable of being 
cytotoxic [141]. One particular study by Lam et al. [142] found that cell damage and necrosis 
were caused by the phagocytosis of PLLA particles by peritoneal macrophages. Hence, it is 
reasonable that the higher degree of inflammatory tissue in the scaffolds of the Control group 
created an unfavorable environment for the proliferation of other cell types such as fibroblasts. 
These results are extremely significant for patients with orthopedic implants. The phagocytosis 
of wear debris from orthopedic implant materials by macrophages have been implicated in the 
pathogenesis of osteolysis and aseptic loosening [143]. The major cause of joint replacement 
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failure and the most important clinical problem associated with total hip and knee replacement is 
the pathologic bone resorption around the prosthetic implant itself [143, 144]. 
Fascinatingly enough, the observed serendipitous phenomenon may be explained in part 
by the same mechanisms that lead to our hypothesis regarding the ability of DRPs to promote 
angiogenesis via the regulation of hemodynamic forces. During a response to a foreign body, 
blood circulating monocytes, a type of leukocyte, move radially from the central blood stream to 
the vessel wall; a process known as margination. Margination is necessary for the monocytes to 
begin to make contact and roll along the vessel wall. RBCs have been shown to be one of the 
most influential contributing factor to leukocyte margination [145, 146]. More importantly, it 
was demonstrated that leukocyte margination is dependent on RBC aggregation (RCA); RCA 
enhanced leukocyte margination and in its’ absence, margination does not occur [147, 148]. 
Interestingly, once animals which have blood that does not normally demonstrate the RBC 
aggregation phenomenon (e.g., ovine, bovine), present with pathological conditions such as 
infection or an inflammatory reaction caused by surgery and implantation of heart-assist devices, 
RBCs start to aggregate (as shown in Figure 6.6), thus promoting leukocyte margination and 
further aggravation of animal conditions. 
 147 
 
Figure 6.6: Blood from a normal healthy bovine and from a bovine calf implanted with 
ventricular-assist device (VAD) 
 
Photomicrographs of bovine blood: (A) Blood from a normal healthy bovine does not demonstrate 
aggregation. (B) Blood from a bovine calf implanted with a VAD demonstrates aggregation due to 
the inflammatory reaction caused by surgery and implantation of heart-assist devices. This would 
thus promote leukocyte margination and further aggravate animal conditions (photos by 
Kameneva MV, with permission). 
 
 
Therefore, margination may be manipulated, either increased or reduced, through the 
regulation of RCA mediators. As the monocytes roll along the surface, signals from cells at the 
foreign body implant site cause endothelial cells to become activated and express adhesion 
molecules. Receptors on the monocytes’ surface allow the cells to then bind to the endothelium 
and become immobilized. At this point, through diapedesis, or extravasation, the cells migrate 
from the intravascular space through the endothelium toward the implant [140, 149]. Our results 
showed that the number of inflammatory cells, macrophage and FBGCs, in the scaffold implants 
of animals infused with DRP solutions was reduced compared to those of Controls. In terms of 
hemodynamic influence, the DRPs’ abilities to redistribute RBCs toward the microvessel wall 
and to remarkably enhance microvascular perfusion would produce considerable effects on the 
wall shear stresses imposed on the endothelium. If the shear rates were to be increased above that 
which would be endurable by adhesive bonds of leukocytes to the endothelium, the end result 
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would be fewer cells available for diapedesis. In an in vitro study, Theilmeier et al. [150] showed 
that the threshold for adherence of human monocytoid THP-1 cells to resting human umbilical 
vein endothelial cells was around 300 s-1. Activation of the endothelial cells by phorbol myristate 
acetate only increased this threshold to 400 s-1. Therefore, it is plausible that the high 
concentration of RBCs near the vessel wall and/or an increase in blood perfusion due to the 
presence of DRPs would have a significant enough effect to hinder or prevent the rolling and 
adhesion of leukocytes. This hypothetical mechanism of reduction of leukocyte margination and 
rolling in small vessels due to the presence of DRPs in blood was proposed by Dr. Kameneva 
several years ago but yet to be proven experimentally. Furthermore, since, RBC aggregates are 
easily break down due to an increase in shear rates, even a minor increase in blood flow would 
result in disaggregation of RBC rouleaux and  reduction of leukocyte margination. Additionally, 
the redistribution and relocation of RBCs from the core flow toward the near-wall space in 
microvessels would hinder margination, rolling and adhesion by: effectively limiting the space 
near the endothelial cell wall for leukocytes, causing RBC-leukocyte collisions and reducing the 
hematocrit in the central core flow which would reduce the propensity for RBCs to aggregate. 
Furthermore, this effect may be of great utility in preventing leukocyte margination in those 
pathologies where RCA is increased due to reduced blood flow such as inflammation, 
hypovolemic and septic shock and ischemia [151]. It may also imply potential beneficial effects 
of DRPs in disorders and diseases associated with hematological and hemorheological 
disturbances such as elevated levels of fibrinogen, polycythemia and changes in RBC 
deformability and surface charge [151]. 
The slight differences we observed in the FBGC and collagen content of scaffolds of the 
animals injected with either PEO-4500 or PMNN may be explained by differences in the 
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circulating half-life of the polymers in-vivo. Future studies may involve more frequent infusions 
of PMNN to determine what regimen is necessary to achieve the desired level of inflammatory 
mediation. 
These results also support the proposed explanation on the similarity of blood vessel 
densities between DRP-treated and saline-treated groups that suggested that the increased 
number of inflammatory cells in the Control group elevated angiogenic molecule production to 
increase the number of blood vessels. The stimulus from the inflammatory response may have 
been greater than the stimulus from the DRP intravascular effect. This is discussed in more detail 
in Section 6.3.6. 
The initial histological examination also found that collagen tissue in the scaffolds of 
animals injected with DRPs was also better organized. Therefore, quantitative digital analysis 
was completed to look at the congruency in the alignment of collagen fiber bundle elements. In a 
study by Noorlander et al. [136], changes in the orientation of collagen fibers in the dermis of pig 
skin were determined after mechanical stretching by placing best fit ovals around collagen 
structures and calculating the mean length of the major axes of the 10 largest ovals. This value 
was considered to be the collagen alignment index. However, this computation only accounts for 
stretching of the collagen fibers and fails to take into account the overall orientation. 
Additionally, the image analysis software may also interpret adjacent collagen fibers as one 
element generating enlarged best-fit ovals, introducing a potential erroneous computation. In our 
analysis, we not only took into account the lengths of the major axes of the best-fit ovals but also 
their angles, as determined from the x-axis. This offers further interpretation on the similarity of 
the orientation of the collagen bundles to each other. The collagen alignment index was 
computed from the coincidence of the angles of the 50 longest ovals. The collagen orientation 
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index ranged from a value of close to 0 (least organized) to a maximum value of 1 (most 
organized). Collagen was statistically significantly more aligned (p<0.0001) in the scaffolds 
explanted from animals injected with PEO-4500 (by 113%, n=9) and PMNN (by 110%, n=9) 
than those of the Control animals (n=10) (Figure 6.7 (C)). 
Collagen fiber orientation dictates the flexibility and tensile mechanical strength of soft 
tissues [152]. Soft tissues with preferential fiber alignment are anisotropic and have 
extraordinary mechanical properties in the direction of the fibers. In the scaffolds of the DRP-
treated animals, the preferred direction of the collagen fibers is typically orthogonal to the skin 
and muscle layers; this is the short axis of the scaffold. Therefore, the largest surface area of 
scaffold is in contact with the skin and muscle layers and provides the most probable means for 
cells to infiltrate the pores. The most possible reason for the observed collagen architecture is the 
migration of fibroblasts along the pores from one surface to the other. However, in the Control 
group, its higher degree of inflammatory tissue had likely eroded the PLLA scaffold at a faster 
rate leaving less bearing on the path of collagen formation. Additionally, since more of the pores 
were filled with FBGCs, fibroblasts would have likely had a more tortuous path to follow. It is 
also possible that since the DRPs might provide better perfusion of the ensuing fibrotic capsule 
surrounding the implant, the fibroblasts and other cellular components would follow the 
direction of shortest distance from supply. 
Future studies may be performed to analyze the types of collagen present in the scaffolds 
as well as the thickness of the collagen fibers. By determining the types of collagen and the 
fibers thicknesses in the scaffold, the progression of the healing process and the foreign body 
reaction could be determined. For instance, type III collagen would be indicative of that 
produced by young fibroblasts in granulation tissue; the tissue that makes up the majority of the 
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scaffold cross sections while Type I collagen is the toughest of all collagen types and is end 
product of scar formation. Additionally, thin fibers are seen at earlier stages than thick fibers 
with close packing. 
 152 
 
Figure 6.7: Effect of the DRPs PEO-4500 and PMNN on macrophage infiltration and granulomatous response 
in subcutaneously implanted PLLA scaffolds 
 
(A) Photomicrographs show sample fields (0.77 mm2) which demonstrate the separation of collagen and 
FBGCs by digital subtraction of threshold HSI selected groups indicating the efficacy of the selection 
algorithm. Rows show the same field either as a 24-bit RGB image or a digitally separated element. (B) Graph 
shows the effect of the infusion of PEO-4500 and PMNN (both at a blood concentration 2 μg/ml (0.3 – 0.4 nM), 
saline in Control) on the percentage of the total stained tissue area in photomicrographs (examples shown 
in Figure 6.5) of Masson’s trichrome stained scaffold cross sections that is FBGCs (white bars) or collagen 
(black bars); #p=0.0012 vs. Control, individual data points > 2 SD from the mean of the remaining data were 
discarded, Control – n = 8, PEO – n = 10, PMNN – n = 9, Mean ± SE. (C) Effect of the infusion PEO-4500 and 
PMNN (both at a blood concentration 2 μg/ml (0.3 – 0.4 nM), saline in Control) on the alignment of collagen 
tissue in a subcutaneously implanted PLLA scaffold. A collagen orientation index was calculated in Masson’s 
trichrome stained scaffold cross section photomicrographs (examples shown in Figure 6.5) to express the degree 
of organization of the collagen tissue within the scaffold. A value close to 0 indicates the least amount of 
organization and a value close to 1 denotes the most amount of organization; *p<0.0001 vs. Control, individual 
data points > 2 SD from the mean of the remaining data was discarded, Control – n = 10, PEO – n = 9, PMNN – 
n = 9, Mean ± SE. 
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6.3.5 Results of PLLA degradation quantification 
The scaffold cross-sections were also observed with polarized light microscopy to quantify the 
residual PLLA polymer and to determine the effect of reducing the inflammatory response on its 
degradation. Photomicrographs in Figure 6.8 (A) show brightfield (left panels) and polarized 
light (right panels) sample fields (0.26 mm2) of the Masson’s trichrome stained sections. In the 
brightfield images, the PLLA appears as a clear non-stained element but in the polarized light 
images, the birefringence of the PLLA was very distinct and appeared as bright areas against the 
dark background of the surrounding tissue. This property made the quantification of the 
remaining PLLA implant with digital image analysis very straightforward because the bright 
areas could be easily discriminated from the dark background. 
The un-degraded scaffold material was quantified in two (10x – 0.95 mm2) polarized 
light photomicrographs per scaffold cross section. The PLLA was significantly more (p < 0.0001 
vs. both DRP groups), and almost entirely, degraded in the scaffolds of the Control group. The 
cross-sectional area of remaining PLLA in the scaffolds of PEO-4500 and PMNN injected 
animals was 24.16x103 ± 3.08x103 μm2 and 18.22x103 ± 3.10x103 μm2 out of a total field area of 
95.04x104 μm2, respectively, versus 0.70x103 ± 0.31 x103 μm2 in Control (Figure 6.8 (B)). This 
corresponds to 2.54 ± 1.02 % and 1.92 ± 1.03 % of the total field area (PEO-4500 and PMNN, 
respectively), versus 0.07 ± 0.09 % in Control. 
Macrophages and their multinucleated variants, foreign body giant cells, are known to 
secrete acidic hydrolases as part of the inflammatory response to phagocytize foreign body 
particles [143]. At a biomaterial interface, macrophages and FBGCs may lower the pH 
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significantly from that of physiological (7.4). In fact, the phagolysosomal vacuoles inside 
macrophages have been described as having a pH as low as 3. Since the degradation of PLLA 
has been recognized to occur by acid hydrolysis [153, 154], it can be concluded that the 
degradation of the PLLA scaffolds in all scaffold groups in this study was by the infiltrating 
FBGCs. This conclusion is well supported by the results of the FBGC area quantification where 
the extent of FBGC infiltration seems to correspond to the degree of degradation of the PLLA 
scaffold. Thus, the Control group which demonstrated the highest level of FBGC infiltration 
showed almost complete degradation of the PLLA and the PEO-4500 group which had the 
lowest level of FBGC infiltration had the lowest degree of PLLA degradation of the three 
groups. The strongest correlation is found when comparing the difference in the percentage of 
FBGC content between PEO-4500 and PMNN (~30%) to the difference in the percentage of 
remaining PLLA of these two groups (~25%). However, the same is not true when comparing 
these differences between the two DRP groups to the Control group. The percentage of FBGC 
area in the scaffolds of the Control group was only ~12% higher than that of the scaffolds of the 
PMNN, which contained the highest level of FBGC infiltration of the two DRP-treated groups. It 
remains unclear whether such a small difference in FBGC infiltration would cause such a 
dramatic degradation of the PLLA. This may be explained by the possibility that the 
quantification of the FBGC area in the Control group does not represent the maximum amount of 
inflammatory tissue that had infiltrated the tissue. What may be seen is the waning of the foreign 
body response in these scaffolds due to almost complete degradation of the PLLA. 
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These results may also explain the difference in collagen alignment between the scaffolds 
of DRP-treated animals and those of the Controls. It is clear that the higher degree of scaffold 
degradation in the Control group would lead to very little control of the collagen fiber orientation 
as the porous structure would have been less defined. 
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Figure 6.8: Reduced degradation of implanted PLLA scaffolds in animals infused with the DRPs PEO-4500 and 
PMNN 
 
(A) Photomicrographs show sample fields (0.26 mm2) (brightfield (left panels) and polarized light (right panels)) 
of the cross sections of PLLA scaffolds stained with Masson’s trichrome that were explanted from animals 
infused with either saline (Control) (top left panel), PEO-4500 (middle left panel) or PMNN (bottom left panel) 
used to quantify the percentage of the remaining PLLA implant. The remaining PLLA implant demonstrated 
birefringence and is shown as the bright areas in the polarized light photomicrographs (right panels). (B) Graph 
shows that the effect of the infusion of PEO-4500 and PMNN on the reduction in the FBGC infiltration reduces 
the degradation of the PLLA implant. Remaining scaffold material was quantified from two (10x – 0.95 mm2) 
polarized light photomicrographs per scaffold cross section. The remaining PLLA in the scaffolds of PEO and 
PMNN injected animals was 2.54±1.02% and 1.92±1.03% of the total field area, respectively, versus 0.07±0.09% 
in Control; *p<0.0001 vs. Control, individual data points > 2 SD from the mean of the remaining data was 
discarded, Control – n = 8, PEO – n = 10, PMNN – n = 10, Mean ± SE. 
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6.3.6 Results of blood vessel density quantification 
Using Masson’s trichrome stained scaffold sections, the blood vessel density was determined 
within the scaffold and within the encapsulation tissue. The vessels were categorized by size (0-
25 μm, 26-50 μm and greater than 50 μm) and identified by locating structures that met the 
selected criteria (luminal structure bordered with endothelial cell pattern containing RBCs within 
the intraluminal space). The results are summarized in Table 6.1. Little to no difference (p > 
0.05) was observed when comparing the blood vessel densities of the DRP-treated animals to 
those treated with saline (Control). 
Endothelial cells are known to be sensitive to intravascular mechanical stimuli such as 
the shear stress caused by blood flow [155]. In vivo observations have shown that high flow 
rates, which generate high intravascular shear stresses on endothelial cells, are important for 
capillary growth [156-159]. Increased capillarity has been shown to occur by intussusceptive 
angiogenesis through the administration of prazosin, an α-sympathetic blocker capable of 
vasorelaxation, to increase blood flow and thus elevate shear stress [160, 161]. We had 
hypothesized based on our in vitro microchannel findings that, the relocation and redistribution 
of RBCs closer to the endothelial cells of the vessel wall (vessels less than 300 μm) due to 
presence of DRPs in blood would increase the near-wall hematocrit, would lead to elevated shear 
stresses which would promote vascular remodeling. At first glance, the results of the blood 
vessel density quantification in the present study may suggest that this hypothesis was disproved. 
However, a possible considerable limitation to testing this hypothesis was the model chosen. 
Biomaterial implants can invoke a substantial foreign body response. It is well known that the 
inflammatory cells related to wound healing, in this case macrophages and FBGCs, secrete the 
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necessary cytokines and growth factors that lead to effective angiogenesis [143] to provide the 
metabolically active fibroblasts and macrophages the necessary supply of oxygen and nutrients. 
For example, macrophages are capable of secreting angiogenic molecules such as basic 
fibroblast growth factor, tumor necrosis factor α and vascular endothelial growth factor [162]. 
The preliminary histological assessment of the scaffolds suggested that the number of 
inflammatory cells was greater in the Control group. In this case, it is possible that the 
inflammatory mediated angiogenic response lead to increased numbers of blood vessels which 
were required to nourish a significantly elevated number of cells over which was necessary in the 
scaffolds of DRP-treated animals. The relocation of RBCs to the near-wall space would also 
improve gas exchange to the tissue in the scaffolds implanted in the DRP-treated animals. This 
would reduce the requirements of the inflammatory cells to signal neovascularization. Thus, it is 
uncertain whether the DRP effect on the endothelium would be great enough to overcome the 
strong angiogenic signaling generated by the inflammatory cells. It is therefore suggested that 
further investigation of this shear stress hypothesis be carried out in a different model such as the 
rabbit with an implanted ear chamber where changes in vascularity could be monitored. 
 
Table 6.1: Blood vessel density measured in PLLA scaffolds and encapsulation tissue 
 
  Blood vessel diameter (μm) 
Treatment Tissue area 0-25 25-50 > 50 
Control Scaffold 4.7±2.1 0.5±0.4 0 
Encapsulation 26.3±13.4 3.9±3.2 0.6±0.8 
PEO Scaffold 4.1±2.1 0.3±0.2 0 
Encapsulation 20.0±14.2 1.1±1.1 0 
PMNN Scaffold 3.6±2.3 0.3±0.2 0 
Encapsulation 27.5±10.8 3.0±2.3 1.8±3.1 
Blood vessel density per mm2 of scaffold and encapsulation tissue as measured in Masson’s 
trichrome stained sections. Mean ± SD, n=5 for each Group. 
 
 
 159 
The methods used here for identifying blood vessels was limited as it only allows for a 
rough interpretation of the blood vessel density accounting for only vessels containing RBCs. 
Therefore, those vessels, functioning or non-functioning, in which RBCs were not contained 
within the intraluminal space were not counted. Additionally, other intracellular spaces 
resembling a luminal structure containing RBCs that may have been dislocated from their 
respective vessels during histological processing may have been falsely counted. More specific 
techniques for the quantification of blood density are recommended for future studies. The 
techniques commonly employed entail the immunolabeling of vascular endothelial cells with 
antibodies for either CD31 or von Willebrand Factor. CD31 (PECAM-1: platelet endothelial 
adhesion molecule) and von Willebrand Factor (vWF; Factor VIII Related Antigen) are 
expressed and synthesized by endothelial cells for various functions and are typically used as cell 
markers for studying angiogenesis/neovascularization. A pilot study to label blood vessels in a 
small number of scaffold sections using immunohistochemical techniques for the detection of 
vWF was unsuccessfully performed in this work. In that study, the immunoperixodase method of 
signal detection was used. This method can be complicated by the presence of endogenous 
peroxidase in the cells and tissues. The scaffold sections were filled with macrophages and 
FBGCs, cells which produce reactive oxygen intermediates such as hydrogen peroxide and 
which are rich in peroxidase activity. The histological outcome was nonspecific staining of the 
tissue sections. Therefore, it may be suggested that an alternative enzyme label, such as calf 
intestinal alkaline phosphatase or a different immunolabeling technique that utilizes a fluorescent 
secondary be used for future investigations of the blood vessel density in these sections. 
 160 
6.4 SUMMARY 
The experiments performed in this chapter followed up the discovery of the DRP effect observed 
in in vitro microchannel studies which showed the axial relocation of RBCs toward the channel 
wall; an effect which when applied to blood flow in microvessels in vivo would increase the 
near-wall hematocrit leading to elevated vessel wall shear stresses. We first hypothesized that the 
chronic intravascular injection of DRPs would facilitate increased blood vessel formation and 
thus improved tissue cell infiltration in a biodegradable synthetic scaffold implanted 
subcutaneously in rat. To study the DRP effects in vivo, experiments were carried out in which 
animals, implanted with subcutaneous porous PLLA scaffolds, were infused with DRPs 
(2x/week for 7 weeks) post implant. Assessment of tissue infiltration and growth and collagen 
deposition inside the scaffold matrix as well as blood vessel growth were made. At 7 weeks post 
implant, using histological and digital analysis techniques, what was found were significant 
differences between the PLLA scaffolds of DRP-treated groups and those of saline-treated 
group. This analysis concluded that scaffolds of the DRP treated groups had significantly less 
granulomatous inflammation and the collagenous tissue was not only greater in concentration but 
also significantly more organized. Vascularization was comparable in all groups. Therefore, the 
mechanism of the observed differences in tissues of Control and DRP-treated animals was not 
directly related to the new vessel formation inside the scaffold tissue (at least as observed at the 7 
week time point). Actually, this may be owed to the differences in the inflammatory response 
due to changes in blood microcirculation rheological behavior in DRP-treated animals in general. 
Additionally, the inflammatory and foreign body responses to the scaffolds of the saline-treated 
animals led to rapid and almost complete degradation of the PLLA implant. 
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Our study has uncovered a beneficial effect of drag reducing polymers with extraordinary 
impact factor. These results are potentially of great utility as treatment of early post-operative 
response to implanted or transplanted materials, organ fibrosis, and diseases producing 
granulomatous inflammation. Due to the potential impact of this work on the development of 
novel anti-inflammatory and anti-rejection therapies, a filing with the US Patent and Trademark 
Office for a provisional patent has been granted and the patent is now pending [163]. 
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7.0  CONCLUSIONS 
The goal of this dissertation was to investigate potential mechanisms of the enhanced 
hemodynamics conferred to the cardiovascular system via the addition of minute concentrations 
of drag reducing polymers and several potential biomedical applications of these effects. The 
specific aims of the study were as following: to determine whether the DRP additives affected 
red blood cell deformability, to demonstrate that the intravenous infusion of DRP preparations 
would enhance the impaired microcirculation in rats with streptozotocin-induced diabetes, and to 
study the ability of DRPs to improve cell proliferation and tissue in-growth and facilitate 
angiogenesis in synthetic scaffolds. 
Two techniques were successfully implemented in order to study the DRP effect on the 
mechanical properties of red blood cells, i.e., their deformability. Using a filtration technique, the 
filterability of normal RBCs in dilute cell suspensions was found to be statistically significantly 
enhanced after the addition of DRPs. The effectiveness of this technique was shown by 
determining the filterability of RBCs treated with glutaraldehyde which significantly reduces 
RBC deformability. The addition of DRPs to glutaraldehyde-treated RBCs was found to cause a 
statistically significant increase in RBC filterability, restoring the filterability index value to that 
of normal RBCs. A rheological technique was also successfully employed to demonstrate that 
measurements of viscoelasticity of animal blood using a Vilastic-3 viscoelastometer (Vilastic 
Scientific), would provide a sensitive standard method of evaluation of changes in RBC 
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deformability. Using this technique, the viscoelasticity of whole blood from diabetic animals was 
found to be significantly higher than that of normal animals. An increase in viscosity and 
elasticity signifies a reduction in RBC deformability. The addition of DRPs to the diabetic blood 
samples resulted in a slight decrease in the viscosity suggesting that the deformability was 
increased. The addition of D-glucose to animal blood, in vitro, resulted in a hyperosmolar 
condition, which unlike the effects observed in human blood, led to RBC shrinkage and a 
reduction in their deformability. This phenomenon did not allow us to observe the effects of 
glycosylation on the cell membranes and hemoglobin. 
A reproducible model of experimental diabetes in small animals (rats) with the ability to 
measure hemodynamic parameters (blood pressure, heart rate and tissue perfusion) using non-
invasive methods was developed. Diabetic rats were found to have statistically significantly 
lower tissue perfusion than their non-diabetic matched control. Intravenous nanomolar 
concentrations of DRPs statistically significantly increased tissue perfusion in diabetic rats (as 
well as in normal animals) without affecting other hemodynamic parameters (blood pressure and 
heart rate). This study demonstrated the beneficial effects of drag-reducing polymers on the 
microcirculation of diabetic animals which most likely was related to the ability of the DRPs to 
enhance blood flow structure and mechanical properties of red blood cells in microvessels. 
Acute and chronic (7 week) injections of DRPs produced no noticeable effects on clotting 
and hemostasis and on hematologic, blood gas and serum chemistry parameters suggesting that 
DRPs do not alter hematology and cardiovascular, respiratory, liver and renal function. In 
another set of experiments, a commercially available pharmaceutical grade hyaluronic acid 
preparation, Hyvisc® (Anika Therapeutics) proven in our laboratory to be a DRP, demonstrated a 
decrease in vascular resistance similar to other previously used DRPs (PEO and PMNN). Pilot 
 164 
studies with bolus injections of solutions with relatively high concentrations of DRPs and slow 
infusions of solutions with extremely high DRP concentrations, up to 150 times the 
hemodynamically effective concentration, showed that hyaluronic acid can be safely delivered 
into the vascular system in small volumes and at a high infusion rate. However, PMNN, which 
was shown to be safe and effective when injected at relatively low concentrations, was found to 
produce hemolysis in blood after a slow injection at extremely high concentrations which can be 
related to the fact that there are still some impurities in this homemade preparation. 
Finally, experiments performed to study the new potential applications of DRPs in tissue 
engineering concluded that chronic injections of DRPs significantly reduced the foreign body 
response in animals subcutaneously implanted with a porous synthetic scaffold. Scaffolds of the 
DRP-treated groups had significantly less granulomatous inflammation. Moreover, the 
collagenous tissue was not only greater in concentration but also significantly more organized in 
the animals treated with DRPs. Vascularization was comparable in all groups. Additionally, the 
inflammatory and foreign body responses to the scaffolds of the saline-treated animals led to 
rapid and almost complete degradation of the scaffold implant while the DRP-treated rats had 
statistically significantly slower rate of the scaffold degradation. DRPs may provide treatment of 
the early post-operative response to implanted or transplanted materials, organ fibrosis, and 
diseases producing granulomatous inflammation. 
This dissertation provided a potential new mechanism behind the intravascular effect of 
DRPs as well as a foundation for several new medical applications of these blood soluble long-
chain viscoelastic polymers. 
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APPENDIX A 
ERROR PROPAGATION 
Many physical quantities can be easily calculated from other directly measurable parameters. 
However, all of these measurements have error associated with them. Therefore, physical 
quantities which are calculated from these measurements will have an error due to the 
contributions of the individual errors from the measured quantities. Propagation of error is the 
effect of variables' errors on the uncertainty of a function that is based on those variables. An 
error analysis can be performed by assuming λ is a computed quantity that can be calculated 
from α, β, and γ, which are either directly measurable or previous calculated quantities. If each 
has an unknown certainty, σ, then propagation of error can be easily calculated by Equation 6 
[164]. 
σ λ2 = dλdα
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σγ2  (6) 
The differentials in Equation 6 represent the effect of a change in α, β and γ on λ. Equation 6 
may be used to derive equations for the propagation of error associated with addition, 
subtraction, multiplication and division of the measured parameters in the computation of λ. 
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In the case of addition, λ can be computed using Equation 7. 
γβαλ ++=  (7) 
Using Equation 7, the differentials of Equation 6 become 
1=== γ
λ
β
λ
α
λ
d
d
d
d
d
d  (8) 
The basic equation for the calculation of propagation of error can be simplified to Equation 9 by 
substituting the results of Equation 8 into Equation 6. 
2222
γβαλ σσσσ ++=  (9) 
If the calculation would involve subtraction, the result would be the same since the partial 
derivatives are squared. Therefore, Equation 9 tells us that the total error of a calculated quantity 
is the sum of all the errors of the measured quantities when addition or subtraction is performed. 
In the case of multiplication, λ can be computed using Equation 10. 
αβγλ =  (10) 
Using Equation 10, the differentials of Equation 6 become 
αβγ
λαγβ
λβγα
λ ===
d
d
d
d
d
d ;;  (11) 
The basic equation for the calculation of propagation of error can be simplified to Equation 12 by 
substituting the results of Equation 11 into Equation 6. 
( ) ( ) ( ) 2222222 γβαλ σαβσαγσβγσ ++=  (12) 
Equation 12 can be further simplified by dividing through by 2222 γβαλ =  to yield 
2222 %%%% γβαλ σσσσ ++=  (13) 
where the percentage of errors are computed as 
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%100% ×=
i
i
i
σσ  (14) 
If the calculation would involve division, the result would be the same since the partial 
derivatives are squared. Therefore, Equation 13 tells us that the total error of a calculated 
quantity is the sum of all the percentage of errors of the measured quantities when multiplication 
or division is performed. 
In the case of multiplication with quantities raised to a power, λ can be computed using 
Equation 15. 
cba γβαλ =  (15) 
Using Equation 15, the differentials of Equation 6 become 
cbaa
d
d γβαα
λ 1−= ; cabb
d
d γαββ
λ 1−= ; bacc
d
d βαγγ
λ 1−=  (16) 
The basic equation for the calculation of propagation of error can be simplified to Equation 19 by 
substituting the results of Equation 16 into Equation 6. 
( ) ( ) ( ) 2212212212 γβαλ σβαγσγαβσγβασ baccabcba cba −−− ++=  (19) 
Equation 19 can be further simplified by dividing through by cba 2222 γβαλ =  to yield 
2222222 %%%% γβαλ σσσσ cba ++=  (20) 
If the calculation would involve division, the result would be the same since the partial 
derivatives are squared. Therefore, Equation 20 tells us that the total error of a calculated 
quantity is the sum of all the percentage of errors of the measured quantities, each multiplied by 
the square of their respective power, when multiplication or division is performed. 
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A.1 PROPAGATION OF ERROR CALCULATIONS FOR VASCULAR 
RESISTANCE 
Peripheral vascular resistance (PVR) represents a physical quantity that is calculated in this 
dissertation from directly measured quantities and can be calculated using Equation 21. 
TP
MAPPVR =  (21) 
where, MAP is the measured mean arterial pressure in mmHg and TP is the measured tissue 
perfusion in TPU. The propagation of error in the calculated quantity (i.e., PVR) can be assessed 
after determining the uncertainty in the directly measured parameters (i.e., MAP and TP). 
 The uncertainty in the measurement of MAP, MAPσ , and TP, TPσ , can be defined by the 
accuracy of the scales by which these parameters are read. Pressure readings were made with a 
disposable strain gauge manometer which was calibrated using a standard clinical 
plethysmography gauge that had a scale that was accurate to ±1.0 mmHg. Since the pressure 
transducers were re-zeroed and re-calibrated immediately prior to data acquisition in each 
experiment, drift was not included in the error. Tissue perfusion measurements were made using 
a laser Doppler flow meter whose scale was readable to ±0.1 TPU. 
Therefore, 
MAPσ  = 1.0 mmHg and TPσ  = 0.1 TPU (22) 
If vascular resistance is calculated using typical values of MAP = 90 mmHg and TP = 18 TPU as 
measured during hemodynamic experiments, then the percentage of errors, calculated by 
substituting the values from Equation 22 in to Equation 14, are 
%1.1%100
90
1% =×=MAPσ  and %6.0%10018
1.0% =×=TPσ  (23) 
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Substitution of the values of Equation 23 into Equation 13 and taking the square root produces 
PVRσ%  = 1.3% (24) 
Using the errors in the measured quantities, the expected total error in the calculation of the 
peripheral vascular resistance is 1.3%. 
 Similarly, the propagation of error in calculations of vascular resistance can be 
determined for the case where carotid blood flow, Q, was measured with an ultrasonic 
perivascular flow probe. The accuracy of the flow probe used in those studies is Qσ%  = ±3% 
[165]. Therefore, by substituting Qσ% and MAPσ%  into Equation 13 and taking the square root 
produces 
VRσ%  = 3.2% (25) 
Using the errors in the measured quantities, the expected total error in the calculation of the 
vascular resistance is 3.2%. 
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APPENDIX B 
EFFECT OF PEO AND PMNN ON MACROPHAGE ADHESION 
Chapter 6.0 presented in vivo experiments performed to investigate new potential applications of 
DRPs in tissue engineering based on findings which demonstrated their ability to regulate the 
axial distribution of flowing RBCs in in vitro models of microvessels with diameters below 300 
μm. This effect leads to a significant increase in wall shear stress via an increase in the near-wall 
viscosity. These studies concluded that chronic injections of DRPs significantly reduced the 
foreign body response in animals subcutaneously implanted with a porous synthetic scaffold. 
The results and a potential mechanism are described in detail in section 6.3. This appendix 
describes a pilot study which was performed to examine the effect of DRPs on macrophage 
adhesion in vitro. 
B.1 TISSUE CULTURE CELL LINES 
RAW 264.7 murine macrophage cell line, obtained from American Type Culture Collection 
(ATCC – TIB71, Manassas, VA) were grown to ~80-90% confluency and routinely passaged in 
Dulbecco’s Modified Eagles Medium (BioWhittaker® DMEM; Lonza, Walkersville, MD) with 
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4.5 g/L glucose and L-glutamine supplemented with 10% heat-inactivated Fetal Bovine Serum 
(FBS; Hyclone, Logan, UT) and 100 U/ml penicillin and 100 μg/ml streptomycin (0.01% P/S). 
Cell passage was performed by: twice washing with Dulbecco’s Phosphate Buffered Saline 
(DPBS; Mediatech, Manassas, VA), treating with Trypsin/EDTA (Gibco®; Invitrogen, Grand 
Island, NY) for 5 min, scraping and resuspending into fresh growth medium, centrifuging at 300 
x g (Sorvall, model number, city, state) for 10 min, washing with fresh medium and re-seeding 
cells onto fresh culture plates (Corning, Lowell, MA). Cells were incubated at 37 °C in 
humidified air with 5% CO2. Sterile tissue-culture techniques in a laminar flow hood were 
followed for all cell manipulations and experimental procedures. The passage number of the cell 
line subcultures used did not exceed fifteen beyond that as received from ATCC. 
B.2 MACROPHAGE ADHESION ASSAY 
B.2.1 Methods 
RAW cells were grown on two 60 mm culture plates (Corning) to ~80% confluency. Cells were 
washed once with DPBS (Mediatech) and harvested by treatment with Trypsin/EDTA 
(Invitrogen) for 5 min and scraping into fresh medium. The cell suspension was pelleted by 
centrifugation at 300 x g for 10 min (Sorvall Biofuge Primo™ R; Thermo Fisher Scientific, 
Waltham, MA), the supernatant was discarded and the cells thoroughly resuspended in 5 ml of 
media. The cell suspension was then divided into three aliquots, centrifuged at 300 x g for 10 
min (Microfuge® 18 Microcentrifuge; Beckman Coulter, Fullerton, CA), the supernatants 
removed, and the cells resuspended in 1.7 ml of one of the following three media: normal growth 
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medium (Control), normal growth medium + 5 μg/ml (1.1 nM) PEO-4500, or normal growth 
medium + 5 μg/ml (0.8 nM) PMNN. One hundred microliters of suspended cells from each of 
the three media was then added to 400 μl of the corresponding media pre-filled in wells of 24-
well plates (Corning). The plates were then incubated for 0, 60 and 120 min at 37 °C in 
humidified air with 5% CO2. Each condition was repeated in triplicate wells of cells. After the 
incubation period, the medium was removed and the wells washed once with DPBS (Mediatech) 
with agitation to remove the non-adherent cells. The adherent cells were fixed by incubation with 
3% formalin at room temperature for 15 minutes after which the formalin was removed and 
DPBS (Mediatech) with 2 mM EDTA (Sigma Aldrich) was added for storage (at 4 °C) until the 
number of attached cells could be quantified. Phase contrast images of the 24-well plates were 
captured with a 4x plan fluorite objective (Plan Fluor DL 4x/NA 0.30 w/phase ring PhL; Nikon 
Instruments) on the same Nikon TE2000 inverted phase-fluorescence microscope system 
described in section 6.2.8.4. Digital analysis to quantify the number of adherent cells/well was 
performed on a personal computer with the NIH Image program. The results are expressed as the 
mean number of adherent cells/well ± S.D. for each condition. A two-way ANOVA with 
Bonferroni post hoc test was used to compare the average number of adherent cells per well of 
each experimental condition to that of the control of the corresponding time point. A p < 0.05 
was considered to be statistically significant. 
 173 
B.2.2 Results and Discussion 
The average number of adherent macrophages after incubation for 0, 60 and 120 minutes in 
growth medium containing either of the two DRPs was compared to that in growth medium 
alone (Control) (Figure 7.1). 
 
 
 
Figure 7.1: DRP effect on RAW 264.7 macrophage cell adhesion 
 
(A) Photomicrographs The average number of adherent macrophages after incubation for 0, 60 and 120 
minutes in growth medium containing either of the two DRPs was compared to that in growth medium 
alone (Control). Results represent mean number of adherent cells per mm2 ± SD in three wells for each 
condition. Statistics were performed using a two-way ANOVA with Bonferroni post hoc test to compare 
each experimental condition to the control of the same time point.*p < 0.01, **p < 0.001. 
 
 
These experiments demonstrated that macrophage cell adhesion was statistically 
significantly increased when DRPs (PEO-4500 and PMNN) were present in their growth 
medium during an incubation period up to 120 minutes. After an incubation time of 60 minutes, 
the number of adherent cells/mm2 was 121% and 110% greater in wells with growth medium 
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containing PEO-4500 (5 μg/ml (1.1 nM)) and PMNN (5 μg/ml (0.8 nM)), respectively, than 
those wells with normal growth medium (Control). After incubation for 120 minutes, the number 
of adherent cells/mm2 in wells with growth medium containing PEO-4500 (5 μg/ml (1.1 nM)) 
and PMNN (5 μg/ml (0.8 nM)) was 200% and 249%, respectively, greater than the wells filled 
with normal growth medium (Control). 
The increase in the adhesion of macrophages in the presence of DRPs may help to 
explain the results which were outlined in Chapter 6.0 In those studies, we found that chronic 
injections of DRPs significantly reduced the foreign body response in animals subcutaneously 
implanted with a porous synthetic scaffold. The results of those studies and a potential 
hemodynamic mechanism were described in detail in section 6.3. The hemodynamic mechanism 
was based on the DRP effect that was observed in in vitro microchannel studies which showed 
the axial relocation of RBCs toward the channel wall; an effect which when applied to blood 
flow in microvessels in vivo would increase the near-wall hematocrit leading to elevated vessel 
wall shear stresses. These elevated vessel wall shear stresses might effectively overcome the 
adhesive bonds of leukocytes to the endothelium, reducing the number of cells available for 
diapedesis. In the pilot study performed here (1 experiment), it is suggested that the DRPs 
influence, in this case increase, the adhesion of the macrophages. This would in turn reduce the 
motility of the macrophages during extravasation and essentially reduce the number of 
macrophages that could reach the foreign body. 
These experiments were limited in that we performed only a small pilot study with 1 
experiment. It is suggested that these experiments be repeated several more times. Additionally, 
to further evaluate the influential role of DRPs on macrophage behavior, experiments should be 
performed to evaluate the DRP effect on macrophage differentiation and migration in vitro. 
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